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Chapter 1
General introduction and 





Colorectal cancer is the third most common malignancy in the Western world and rectal 
cancer accounts for approximately one third of the colorectal cancer patients.(1) In 2018, 
almost 4,000 patients were newly diagnosed with rectal cancer in the Netherlands and this 
number is stable over the last four years.(2) Despite these stabilizing numbers, the burden 
of rectal cancer is high and treatment remains a challenge. In most rectal cancer cases, 
the local tumour growth is limited within the layers of the rectal wall and has not spread 
to local lymph nodes. At the time of diagnosis of primary rectal cancer, in approximately 
10% of the rectal cancer patients, the tumour is close to the mesorectal fascia and may 
invade surrounding organs such as the bladder or male and female reproductive organs.(3, 
4) These patients have locally advanced rectal cancer (LARC). After treatment for primary 
rectal cancer, the tumour may recur locally in the rectum or in surrounding structurers 
within the pelvic area in approximately 5-10% of the patients. These patients have locally 
recurrent rectal cancer (LRRC).(3-5)
Surgery remains the cornerstone of treatment in (recurrent) rectal cancer patients. Many 
studies over the last decades described a clear resection margin as the single most impor-
tant prognostic factor for overall survival and local control in rectal cancer surgery.(3, 6-9) 
This emphasizes the importance of a radical resection margin with surgery. Achievement 
of a clear resection margin in lower stages of rectal cancer by standard total mesorectal 
excision surgery may be more straightforward than in advanced stages of rectal cancer. To 
achieve a clear resection margin in patients with LARC and LRRC a multimodality treatment 
with a more complex surgical dissection is required. These procedures, such as extraleva-
tory abdominoperineal resections and partial or total pelvic exenteration, require a surgical 
dissection beyond the standard total mesorectal excision plane.(10) 
Over the past decades treatment of rectal cancer has evolved into a ‘’tailor made’’ mul-
tidisciplinary approach including neoadjuvant chemo- and radiotherapy, total mesorectal 
excision surgery, and intraoperative radiation therapy (IORT) which improved overall 
survival and local control after treatment.(3, 11-15) Optimal treatment of rectal cancer is 
dependent on local tumour stage and the presence of locoregional or distant metastases. 
Neoadjuvant chemo- and radiotherapy leads to tumour shrinkage, thereby facilitating 
complete resections and a decrease in local recurrence rate.(12, 14-16) In more advanced 
stages of rectal cancer chemo- and radiotherapy is an essential part of the treatment.(3) 
Several years ago the effect of neoadjuvant therapy in early stages of rectal cancer was 
limited, but nowadays may play an important role in case of organ preserving treatment, 
as described by Habr-Gama and colleagues and as currently investigated in the multicentre 
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STAR-TREC study.(17-19) These new treatment strategies will not be discussed in this 
thesis, but will be outlined in the future perspectives. 
The introduction of standardized total mesorectal excision (TME) combined with neoad-
juvant therapies has led to improved oncological results after surgery for rectal cancer. 
Adjustment of radiotherapy regimens and time to surgery, as presented in the Stockholm 
trial, also reduced perioperative complications and improved outcomes.(3, 14, 15, 20) 
During surgery, patients can be treated with IORT to reduce local recurrence rates or even 
improve overall survival, when there is a known pre-operative or possible per-operative risk 
of a microscopically involved resection margin.(13, 21, 22). 
The current multimodality treatment with surgery beyond the standard TME-plane for 
LARC and LRRC brings new challenges in terms of morbidity and mortality, especially with 
an incidence of rectal cancer increasing with age.(23) The improved oncological outcomes 
over the past decades are encouraging, but this multimodality treatment of rectal cancer 
and especially LARC and LRRC may have a major impact on quality of life.(24, 25) Despite 
all improvements, the treatment of rectal cancer remains a challenge.
GeneRal aiM of This Thesis
The aim of this thesis is to further improve the multimodality treatment for rectal cancer, 
locally advanced rectal cancer and locally recurrent rectal cancer. Currently investigated 
modern treatment strategies such as organ preserving treatment and ‘watchful waiting’ 
will not be discussed in this thesis. 
ouTline of This Thesis
In Part I of this thesis the first chapters focus on the association between hospital volumes 
and outcomes in rectal cancer surgery on a population-based level. The impact of hospital 
volume on surgical outcomes after rectal cancer surgery are still under debate. The Dutch 
Foundation for Oncological Collaboration defined standards for cancer treatment and 
included a minimum volume of 20 rectal cancer resections annually per hospital in their 
first report in 2012, irrespective of the tumour stage. Until then, rectal cancer surgery was 
performed in every Dutch hospital with a few specialized centres treating locally advanced 
and recurrent rectal cancer, to which referral was recommended in the Dutch colorectal 
cancer guideline.(26) These guidelines recommend centralization of care for patients 
with advanced stages of rectal cancer in specialized colorectal cancer hospitals. A recent 
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Chapter 1
1population-based study revealed no differences in 5-year survival rates between hospital 
volumes for patients with colorectal cancer; however, outcomes were not stratified for 
rectal cancer, nor for tumour stage.(27) 
In chapter 2 of this thesis we aim to investigate the influence of hospital volume on 
long-term oncological outcome after rectal cancer surgery in the Netherlands in 2011, 
based on population-based data provided by the Dutch Snapshot Research Group.(28) The 
purpose of this study was to assess the impact of hospital volume on short- and long-term 
outcomes of rectal cancer surgery in the Netherlands in 2011 stratified for hospital volume. 
Clinically staged T1-3 rectal cancer (cT1-3) is generally treated by TME-surgery with or 
without neoadjuvant therapy and sometimes requires beyond TME-surgery, whereas cT4 
rectal cancer often requires both. Due to the more complex treatment of the advanced 
stages of rectal cancer, a personalized ‘tailor made’ multimodality treatment is needed. 
Moreover, cT4 rectal cancer is relatively rare and multivisceral surgery is technically de-
manding with higher amounts of blood loss, operation time and increased morbidity and 
mortality.(10) We hypothesize that hospital volumes may be more important in cT4 rectal 
cancer than in patients with cT1-3 rectal cancer. In chapter 3, we analyse the long-term 
results of cT1-3 and cT4 rectal cancer according to hospital volume in the Netherlands 
between 2005 and 2013 from data of the National Cancer Registry. 
Quality of rectal cancer surgery with respect to short-term outcomes is being monitored 
by the Dutch Surgical Colorectal Audit (DSCA) since 2009. Although not uniformly re-
ported, hospital volume has been associated with operative mortality and morbidity.(29) 
In chapter 4, the purpose of the study was to investigate the impact of hospital volume 
on perioperative outcomes of rectal cancer stratified for cT1-3 and cT4 rectal cancer from 
population-based data provided by the DSCA.(30)
The following chapter focusses on treatment of locoregional lymph node metastases of 
rectal cancer. Rectal cancer is associated with locoregional pelvic lymph node metastases in 
and outside the mesorectum. In some cases inguinal lymph node metastases (ILNM) may 
occur, particularly in lower rectal cancer, due to the lymphatic drainage by inguinal lymph 
nodes.(31) The American Joint Committee on Cancer (AJCC) Cancer Staging Manual 
considers ILNM from rectal cancer as a systemic disease.(32) Obviously, patients with ILNM 
have a worse prognosis than patients without ILNM, but even patients with lung or liver 
metastases are not always restrained from curative treatment.(33) Chapter 5 describes 
the outcome for patients treated with both curative inguinal lymph node dissection and 
palliative treatment for ILNM from rectal cancer.
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The last two chapters of part I of this thesis concentrates on perineal wound morbidity 
after abdominoperineal resection for rectal cancer. The pelvic wound bed after abdomino-
perineal resection (APR) carries a high risk of morbidity.(34, 35) This is likely related to the 
contaminated operative field and dead space formation with fluid accumulation, and may 
be further increased by extended resections and compromised perfusion post-radiotherapy. 
A randomized controlled trial showed that perineal complications within one year after 
APR with primary perineal closure may occur in up to 48%.(36) Patients frequently develop 
perineal wound dehiscence and infection, and often endure delayed healing. Secondary 
wound healing can take several months and may eventually result in perineal pain, sitting 
problems, a chronic perineal sinus and a perineal hernia.(37-39) There is no consensus on 
the optimal method for perineal wound closure after APR. Several techniques are used to 
improve perineal wound healing, including reconstruction using a V-Y fasciocutaneous 
flap, a vertical rectus abdominis myocutaneous (VRAM) flap, a gluteal or a gracilis flap, 
use of biological mesh and tissue flaps, such as a pedicled omentoplasty to fill the dead 
space. (36, 40-42) In Chapter 6, a feasibility study of a novel gluteal turnover flap without 
additional scarring or donor site morbidity is described. 
The omentum is supposedly an ideal option to prevent dead space formation after APR. 
It has a rich blood supply, expresses anti-inflammatory cytokines, often provides for 
abundant bulk and appears relatively easy to release.(43) However, in a recent nationwide 
study of omentoplasty no improvement in perineal wound healing was observed and an 
omentoplasty seemed to increase the risk of perineal herniation.(38) In chapter 7 a sys-
tematic review and meta-analysis of the effects of omentoplasty on pelviperineal morbidity 
following abdominoperineal resection (APR) in mostly rectal patients is presented.
Part II of this thesis focusses on several aspects of the multimodality treatment for both 
LARC and LRRC. LRRC has a major impact on quality of life, mostly by the occurrence of 
severe pain, bleeding and fistulation.(24) Since most patients presenting with LRRC present 
with extensive metastatic disease or an unresectable local recurrence, only a minority are 
suitable candidates for surgery.(44-47) These patients can be offered non-surgical treat-
ment, consisting of external beam radiotherapy, chemotherapy, a combination of both or 
comfort care.(48) The only potential curative option for LRRC is surgical resection and the 
long-term outcome of surgical treatment mainly depends on the ability to achieve a clear 
resection margin.(6, 8, 47, 49) Management of LRRC remains a challenge for both curative 
surgical treatment and non-surgical treatment. In chapter 8, the long-term outcomes of 
a large cohort of patients with LRRC who underwent curative surgical treatment or non-
surgical treatment are evaluated. 
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Chapter 1
1If rectal cancer invades adjacent organs, such as bladder, ureters or male and female 
reproductive organs a more radical approach such as pelvic exenteration is required. Pelvic 
exenteration for advanced pelvic malignancies was first described in 1948 by Brunschwig 
et al.(50) as a palliative treatment of gynaecological cancer. Over time pelvic exentera-
tion developed as a surgical technique for curative treatment of rectal cancer. Chapter 9 
provides an overview of pelvic exenteration for rectal cancer invading the male and female 
urogenitary tract.
Total pelvic exenteration is radical surgery with considerable morbidity and mortality.(6, 
51, 52) Although it is generally known that elderly patients often present with more co-
morbidities and surgical outcomes are worse than in younger patients, there is controversy 
whether the cancer specific survival is also worse in elderly patients.(53-55) The question 
remains, with an increasing elderly population with rectal cancer, whether it is justified to 
withhold extensive surgery from the elderly patient because of high mortality and morbid-
ity. Chapter 10 aims to compare mortality, morbidity, surgical and oncological outcomes 
between elderly and younger patients who underwent total pelvic exenteration for LARC 
or LRRC. When total pelvic exenteration including cystectomy is performed patients require 
a urinary deviation.(56, 57) Historically there are several urinary deviations, but in the cur-
rent practice, the most common urinary deviation after complete bladder resection is an 
ileal conduit (i.e. Bricker) and more recently followed by a colon conduit.(58-60) Both 
procedures are associated with general surgical and urological complications, but also 
conduit specific complications may occur, such as metabolic changes or intra-abdominal 
complications of the loop diversion.(58, 61-63) In Chapter 11, short- and long-term com-
plications of an ileal and colon conduit after surgery for LARC or LRRC are presented in 
cohort of two large tertiary referral hospitals.
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The association between hospital volume and outcome in rectal cancer surgery is still 
subject of debate. The purpose of this study was to assess the impact of hospital volume 
on rectal cancer surgery in the Netherlands in 2011. 
Methods
In this collaborative research with a cross-sectional study design, patients who underwent 
rectal cancer resection in 71 Dutch hospitals in 2011 were included. Annual hospital vol-
ume was stratified as low (< 20), medium (20-50) and high (≥ 50).
Results
Of 2095 patients, 258 patients (12.3%) were treated in 23 low-volume hospitals, 1329 
(63.4%) in 40 medium volume hospitals, and 508 (24.2%) in 8 high-volume hospitals. 
Median length of follow-up was 41 months. Clinical tumour stage, neoadjuvant therapy, 
extended resections, circumferential resection margin (CRM) positivity, and 30- day or in-
hospital mortality did not differ significantly between volume groups. Significantly, more 
laparoscopic procedures were performed in low-volume hospitals, and more diverting 
stomas in high-volume hospitals. Three year disease-free survival for low-, medium-, and 
high volume hospitals was 75.0%, 74.8%, and 76.8% (p = 0.682). Corresponding 3-year 
overall survival rates were 75.9%, 79.1%, and 80.3% (p = 0.344). In multivariate analysis, 
hospital volume was not associated with long-term risk of mortality.
Conclusions 
No significant impact of hospital volume on rectal cancer surgery outcome could be 
observed among 71 Dutch hospitals after implementation of a national audit, with the 





The association between hospital volume and outcome in rectal cancer surgery is still sub-
ject of debate, because current literature is difficult to interpret given the variety in volume 
definitions and outcome indicators. Furthermore, studies on this topic come from different 
health care systems, and hospitals may substantially differ in case mix and specialization 
level regardless volume. Although not uniformly reported, hospital volume has been as-
sociated with operative mortality.(1) More sphincter-saving surgery and lower permanent 
colostomy rates are more consistently reported outcomes for high-volume hospitals.(2,3) 
The association with long-term risk of recurrence or survival has almost never been ob-
served.(4,5)
The Dutch Foundation for Oncological Collaboration (www.soncos.nl) defines standards for 
cancer treatment and included a minimum volume of 20 rectal cancer resections annually 
per hospital in their first report in 2012. Until then, rectal cancer surgery was performed in 
every Dutch hospital with a few specialized centres treating locally advanced and recurrent 
rectal cancer, to which referral was recommended in the Dutch colorectal cancer guideline. 
These recommend centralization of care for patients with advanced stages of rectal cancer 
in specialized colorectal cancer hospitals. Quality of rectal cancer surgery with respect to 
short-term outcome is being monitored by the Dutch Surgical Colorectal Audit (DSCA) 
since 2009, and participation by each hospital is mandatory by the National Inspectorate 
of Health Care.
The purpose of this study was to assess the impact of hospital volume on short- and long-
term outcomes of rectal cancer surgery in the Netherlands in 2011.
MeThods
study design and data collection
All 94 hospitals that registered in the Dutch Surgical Colorectal Audit (DSCA) in 2011 were 
asked to participate in a resident-led collaborative research project in 2015. A total of 71 
hospitals agreed to participate. Registered rectal cancer resections that were performed 
in these hospitals in 2011 were identified from the DSCA.(6) In the second half of 2015, 
additional procedural data and long-term surgical and oncological outcomes were retro-
spectively added to the perioperative DSCA data using a specifically developed web-based 
and privacy controlled data-entry tool for this purpose. Data-entry in this cross-sectional 
study was performed by one or two surgical residents supervised by a consultant surgeon. 
Medical ethics committee of the Academic Medical Centre, Amsterdam, the Netherlands 
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decided that approval was not required for this study as all data were anonymized and no 
there was no additional burden for the patient. Details of this Snapshot study cohort have 
been published previously.(7)
hospital volume
Annual hospital volume was defined as the total number of rectal cancer resections per-
formed in 2011. This volume was classified as low (< 20), medium (20-50) or high (> 50). 
Patient characteristics, stage distribution, type of treatment, postoperative outcome, and 
disease-free and overall survival were calculated for the three categories of annual hospital 
volume.
data analysis
Missing data were not defaulted to negative and denominators reflect only actual reported 
cases. Nominal variables were compared between the three groups using the Chi-square 
test, and continuous variables using the Student’s t test. Kaplan Meier survival analysis 
with log rank test was used to compare disease-free and overall survival rates at 3 years 
between volume groups. Multivariable Cox regression analysis was performed to deter-
mine independent predictors of long-term mortality. Hospital volume was included in this 
model besides all variables that were significant in univariable analysis (p < 0.05). SPSS 22 
was utilized for the analyses, and a p value < 0.05 was considered significant. The STROBE 
guidelines were used to ensure the reporting of this observational study.(8)
ResulTs
baseline characteristics
A total of 2095 patients with rectal cancer were included, of which 258 patients (12.3%) 
were treated in 23 low-volume hospitals, 1329 (63.4%) in 40 medium-volume hospitals, 
and 508 (24.2%) in 8 high-volume hospitals. Baseline characteristics are displayed in Table 
1, stratified for annual hospital volume. Demographics, medical history, clinical tumour 
stage, distance of the tumour to the anorectal junction, type of surgical procedure, and 
extended resection for cT4 did not differ significantly between different volume groups. 
Overall, approximately 90% of patients underwent neoadjuvant therapy, while there were 
small in differences in neoadjuvant regimes between different volume groups (Table 1). 
High volume hospitals diagnosed significantly more often a clinical node-positive status 
compared to low and medium volume hospitals (p < 0.001), mainly as cN2-stage. A laparo-
scopic approach was more frequently used in low-volume hospitals compared to medium 




anterior resection, the anastomosis was more frequently diverted in high-volume hospitals 
compared to low and medium-volume hospitals (80.3% vs. 65.5% and 68.5%, p = 0.001). 











Age (year) 66.0 ±12.3 66.9 ±11.1 66.7 ±11.2 0.448
Male gender 153 (59.3%) 855 (64.4%) 309 (60.8%) 0.164
Medical history
   Cardiac 58 (31.4%) 295 (33.4%) 107 (30.2%) 0.380
   Vascular 91 (49.5%) 441 (49.9%) 174 (49.2%) 0.862
   Pulmonal 36 (19.5%) 147 (16.6%) 59 (16.7%) 0.790
   Diabetes 37 (20.0%) 170 (19.2%) 66 (18.6%) 0.960
   Neurologic 24 (13.0%) 153 (17.3%) 60 (16.9%) 0.622
ASA class 3/4 39 (15.7%) 223 (17.2%) 81 (16.3%) 0.796
Multidisciplinary tumour 
board meeting
241 (98.4%) 1243 (95.8%) 481 (96.6%) 0.130
Neoadjuvant therapy 232 (89.9%) 1187 (89.3%) 457 (90.0%) 0.901
   Short-course (5x5 Gy) 116 (45.0%) 620 (46.7%) 219 (43.1%)
   Long-course 8 (3.1%) 53 (4.0%) 8 (1.6%)
   Chemoradiotherapy 91 (35.3%) 465 (35.0%) 155 (30.5%)
   Different regimen 17 (6.6%) 49 (3.7%) 75 (14.8%) <0.001
cT stage
   cT1 6 (2.8%) 56 (4.8%) 18 (4.2%)
   cT2 55 (25.9%) 289 (25.0%) 129 (30.0%)
   cT3 128 (60.4%) 709 (61.2%) 230 (53.5%)
   cT4 23 (10.8%) 104 (9.0%) 53 (12.3%) 0.070
cN stage
   cN0 89 (45.4%) 517 (45.9%) 146 (35.3%)
   cN1 76 (38.8%) 440 (39.1%) 167 (40.3%)
   cN2 31 (15.8%) 169 (15.0%) 101 (24.4%) <0.001
cM1 19 (8.3%) 90 (7.1%) 30 (6.8%) 0.777
Distance to anal verge (cm) 5.6 ±3.6 5.9 ±3.9 6.2 ±4.0 0.152
Operative characteristics
   LAR 113 (43.8%) 635 (47.8%) 250 (49.2%)
   APR 79 (30.6%) 401 (30.2%) 159 (31.3%)
   Low Hartmann 53 (20.5%) 261 (19.6%) 88 (17.3%)
   Different 13 (5.0%) 32 (2.4%) 11 (2.2%) 0.142
Deviating stoma (in LAR) 76 (65.5%) 440 (68.5%) 204 (80.3%) 0.001
Laparoscopic 149 (59.8%) 582 (44.8%) 227 (45.7%) <0.001
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Additional resection 18 (7.2%) 94 (7.2%) 42 (8.4%) 0.676
   Partial vaginectomy 13 (5.0%) 29 (2.2%) 12 (2.4%) 0.028
   Uterus resection 2 (0.8%) 20 (1.5%) 7 (1.4%) 0.656
   Ovariectomy 1 (0.4%) 18 (1.4%) 11 (2.2%) 0.136
   Vesicula seminalis 
resection
2 (0.8%) 10 (0.8%) 10 (2.0%) 0.066
   Partial prostatectomy 2 (0.8%) 18 (1.4%) 5 (1.0%) 0.649
   Partial bladder resection 1 (0.4%) 9 (0.7%) 4 (0.8%) 0.812
   Total exenteration 2 (0.8%) 12 (0.9%) 4 (0.8%) 0.960
ASA: American Society of Anaesthesiologists
LAR: low anterior resection; APR: abdominoperineal resection; low Hartmann: total mesorectal excision with 
end-colostomy. 
Different included proctocolectomy or local excision followed by rectal resection. 












    (y)pT0 28 (11.3%) 86 (6.8%) 19 (4.0%)
    (y)pT1 21 (8.5% 94 (7.4%) 41 (8.6%)
    (y)pT2 81 (32.8%) 413 (32.7%) 164 (34.3%)
    (y)pT3 103 (41.7%) 610 (48.3%) 225 (47.1%)
    (y)pT4 14 (5.7%) 61 (4.8%) 29 (6.1%) 0.027
Pathologic lymph node stage
    (y)pN0 163 (66.8%) 787 (62.5%) 328 (66.3%)
    (y)pN1 63 (25.8%) 331 (26.3%) 126 (25.5%)
    (y)pN2 18 (7.4%) 142 (11.3%) 41 (8.3%) 0.172
CRM involvement a 17 (8.9%) 96 (9.2%) 35 (9.2%) 0.993
Postoperative outcomes
   Overall complication 81 (32.5%) 506 (39.2%) 186 (37.7%) 0.004
   Reintervention 30 (14.1%) 186 (17.2%) 53 (13.6%) 0.184
   30-day or in-hospital mortality 7 (2.8%) 34 (2.6%) 14 (2.8%) 0.970
a CRM (circumferential resection margin) involvement: if the smallest non-peritoneal resection margin to the 





Pathological tumour stage slightly differed among the volume groups with more complete 
response (y) pT0 (11.3% vs. 6.8% and 4.0%) and less (y) pT3 stage (41.7% vs. 48.1% 
and 47.3%, p = 0.027) in low-volume compared to medium and high-volume hospitals. 
The overall higher cN stage in high-volume hospitals did not translate into high (y)pN stage 
(p = 0.172). Circumferential resection margin involvement was found in approximately 
9% and did not differ among volume groups (Table 2; p = 0.993). Overall complication 
rate was lower in low-volume hospitals compared to medium and high-volume hospitals, 
with non-significantly different reintervention rates. The 30-day or in-hospital mortality 
rate was 2.8% in low volume hospitals as compared to 2.6% and 2.8% in medium and 
high-volume hospitals, respectively (p = 0.970). 
long-term oncological outcomes
Median length of follow-up was 41 months (interquartile range 30 - 52 months). Disease-
free survival at 3 years was 75.0% for patients operated in low-volume hospitals, compared 






Figure 1. Disease-free survival after rectal cancer surgery, stratified for hospital volume. 
Disease-free survival at 3 years was 75.0% for patients operated in low-volume hospitals, 
















figure 1. Disease-free survival after rectal cancer surgery, stratified for hospital volume. Disease-free 
survival at 3 years was 75.0% for patients operated in low-volume hospitals, compared to 74.8% in and 
76.8% in medium and high-volume hospitals (p = 0.682).
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Three-year overall survival was 75.9% for patients operated in low-volume hospitals, com-
pared to 79.1% in and 80.3% in medium and high-volume hospitals (Figure 2, p = 0.344).
Independent predictors of long-term mortality in Cox regression analysis were age above 
70 years, ASA class 3 or 4, pathological tumour and nodal stage, synchronous metas-
tasis, extended resection because of suspected tumour involvement, and circumferential 
resection margin (CRM) involvement (Table 3). After adjustment for these factors, annual 






Figure 2. Overall survival after rectal cancer surgery, stratified for hospital volume. The 
overall survival rate at 3 years was 75.9% for patients operated in low-volume hospitals, 







figure 2. Overall survival after rectal cancer surgery, stratified for hospital volume. The overall survival 
rate at 3 years was 75.9% for patients operated in low-volume hospitals, compared to 79.1% in and 





In this Snapshot study, including 2095 patients treated in 71 Dutch hospitals, annual hos-
pital volume was not significantly associated with any outcome measure after rectal cancer 
surgery. The only differences that were observed among volume groups were related to 
clinical nodal staging and the surgical treatment, regarding the use of minimally invasive 
surgery and diverting stoma. Treatment of locally advanced disease did not seem to be 
related to annual hospital volume.
This cross-sectional study design enabled evaluation of a much debated volume-outcome 
relationship within the context of most recently provided rectal cancer care in the Neth-
erlands. Since the TME trial in the late 1990s, rectal cancer care has increasingly been 
provided by dedicated multidisciplinary teams in the Netherlands, with rectal resections 
almost exclusively performed by specialized surgeons in recent years. The Association of 
Table 3. Multivariate cox regression analysis of predictors of long-term mortality after rectal cancer 
surgery
Variable Odds ratio 95% CI p value
Age > 70 2.28 1.84-2.82 <0.001
Female gender 0.84 0.67-1.04 0.114
ASA class 3/4 2.08 1.65-2.63 <0.001
Neoadjuvant therapy 0.85 0.62-1.17 0.320
Laparoscopic 1.02 0.82-1.26 0.883
Pathologic tumour stage
   pT0 1.00 - -
   pT1 0.37 0.16-0.83 0.016
   pT2 0.60 0.33-1.08 0.089
   pT3 1.07 0.61-1.88 0.815
   pT4 1.01 0.52-1.94 0.979
Pathologic nodal stage
   N1/N2 1.15 1.05-1.26 0.003
Synchronous metastasis 2.71 2.08-3.52 <0.001
Additional resection 2.07 1.49-2.89 <0.001
CRM involvement 1.78 1.34-2.34 <0.001
Hospital volume a
   Low volume (0-19) 1.00 - -
   Medium volume (20-50) 0.93 0.68-1.27 0.635
   High volume (>50) 0.93 0.65-1.32 0.676
a Low volume was used as reference category
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Surgeons of the Netherlands initiated a colorectal audit in 2009. The first report revealed 
substantial inter-hospital variability in process and outcome indicators. Regularly updated 
feedback and quality improvement projects led to substantial improvements in the next 
few years.(6) This probably explains the overall high performance independent of hospital 
volume as observed in the present snapshot of 2011. 
Limitations of the present study are related to potential incompleteness and validity of 
the data. The hospital volume was based on the number of cases originally registered 
in the DSCA and data are self-reported. However, validation of the DSCA against the 
Dutch National Cancer Registry showed high accuracy and completeness of the data.(9) 
Furthermore, it should be noted that participation in this snapshot study was voluntary, 
while registration in the DSCA is mandatory. Some small non-teaching regional hospitals 
that did not participate in this resident-led research project could have influenced the 
results. In contrast to a similar CRM positivity among volume groups in the current study, 
a significant higher CRM positivity was found among volume groups in the current study, 
a significant higher CRM positivity was found in low-volume hospitals in 2011 and 2012 
using DSCA data of all 94 Dutch hospitals.(10) This underlines the difficulty in interpreta-
tion of hospital volume as a single discriminator, while some low-volume hospitals might 
be high-performing hospitals.(11)
Treatment of rectal cancer has become more and more complicated considering several 
clinically relevant subgroups of patients regarding clinical condition, clinical staging, and 
types of neoadjuvant therapy, different surgical approaches, pathological and molecular 
assessment, and an increasing number of systemic therapy options. It seems likely that a 
certain volume is needed to manage this increasing complexity of care. In the Netherlands, 
centralization of rectal cancer has been recently initiated through a minimum volume of 20 
rectal resections annually, with involvement of patient societies and insurance companies 
besides the relevant national medical societies. Hospitals that did not reach the minimum 
of 20 resections a year were encouraged to stop performing rectal surgery since 2012, 
which resulted in collaboration initiatives with concentration of specific patient groups. 
It may well be that specific subgroups do benefit from centralized care in high-volume 
centres. However, our patient cohort might not be able to show this because of already 
implemented quality improvement measures, and because the sample size is still relatively 
small to show subtle differences between subgroups. 
Data from previous studies regarding hospital volume and rectal cancer care are conflict-
ing, and definitions of high and low volume vary considerably. According to the Californian 
Office of State-wide Health planning and Development database(12) and the Swedish 




significantly lower in medium and high-volume hospitals (0.9% - 2.2%) as compared to low-
volume centres (2.1% - 3.6%). Noteworthy is the definition of low volume in the Californian 
study, being 30 procedures or less during a six-year study period, corresponding to an annual 
volume of 5 or less. A recent analysis from the Rectal Cancer Project of the Spanish Society 
of Surgeons of 9809 consecutive patients showed an overall postoperative mortality rate of 
1.8%, which varied significantly among hospitals, but this could not be attributed to the 
hospital volume.(14) The same authors could not demonstrate a significant influence of 
hospital volume on the anastomotic leakage rate after LAR in another study.(15) PROCARE 
investigators recently found some volume effects in the quality of care in the treatment of 
rectal cancer, but concluded that their effect size was limited.(4) The authors underline that 
PROCARE is a voluntary registry, which cannot be extrapolated to the Belgian population.
Regarding the effects of hospital volume on long-term survival after rectal cancer surgery, 
data is limited. Overall survival rates after 5 years appear not to be associated with hospital 
volume.(3,13,16,17) Only two studies including patients treated between 1992 and 1997 
found a slightly better survival rate after 2 years for high-volume hospitals.(2,18) However, 
the validity of these historical data for modern rectal cancer management are questionable. 
In the present study, overall survival rates slightly differed with higher probabilities in high-
volume hospitals. However, this did not reach statistical significance and multivariate analysis 
confirmed that there was no impact of hospital volume on survival. Combining these findings 
and the previously reported results in the literature, the influence of overall hospital volume 
on long-term outcomes after rectal cancer resection appears to be limited, if it exists at all.
Care for patients with locally advanced tumours was already centralized in the Netherlands 
before 2011. If exenterative procedures, sacral resection or intraoperative radiotherapy are 
indicated, the previous Dutch guideline from 2008 already recommended referral to special-
ized centres.(19) The similar percentages of extended resections and ypT4 stage among the 
different volume groups suggest that treatment of locally advanced disease is not related to 
volume, but more related to availability of expertise and treatment modalities. Patients with 
cT4 tumours are potentially more accurately assessed in experienced multidisciplinary tumour 
board meetings and treated by specialized surgeons for ‘beyond TME’ surgery in centres for 
locally advanced disease. These centres may not necessarily be high-volume, because of their 
focus on referred patients with less use of their capacity for patients with cT1-3 tumours. 
In conclusion, no impact of hospital volume on outcome after rectal cancer surgery could 
be demonstrated among 71 Dutch hospitals at the time already significant improvements 
in rectal cancer care were achieved. Hospital volume as a single discriminator should be 
used with caution, although a certain unspecified volume is likely needed to gain and retain 
expertise in rectal cancer care with increasing complexity.
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Clinically staged T1-3 rectal cancer (cT1-3) is generally treated by total mesorectal excision 
(TME) with or without neoadjuvant therapy and sometimes requires beyond TME-surgery, 
whereas cT4 rectal cancer often requires both. This study evaluates the outcome of cT1-3 
and cT4 rectal cancer according to hospital volume.
Methods
Patients undergoing rectal cancer surgery between 2005 and 2013 in the Netherlands 
were included from the National Cancer Registry. Hospitals were divided into low (1 - 20), 
medium (21 - 50) and high (> 50 resections/year) volume for cT1-3 and low (1- 4), medium 
(5- 9) and high (≥ 10 resections/year) volume for cT4 rectal cancer. Cox-proportional haz-
ards model was used for multivariable analysis of overall survival (OS).
Results
A total of 14.050 confirmed cT1-3 patients and 2.104 cT4 patients underwent surgery. 
In cT1-3 rectal cancer, there was no significant difference in 5-year OS related to high, 
medium and low hospital volume (70% vs. 69% vs. 69%). In cT4 rectal cancer, treatment 
in a high volume cT4 hospital was associated with a survival benefit compared to low 
volume cT4 hospitals (HR 0.81 95% CI 0.67 - 0.98) adjusted for non-treatment related 
confounders, but this was not significant after adjustment for neoadjuvant treatment. 
Patients with cT4-tumours treated in high volume hospitals had a significantly lower age, 
more synchronous metastases, more patients treated with neoadjuvant therapy and a 
higher pT-stage. 
Conclusions
Hospital volume was not associated with survival in cT1-3 rectal cancer. In cT4 rectal cancer, 
treatment in high volume cT4 hospitals was associated with improved survival compared 
to low volume cT4 hospitals, although this association lost statistical significance after 





Colorectal cancer is the third most common malignancy in the Western world and rectal 
cancer accounts for approximately one third of the colorectal cancer patients.(1) Outcome 
of rectal cancer has improved over the last two decades, mainly due to the introduction of 
improved imaging modalities, total mesorectal excision (TME) and neoadjuvant (chemo-)
radiotherapy.(2-6) 
Optimal treatment of rectal cancer is dependent on local tumour stage and the presence 
of distant metastases. In lower stages of rectal cancer, the effectiveness of neoadjuvant 
(chemo-)radiotherapy is limited, whereas in more advanced stages of rectal cancer (chemo-)
radiotherapy is an essential part of the treatment.(7) It leads to tumour shrinkage, thereby 
facilitating complete resections and a decrease in local recurrence rate.(3, 8)
Local tumour stage is also important to determine the optimal surgical treatment. Lower 
stages of rectal cancer can be treated by standard TME procedures or even rectal sparing 
surgery in selected patients.(9) Advanced stages of rectal cancer with tumours invading 
the mesorectal fascia often require a more radical surgical approach to achieve a complete 
resection. These procedures, such as extralevatory abdominoperineal resections and partial 
or total exenterations, require a surgical dissection beyond the standard TME plane.(10) 
To improve the outcome of rectal cancer, the current Dutch standard indicates a minimum 
of 20 surgical resections of rectal cancer per year per hospital and advises centralization 
of care for patients with advanced stages of rectal cancer (i.e. clinically staged T4 and 
locally recurrent rectal cancer) in specialized colorectal cancer hospitals.(11) Due to the 
more complex treatment of the advanced stages of rectal cancer, a personalized ‘tailor 
made’ multimodality treatment is needed. Moreover, cT4 rectal cancer is relatively rare and 
multivisceral surgery is technically demanding with higher amounts of blood loss, opera-
tion time and increased morbidity and mortality.(12) We hypothesize that hospital volumes 
may be more important in cT4 rectal cancer than in patients with cT1-3 rectal cancer. This 
study analyses the long-term results of cT1-3 and cT4 rectal cancer according to hospital 




Data of all rectal cancer patients diagnosed between 2005 and 2013 in the Netherlands 
were retrieved from the nationwide population-based Netherlands Cancer Registry (NCR). 
Registration is mainly based on notification by the automated pathological archive (PALGA) 
and the National Registry of Hospital Discharge Diagnosis. Trained registrars of the NCR 
collected data from the medical records of the different hospitals. The population based 
NCR database has a 95% completeness of cancer registrations.(13) Information concern-
ing the cause of death was not available. No ethical approval was required for this study. 
study population
All patients undergoing surgery for rectal cancer were included. The following patient/
tumour related variables were available: year of diagnosis, age, gender, clinical and patho-
logical TNM stage, histopathology and the presence of synchronous distant metastases. 
Available treatment related variables were: neoadjuvant treatment, adjuvant treatment, 
hospital volume based on number of rectal cancer resections per year, type of surgical 
procedure (low anterior resection, abdominoperineal resection or proctocolectomy). In-
volvement of circumferential resection margin (CRM) was available from 2008 onwards. 
Clinically staged T1-3 and T4 rectal cancer were analysed separately. Patients with an 
unknown cT-stage were excluded from analysis, but were included in the determination 
of rectal cancer hospital volume. For cT1-3 rectal cancer, hospitals were divided into low 
volume hospitals (1 - 20 resections), medium volume hospitals (21 - 50 resections) and high 
volume hospitals (> 50 resections), based on the total number of rectal cancer resections 
performed annually in one hospital. For cT4 rectal cancer, hospitals were divided into low 
(1 - 4 resections), medium (5 - 9 resections) and high (≥ 10 resections) volume based on 
cT4 rectal cancer resections performed annually in one hospital.
The TNM-classification was used according to the edition valid at the time of cancer diag-
nosis (6th edition for 2005-2009 and 7th edition for 2010-2013). The 7th edition included a 
distinction between cT4a (tumour penetrates the surface of the visceral peritoneum) and 
cT4b tumours (tumour invades or is adherent to surrounding organs or structures). 
endpoints
The primary endpoint was overall survival according to the total hospital volume for cT1-3 





Vital status of patients was retrieved by linkage of the NCR to the nationwide municipal 
population registries network. 
statistical analysis
Data were reported as median (interquartile range) or mean (standard deviation) as ap-
propriate. Categorical data were reported as count (percentage). The Chi-square was used 
for comparison of groups. For comparison of the proportion of patients treated per volume 
category over time the Chi-square test for linear trend was used. For survival analysis, 
follow-up time was calculated from date of diagnosis until date of death or end of follow-
up. Patients who were alive at the end of follow-up were censored. Three and five-year 
survival rates were calculated by Kaplan-Meier analysis and comparisons between groups 
were made using log-rank tests. Multivariable Cox’s proportional hazards analysis was 
performed to analyse differences in overall survival according to hospital volume. Variables 
with p-values < 0.10 in the univariate analysis were included in the multivariable analysis. 
Only variables available for the whole study period were included in the multivariable 
analysis. Two sided p-values < 0.05 were considered statistically significant. 
ResulTs
16.154 patients underwent rectal cancer surgery and had a confirmed clinical T-stage, 
while in 6394 patients the cT-stage was unknown. The number of patients with an un-
known cT-stage was especially high in the first years and this decreased over the study 
period (55% in 2005 and 7% in 2013). Of those patients with a known cT-stage, 14.050 
patients (87%) had a cT1-3 tumour and 2.104 patients (13%) had a cT4 tumour. 
cT1-3 rectal cancer
The baseline characteristics of the 14.050 patients with cT1-3 rectal cancer are outlined in 
Table 1. The majority of these patients underwent surgery in medium volume hospitals (62%), 
followed by high volume hospitals (21%) and low volume hospitals (17%). An increase was 
seen in patients treated in high volume hospitals (2005-2007: 13% vs. 2011-2013: 23%, p 
< 0.001). Neoadjuvant chemoradiotherapy was administered more often to patients in high 
volume hospitals compared to medium volume and low volume hospitals (43% vs. 37% and 
32%, p < 0.001). High volume hospitals performed less abdominoperineal resections (31% 
vs. 34% vs. 35%, p = 0.002) and had a higher percentage of ypT0 stage (9% vs. 7% vs. 8%, 
P = 0.010). There was no difference in nodal stage and CRM-involvement. Patients treated in 
low volume hospitals received adjuvant chemotherapy less often (11% in high and medium 
volume hospitals compared to 8% in low volume hospitals, p < 0.001). 
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Total patients 2452 8708 2890
Gender
   Male 1526 (62) 5573 (64) 1824 (63) 0.25
   Female 926 (38) 3135 (36) 1066 (37)
Median age 67 67 67 0.10
year of diagnosis *
   2005-2007 685 (24) 1791 (63) 380 (13) < 0.001
   2008-2010 780 (16) 2985 (62) 1017 (21)
   2011-2013 987 (15) 3932 (61) 1493 (23)
neo-adjuvant treatment
  None 252 (10) 1007 (12) 280 (9) < 0.001
  Radiotherapy 1408 (57) 4448 (51) 1359 (47)
  Chemotherapy 7 (1) 48 (1) 16 (1)
  Chemoradiotherapy 785 (32) 3205 (37) 1235 (43)
Type of surgery
  LAR/Hartmann 1569 (64) 5575 (64) 1952 (68) 0.002
  APR 854 (35) 2980 (34) 892 (31)
  Proctocolectomy 12 (1) 65 (1) 27 (1)
  Not otherwise specified 17 (1) 88 (1) 19 (1)
Pathological tumour stage 0.01
   T0 190 (8) 648 (7) 269 (9)
   T1 183 (7) 627 (7) 209 (7)
   T2 824 (34) 2788 (32) 929 (32)
   T3 1174 (48) 4270 (49) 1384 (48)
   T4 50 (2) 191 (2) 57 (2)
   TX 31 (1) 184 (2) 42 (1)
Pathological nodal stage
  N0 1592 (65) 5519 (63) 1863 (64) 0.17
  N+ 835 (34) 3087 (36) 993 (35)
  NX 25 (1) 102 (1) 34 (1)
Pathological distant metastases
  M0 2381 (97) 8317 (96) 2767 (96) 0.002
  M+ 71 (3) 391 (4) 123 (4)
Tumour grade
  Well differentiated 70 (3) 259 (3) 168 (2) < 0.001





The median follow up was 31 months (IQR 15 – 54 months). The estimated 5-year survival 
rates of patients with cT1-3 rectal cancer who were treated in low, medium or high volume 
hospitals were similar (70%, 69%, 69% respectively; p = 0.88). Survival curves are shown 
in Figure 1. Univariate Cox regression analysis showed no significant difference in survival 
between different hospital volumes. Univariate hazard ratios for survival of medium and 
high volume hospitals compared to low volume hospitals were 1.01 (95% CI: 0.92 – 1.11) 
and 1.03 (95% CI: 0.92 – 1.16), respectively. 
cT4 rectal cancer
The baseline characteristics of 2.104 patients with cT4 rectal cancer are depicted in Table 
2. The majority of patients (60%) underwent surgery in low volume cT4 hospitals (1 - 4 
resections/year), followed by 25% in high volume hospitals (≥ 10 resections/year) and 15% 
in medium volume hospitals (5 - 9 resections/year). Eight hospitals performed less than one 
surgical procedure for cT4 rectal cancer per year on average (2005 - 2013). An increase 
was seen in patients treated in high volume hospitals (2005 - 2007: 21% vs. 2011 - 2013: 
28%, p = 0.03). There was an increase in referral of cT4 rectal cancer patients for resection 
to any other hospital from 23% in 2005 to 38% in 2013 (p = 0.003) (Figure 2a). CT4 
patients were most often referred by low volume hospitals, followed by medium and high 













Total patients 2452 8708 2890
  Poorly differentiated/
undifferentiated
161 (7)
532 (6) 159 (6)
  Unknown 1212 (49) 4451 (51) 1623 (56)
CRM-involvement #
   Involved 125 (7) 477 (7) 180 (7) 0.50
   Not involved 1292 (73) 4967 (72) 1779 (71)
   Unknown 349 (20) 1470 (21) 551 (22)
adjuvant chemotherapy 201 (8) 980 (11) 326 (11) < 0.001
LAR; Low anterior resection, APR, Abdominal perineal resection, CRM; Circumferential resection mar-
gin, *, percentages are calculated within years of diagnosis. #, CRM was reported in the database 
starting from 2008
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volume hospitals (Figure 2b) and most often referred to high volume hospitals, but also to 
medium volume hospitals and even to other low volume hospitals (Figure 2c).
Patients treated in high volume cT4 hospitals had a significantly lower age compared to 
medium and low volume hospitals (p < 0.001). The number of synchronously metastasized 
patients was significantly higher in high volume hospitals compared to low volume cT4 
hospitals (11% vs. 7%, p = 0.001) and was similar in medium cT4 hospitals (11% vs. 10%, 
p = 0.66). The percentage of patients who received neoadjuvant therapy was higher in high 
volume cT4 hospitals (98%) than in medium and low volume cT4 hospitals (respectively 
91% and 88%, p < 0.001). In high volume cT4 hospitals, 83% of the patients received 
chemoradiotherapy, compared to 70% in medium volume cT4 hospitals and 62% in low 
volume cT4 hospitals. The proportion of patients with a pathological T4-stage was higher 
in high volume hospitals compared to low volume hospitals (28% vs. 23%, p = 0.02). Low 
volume hospitals had the highest proportion of node positive patients: 41% compared to 
34% in both medium volume and high volume hospitals (p=0.04). 
In a subgroup analysis of the cT4 patients diagnosed between 2010 and 2013, more 
patients were staged cT4b in high volume hospitals compared to medium volume hospitals 
(82% vs. 70%, p = 0.007) and low volume hospitals (82% vs. 68% p < 0.001). However, 
there was no significant difference between the proportion of patients with pT4b stage 
in high volume hospitals compared to medium volume (20% vs. 22%, p = 0.86) or low 
volume hospitals, (20% vs 26%, p = 0.48). In the period 2008 - 2013, there was no 












Total patients 1.256 328 520
Gender
   Male 622 (50) 175 (53) 294 (57) 0.02
   Female 634 (50) 153 (47) 226 (43)
Median age 67 65 63 <0.001
year of diagnosis *
   2005-2007 433 (64) 102 (15) 142 (21) 0.03
   2008-2010 442 (59) 120 (16) 188 (25)
   2011-2013 381 (56) 106 (16) 190 (28)
neo-adjuvant treatment
















  Radiotherapy 308 (25) 53 (16) 58 (11)
  Chemotherapy 10 (1) 16 (5) 15 (3)
  Chemoradiotherapy 782 (62) 230 (70) 434 (83)
Type of surgery <0.001
  LAR/Hartmann 528 (42) 103 (31) 138 (27)
  APR 590 (47) 157 (48) 259 (50)
  Proctocolectomy 121 (10) 63 (19) 114 (22)
  Not otherwise specified 17 (1) 5 (2) 9 (2)
Pathological tumour stage
   T0 87 (7) 23 (7) 47 (9) 0.02
   T1 26 (2) 10 (3) 19 (4)
   T2 198 (16) 43 (13) 59 (11)
   T3 610 (49) 142 (43) 239 (46)
   T4 287 (23) 95 (29) 143 (28)
   TX 48 (4) 15 (5) 13 (3)
Pathological nodal stage
  N0 710 (57) 204 (62) 330 (64) 0.04
  N+ 512 (41) 113 (34) 179 (34)
  NX 34 (3) 11 (3) 11 (2)
Pathological distant 
metastases
  M0 1,174 (93) 294 (90) 461 (89) 0.001
  M+ 82 (7) 34 (10) 59 (11)
Tumour grade
  Well differentiated 34 (3) 6 (2) 18 (3) <0.001
  Moderately differentiated 455 (36) 87 (27) 147 (28)
  Poorly differentiated/
undifferentiated
116 (9)
25 (8) 38 (7)
  Unknown 651 (52) 210 (64) 317 (61)
CRM-involvement #
   Involved 160 (19) 45 (20) 63 (17) 0.58
   Not involved 466 (57) 131 (58) 213 (56)
   Unknown 197 (24) 50 (22) 102 (27)
adjuvant chemotherapy 172 (14) 52 (16) 54 (10) 0.05
LAR; Low anterior resection, APR, Abdominal perineal resection, CRM; Circumferential resection mar-
gin, *, percentages are calculated within years of diagnosis. #, CRM was reported in the database starting 
from 2008
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signifi cant difference in CRM-involvement between high, medium and low volume cT4 
hospitals (respectively 19%, 20%, 17%, p = 0.58). 
Outcomes
There was no difference in 30-days mortality and 90-days mortality according to hospital 
volume. Patients were followed with a median of 33 (IQR 16 - 60) months. The estimated 
overall survival of cT4 patients treated in high volume cT4 hospitals was signifi cantly longer 
than in medium and low volume cT4 hospitals (p =0 .001). The estimated 3-year survival 
rate was 76%, 71% and 67% respectively and the 5-year survival rate was 63%, 53% 
and 54% respectively (Figure 3). Multivariable analysis demonstrated that resection in high 
volume cT4 hospitals was independently associated with a better overall survival compared 
to low volume cT4 hospitals (HR 0.81, 95% CI 0.67-0.98), after adjusting for patient/
tumour related confounders (age, pTNM-stage and tumour differentiation) (Table 3). When 
treatment related confounders were included in the multivariate analysis, neoadjuvant 
chemoradiotherapy was associated with improved survival. Adjustment for neoadjuvant 
therapy resulted in the disappearance of a signifi cant difference between high, medium 
and low volume hospitals. 




figure 2a. Referral of cT4 rectal cancer patients for resection
figure 2b. Volume of hospital of diagnosis of the referred patients 
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figure 3. Overall survival of cT4 rectal cancer according to the cT4 hospital volume




Table 3. Univariate and multivariable survival analysis for overall survival of cT4 tumours with and with-

















hospital volume (procedure 
per year)
<0.001
   1-4 1 1 1
   5-9 0.93 (0.76-1.14) 0.97 (0.79-1.19) 0.99 (0.81-1.22)
   ≥10 0.71 (0.59-0.85) 0.81 (0.67-0.98) 0.87 (0.71-1.05)
Gender 0.98
   Male 1 - -
   Female 1.00 (0.87-1.15) - -
age 1.03 (1.02-1.04) <0.001 1.03 (1.03-1.04) 1.03 (1.02-1.04)
year of diagnosis 0.98 (0.95-1.02) 0.32
neo-adjuvant therapy <0.001
   None 1 -
   Radiotherapy 0.58 (0.46-0.73) - 0.70 (0.54-0.88)
   Chemotherapy 0.59 (0.35-0.97) - 0.69 (0.41-1.17)
  Chemoradiotherapy 0.32 (0.26-0.39) - 0.53 (0.42-0.68)
Type of surgery 0.02
   LAR/Hartmann 1 - 1
   APR 0.81 (0.69-0.95) - 0.99 (0.84-1.17)
   Proctocolectomy 0.95 (0.78-1.16) - 0.95 (0.77-1.18)
  Not otherwise specified 1.42 (0.83-2.43) - 1.47 (0.85-2.53)
Pathological tumour stage
   T0 1 <0.001 1 1
   T1 0.89 (0.35-2.24) 0.92 (0.37-2.32) 0.87 (0.35-2.21)
   T2 2.02 (1.20-3.39) 1.84 (1.09-3.10) 1.75 (1.04-2.94)
   T3 3.57 (2.22-5.72) 2.73 (1.69-4.41) 2.53 (1.56-4.09)
   T4 5.89 (3.65-9.50) 4.30 (2.65-6.99) 3.89 (2.38 (6.37)
   TX 2.64 (1.46-4.78) 2.50 (1.38-4.56) 2.42 (1.33-4.41)
Pathological nodal stage <0.001
   N0 1 1 1
   N1 1.64 (1.38-1.95) 1.34 (1.12-1.61) 1.32 (1.10-1.58)
   N2 2.74 (2.29-3.28) 2.06 (1.71-2.49) 1.95 (1.61-2.36)







The current population-based study found an overall survival benefit for cT4 rectal cancer 
patients treated in high volume cT4 hospitals compared to low volume cT4 hospitals. This 
overall survival difference related to hospital volume was not found in cT1-3 rectal cancer. 
Patients with locally advanced (cT4) rectal cancer treated in high volume hospitals (≥ 10 
resections/year) had a significantly improved 5-year overall survival of 63% compared to 
53% in low volume (1 - 4 resections) and 54% in medium volume cT4 hospitals (5 - 9 
resections), when corrected for patient and tumour related confounders, but this differ-
ence disappeared after adjustment for neoadjuvant therapy. The referral of cT4 tumours to 
high volume hospitals has increased during the study period, but in the period 2011-2013, 
the majority of patients (56%) were still treated in a low volume cT4 hospital.
Patients with cT1-3 rectal cancer are suitable candidates for a standard TME procedure, 
although beyond TME surgery is sometimes required if the mesorectal fascia is involved. 
Standard TME in patients with close tumour contact to the mesorectal fascia (cT4 or 
cT3MRF+/) often leads to incomplete resections (R1/2-resections).(14) Incomplete resec-
tions are deleterious for oncological outcome and all efforts should be aimed at avoiding 
R1/2-resections.(15) The advanced stages of rectal cancer have the greatest benefit of 
Table 3. Univariate and multivariable survival analysis for overall survival of cT4 tumours with and with-


















  M0/X 1 <0.001 1 1
  M+ 2.14 (1.71-2.67) 2.12 (1.68-2.69) 1.99 (1.56-2.52)
Tumour grade <0.001
  Well differentiated 0.93 (0.62-1.42) 1.04 (0.69-1.60) 1.11 (0.73-1.69)
  Moderately differentiated 1 1 1
  Poorly differentiated/
undifferentiated
1.66 (1.32-2.09) 1.49 (1.18-1.88)
1.47 (1.16-1.86
  Unknown 0.83 (0.71-0.97) 1.01 (0.86-1.19) 1.14 (0.96-1.35)
Adjuvant chemotherapy
   No 1 - -
   Yes 1.06 (0.87-1.30) 0.54 - *




multimodality treatment, including neoadjuvant chemoradiotherapy, which potentially 
leads to tumour shrinkage, more complete resections and reduces local recurrence rates.
(3, 8) Accurate staging of the rectal tumour is essential in selecting patients who should be 
treated with neoadjuvant therapy, and to differentiate between those who can be treated 
by a standard TME procedure and those who require beyond TME surgery. The quality 
of this assessment may be enhanced by multidisciplinary tumour board meetings (MDT), 
including dedicated radiologists, radiation oncologists, medical oncologists and surgeons. 
Nowadays, almost all rectal cancer patients in the Netherlands undergo MRI staging of 
the primary tumour and are discussed in an MDT.(2) In an experienced MDT, cT4 tumours 
are potentially more accurately assessed and a more appropriate neoadjuvant and surgical 
strategy may be selected. This may explain why more patients in low volume hospitals 
did not receive chemoradiotherapy despite the clear indication for chemoradiotherapy. 
Furthermore, in experienced MDTs, standardized care for patients with advanced stages 
of rectal cancer may result in an improved long-term outcome. Other legitimate reasons 
for refraining from chemoradiotherapy in low or medium volume centres including patient 
factors, such as comorbidities, age or patient preference, cannot be retrieved form the 
NCR. 
Several studies have reported survival differences according to hospital volume in complex 
surgical procedures in other malignancies, such as oesophagus, pancreas and bladder 
cancer.(16-18) The hypothesis of this survival benefit is that more exposure and experience 
in the multimodality treatment (staging, induction therapy and surgical expertise) of these 
relatively rare malignancies results in an improved long-term outcome.(16-18) In line with 
the findings of studies in other malignancies, the current study showed a survival benefit 
in the treatment of cT4 rectal cancer in high volume cT4 hospitals, but not in the more 
common cT1-3 rectal tumours. A previously published Dutch population based study in 
a smaller cohort described no differences in long-term oncological outcomes for rectal 
cancer (cT1-4) based on hospital volume, but no separate analysis for cT4 rectal cancers 
were performed.(19)
Presumably, the overall survival benefit of cT4 rectal cancer in high volume cT4 hospitals 
is caused by multiple factors. Optimal staging, neoadjuvant therapy, surgical treatment 
differences and experience of the MDT may lead to superior selection, treatment and 
results when optimally combined. Optimal staging may result in the selection of appropri-
ate neoadjuvant treatment. Experience with extensive rectal resections in high volume 
hospitals may contribute, but did not lead to a lower percentage of CRM-involvement 
in high volume cT4 hospital compared to medium and low volume cT4 hospital in the 
years evaluated. This may partly be explained by referral of patients with more advanced 
tumours to high volume cT4 hospitals, which explains the higher pathological stage (pT4) 
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in high volume cT4 hospitals compared to low volume hospitals, regardless of the higher 
percentage of neoadjuvant therapy administered. In a subgroup analysis the proportion of 
pT4b tumours was higher in high volume hospitals compared to medium and low volume 
hospitals (26% vs. 22% vs 20%), but not significantly so. Even in an experienced high 
volume hospital, radical resection of cT4b tumours is challenging and referral of these 
patients to high volume hospitals could offer an explanation for similar CRM involvement 
in different volume hospitals. Our data cannot prove this referral pattern. Moreover, a 
difficult resection does not automatically translate in a pT4b stage, especially since most 
patients undergo neoadjuvant chemoradiotherapy. The number of multivisceral resections 
per hospital may also provide an indication of the complexity and difficulty of the proce-
dures performed in different volume hospitals. The NCR, however, started gathering data 
on multivisceral resections since 2010 only. Secondly, multivisceral resections were not 
registered as such in the Dutch registry of surgical procedures resulting in a large amount 
of missing data with regard to this variable. In addition, the availability of intraoperative 
radiotherapy (IORT) may have contributed to the survival benefit is. High volume cT4 hos-
pitals in the Netherlands have the ability to apply an extra radiation dose during surgery. 
IORT may eradicate remaining tumour cells and this may lead to a survival benefit.(20, 
21) Unfortunately, IORT was not comprehensively registered in the NCR making further 
evaluation of the role of IORT impossible. 
The relatively high CRM-involvement (17%) in cT4 rectal cancer patients treated in high 
volume hospitals in our study suggests that even in high volume hospitals there is room 
for improvement. A more recent cohort by Jonker et al. (22) on perioperative outcomes 
for cT1-3 and cT4 rectal cancer by hospital volumes did find a significantly higher rate of 
irradical resections for cT4 rectal cancer in low volume hospitals compared to medium and 
high volume hospitals, and therefore advocates that centralization may be beneficial for 
cT4 patients. Further centralization leading to an increase in the number of patients treated 
in high volume hospitals could further improve treatment in these centres, and eventually 
result in a higher percentage of clear margins, a decrease in local recurrence rates and an 
increase in overall survival. The total number of cT4 rectal cancer diagnosed annually in the 
Netherlands (approximately 250) is limited. The appointment of 4 or 5 cT4 rectal cancer 
centres would seem appropriate and result in an adequate number of patients in special-
ized centres. Excluding cT4 rectal cancer from the required total number of rectal cancer 
procedures per hospital may eliminate the stimulus to treat these patients in hospitals 
without T4 rectal cancer experience.
Due to its retrospective nature, this study has limitations. Patients referred to high volume 
centres for extensive surgery were younger, and probably in a relatively good clinical condi-




the number of metastasized patients was higher in high volume cT4 hospitals, suggesting 
that advanced stages of disease were referred to high volume cT4 hospitals, which would 
decrease overall survival in these patients. This type of discussion on the profile of patient 
groups in different hospitals is often referred to as the ‘case mix’ discussion. Unfortunately, 
for reasons described earlier, we cannot conclude whether ‘case mix’ is the driver behind 
the differences that we did and did not find. 
In conclusion, hospital volume was not associated with overall survival after surgery for 
cT1-3 rectal cancer. The treatment of cT4 rectal cancer in high volume cT4 hospitals was as-
sociated with an improved survival compared to low volume cT4 hospitals when corrected 
for patient and tumour related confounders. This association was no longer statistically 
significant after correction for neoadjuvant treatment, but the omission of neoadjuvant 
treatment in cT4 rectal cancer may also reflect lower quality of care. There was a small 
increase in referral of cT4 rectal cancer to high volume cT4 hospitals, but further centraliza-
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The purpose of this study was to investigate the impact of hospital volume on perioperative 
outcomes of clinical tumour stage (cT)1-3 rectal and cT4 rectal cancer.
Methods
16.162 patients operated for rectal cancer enrolled in the Dutch Surgical Colorectal Audit 
were included. Hospitals were divided into low (< 20 cases/year), medium (21-50 cases/
year) and high (> 50 cases/year) volume for cT1-3 rectal cancer, and for cT4 rectal cancer 
into low (1-4 cases/year), medium (5-9 cases/year) and high (≥ 10 cases/year) volume. The 
influence of hospital volume on perioperative outcomes was investigated. 
Results
With regards to cT1-3 tumours, low volume hospitals had lower rates of complications 
(33.8% vs. 36.6% and 38.1%, p = 0.009), anastomotic leakage (5.4% vs. 8.1% and 
8.6%), and reintervention (11.5% vs. 12.6% and 14.8%, p = 0.002) as compared to 
medium and high volume hospitals. Thirty-day mortality and R0 rates were comparable 
between groups. 
In high cT4 volume hospitals, rates of extensive resection of tumour involvement (49.4% 
vs. 25.4% and 15.5%, p < 0.001) and additional resection of metastasis (17.5% vs. 14.4% 
and 3.0%, p < 0.001) were increased as compared to medium and low volume hospitals. 
Thirty-day mortality and R0 rates were comparable between groups. In a sub-analysis of 
pathologic tumour stage 4 patients, irradical resections were increased in low volume 
hospitals (33.8% vs. 22.5% and 20.8% in medium and high volume hospitals, p = 0.031).
Conclusions
For cT4 rectal cancer, high volume hospitals may offer a better multimodality treatment, 





The introduction of standardized total mesorectal excision (TME) and neoadjuvant thera-
pies has led to improved oncological results after low anterior resection (LAR) for rectal 
cancer.(1, 2) The primary goal of surgical treatment of rectal cancer is to achieve a radical 
resection (R0) since a positive circumferential resection margin (CRM) is a poor prognostic 
factor, associated with local recurrence, distant metastasis, and inferior survival after rectal 
cancer surgery.(3, 4) Generally, neoadjuvant (chemo) radiotherapy is administered for the 
more advanced stages of rectal cancer, to induce tumour shrinkage to facilitate complete 
resections and reduce local recurrence rates.(5, 6) Neoadjuvant treatment is usually not 
necessary for lower stages of rectal cancer, which can be treated by standard TME proce-
dures or even rectal sparing surgery in selected patients.(5, 6, 7) The most advanced stage 
of rectal cancer, including clinically staged 4 tumours (cT4) invading the mesorectal fascia 
and/or surrounding organs, often require an induction treatment for tumour downsizing 
and a more radical surgical approach to achieve a complete resection. These procedures, 
such as extralevatory abdominoperineal resections (APR) and exenterative procedures, 
require a more complex surgical dissection beyond the standard TME plane.(8) 
In order to further improve the outcome of rectal cancer, the current Dutch standard 
indicates an overall minimum of 20 rectal resections annually per hospital, irrespective of 
the tumour stage. In addition, the Dutch guideline recommends centralization of care for 
patients with advanced stages of rectal cancer in specialized colorectal cancer hospitals.(9) 
The impact of hospital volume on surgical outcomes after rectal cancer surgery are under 
debate. A recent population-based study revealed no differences in 5-year survival rates 
between hospital volumes for patients with colorectal cancer; however, outcomes were 
not stratified for rectal cancer, nor for tumour stage.(10) Little is known regarding the exact 
effects of hospital volume on different cT1-T4 stages of rectal cancer. The purpose of this 
study was to evaluate the impact of hospital volume on surgical resection and perioperative 
outcomes of cT1-3 rectal cancer and cT4 rectal cancer using data from a national registry.
MeThods
dsCa
All patients undergoing resection of colorectal cancer in the Netherlands are since 2009 
registered in the Dutch Surgical Colorectal Audit (DSCA). The DSCA was initiated by the 
Dutch Surgical Society to monitor and improve the quality of oncological care in colorectal 
cancer patients on a national level.(11) Nowadays, all 92 Dutch hospitals participate in 
the DSCA and its data shows a nearly 100% concordance on validation against the Na-
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tional Cancer Registry dataset.(12) Data on patient and tumour characteristics, diagnostics, 
treatment and short term outcome were collected. Medical ethics committee approval 
was not required for this study as all patients and hospital information in the DSCA was 
de-identified. Individual patient data were collected in the treating hospital and transferred 
in encrypted form to the DSCA database. 
Patient selection
All patients operated for rectal cancer, defined as a tumour within 15 cm of the anal verge, 
enrolled in the DSCA between January 2009 and December 2015 were included. Overall, 
19.354 patients with presumed rectal cancer were enrolled in the DSCA. After exclud-
ing tumours > 15 cm of the anal verge, those with unknown distance between tumour 
and anal verge, unknown procedures, or other procedures than rectal cancer surgery (i.e. 
left-sided colectomy), 17.477 patients remained. After excluding tumours with unknown 
clinical tumour stage, 16.162 patients remained. 
Patients with cT1-3 tumours were stratified based on median annual cT1-3 hospital vol-
ume, which was defined as low volume (0-19 cases/year), medium volume (20-50 cases/
year) or high volume (> 50 cases/year). In addition, cT4 tumours were stratified based on 
median annual cT4 hospital volume, which was defined as low volume (0-4 cases/year), 
medium volume (5-9 cases/year), or high volume (> 9 cases/year). Subsequently, baseline 
and operative characteristics, pathologic and postoperative outcomes were compared 
between cT1-3 hospital volume groups, and cT4 hospital volume groups. 
data analysis
Missing data were not defaulted to negative and denominators reflect only actual reported 
cases. Nominal variables were compared between groups using the Chi-square test, con-
tinuous variables using the One-Way ANOVA test. Multivariable regression analysis was 
performed to investigate independent effects of hospital volume on a complicated course 
after resection of cT4 rectal cancer. Hospital volume and variables that were significant in 
univariable analysis (p < 0.05), were included in a multivariable logistic regression model 
to determine independent associations with this endpoint. SPSS 22 was utilized for the 
analyses, and a P value < 0.05 was considered significant. The STROBE guidelines were 
used to ensure the reporting of this observational study.(13)
ResulTs
Overall, 14.651 patients (90.7%) had clinical tumour stage 1, 2 or 3, of which 3.210 




medium volume hospitals, and 2.711 patients (18.5%) were operated in 8 high volume 
hospitals. In addition, there were 1.511 (9.3%) patients with clinical tumour stage 4 (cT4), 
of which 759 (50.2%) were operated in 72 low volume hospitals; 336 (22.2%) were oper-
ated in 8 medium volume hospitals, and 416 (27.5%) were operated in 3 high volume 
hospitals.
Clinical tumour stage 1-3
Baseline and operative characteristics
Fewer cT1-3 patients underwent neoadjuvant therapy in high volume hospitals (72.7% 
vs. approximately 75% in medium and high volume hospitals, p = 0.026). Clinical tumour 
stage 3 was more common in medium volume hospitals, while clinical nodal stage 0 was 
more frequently seen in low volume hospitals (p < 0.001). An abdominoperineal resec-
tion was more often performed in medium (28.1%) and high volume hospitals (27.8%) 
as compared to low volume hospitals (26.4%, p < 0.001). A laparoscopic approach was 
slightly more common in low volume hospitals, while resection of synchronous metastases 
was more frequently performed in medium volume hospitals (Table 1).
Postoperative outcomes
In high volume hospitals, pathologic tumour stage 3 was more often found. A radical 
resection was achieved in 96.7% and did not differ significantly between the three volume 
groups (Table 2). A complicated course was more often seen in high volume hospitals 
(38.1% vs. 33.8% and 36.6% in low and medium volume hospitals, respectively, p = 
0.009). Reintervention including (re)laparotomy were more frequently performed in high 
volume hospitals (14.8% vs, 11.5% and 12.6% in low and medium hospitals (p = 0.002). 
Anastomotic leakage after LAR was lower in low volume hospitals (5.4% vs. 8.1% and 
8.6% in medium and high volume hospitals, respectively, p = 0.001). The overall 30-day 
mortality rate was 1.9% and did not differ significantly between groups, while the median 
length of stay was one day longer in high volume hospitals (Table 2). 
Clinical tumour stage 4
Baseline and operative characteristics
Mean age of cT4 patients was lower in high volume hospitals and these were less fre-
quently classified as ASA 3 or 4, but more often discussed in multidisciplinary tumour 
board (MDT) meetings preoperatively (Table 3). Overall, neoadjuvant therapies were less 
frequently offered in high volume hospitals, while cT4 patients did receive more often 
chemoradiotherapy in these clinics (69.2% vs. 66.4% and 65.0% in low and medium 
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Age (y) 68.1±10.7 67.1±10.7 67.5±10.4 <0.001
Male gender 2030 (63.3%) 5674 (65.0%) 1740 (64.2%) 0.195
BMI 26.3±4.1 26.3±4.1 26.2±4.1 0.673
Medical history
   Cardiac 719 (31.1%) 1934 (32.0%) 597 (30.6%) 0.633
   Vascular 1153 (51.4%) 3153 (52.1%) 1010 (51.7%) 0.832
   Pulmonal 409 (18.3%) 1017 (16.9%) 341 (17.5%) 0.125
   Diabetes 446 (20.0%) 1197 (19.8%) 358 (18.3%) 0.159
   Neurologic 340 (15.2%) 1011 (16.8%) 325 (16.6%) 0.222
ASA class 3 or 4 584 (18.4%) 1366 (15.7%) 459 (16.9%) 0.001
MDT meeting preoperative 3080 (96.0%) 8464 (97.1%) 2631 (97.1%) <0.001
Neoadjuvant therapy 2392 (75.3%) 6555 (75.2%) 1964 (72.7%) 0.026
   Short-course (5x5 Gy) 1468 (46.2%) 3433 (39.6%) 1169 (43.3%)
   Long-course 107 (3.4%) 261 (3.0%) 46 (1.7%)
   Chemoradiotherapy 816 (25.7%) 2803 (32.4%) 746 (27.7%) <0.001
cT stage
   cT1 160 (5.0%) 475 (5.4%) 173 (6.4%)
   cT2 965 (30.1%) 2226 (25.5%) 908 (33.5%)
   cT3 2085 (65.0%) 6029 (69.1%) 1630 (60.1%) <0.001
cN stage
   cN0 1585 (51.9%) 3889 (46.6%) 1180 (44.7%)
   cN1 1043 (34.2%) 2784 (33.3%) 961 (36.4%)
   cN2 426 (13.9%) 1677 (20.1%) 498 (18.9%) <0.001
cM1 102 (3.8%) 624 (7.2%) 156 (5.8%) <0.001
Distance to anal verge (cm) 7.5±4.1 7.3±4.2 7.4±4.2 0.079
Operative characteristics
   LAR 1701 (53.1%) 4436 (50.8%) 1399 (51.6%)
   Low Hartmann 604 (18.8%) 1504 (17.2%) 445 (16.4%)
   APR 847 (26.4%) 2453 (28.1%) 753 (27.8%)
   Different 54 (1.7%) 332 (3.8%) 114 (4.2%) <0.001
Elective resection 3132 (97.6%) 8610 (98.7%) 2674 (98.7%) <0.001
Laparoscopic 2018 (63.1%) 5171 (59.3%) 8891 (60.8%) <0.001
Additional resection metastasis 23 (0.7%) 265 (3.1%) 43 (1.7%) <0.001
Blood transfusion needed 297 (9.6%) 921 (11.0%) 200 (7.7%) <0.001
BMI: body mass index; ASA: American Society of Anaesthesiologists; MDT meeting: multidisciplinary tumour 
board meeting; LAR: low anterior resection; low Hartmann: LAR with end-colostomy; APR: abdominoperineal 




volume hospitals, p < 0.001). Clinical nodal stage 0 was more frequently seen in low 
volume hospitals, while synchronous metastasis was less common (Table 3). 
An abdominoperineal resection was less frequently performed in low volume hospitals, 
while laparoscopic resection of cT4 rectal cancer was more common in these centres 
(52.2% vs. 32.7% and 0.2% in medium and high volume hospitals, respectively, p < 0.001). 
Additional extensive resection of suspected tumour involvement of cT4 rectal cancer was 
performed in 49.4% in high volume hospitals, as compared to 25.4% in medium volume 
hospitals and 15.5% in low volume hospitals (p < 0.001). Additional resection of metas-
tasis was more frequently performed as well in high volume hospitals (17.5% vs. 14.4% 
and 3.0% in medium and low volume hospitals, respectively, p < 0.001). Intra-operative 
radiotherapy was used more often as well for cT4 patients in high volume hospitals (Table 3).












    pT0 198 (6.3%) 576 (6.8%) 139 (5.3%)
    pT1 297 (9.5%) 930 (10.9%) 275 (10.5%)
    pT2 1124 (36.0%) 2811 (33.0%) 893 (34.0%)
    pT3 1446 (46.3%) 3989 (46.9%) 1265 (48.2%)
    pT4 61 (2.0%) 206 (2.4%) 53 (2.0%) 0.007
Pathologic lymph node stage
    pN0 2112 (67.4%) 5471 (65.7%) 1706 (66.0%)
    pN1 727 (23.2%) 1931 (23.2%) 601 (23.3%)
    pN2 293 (9.4%) 927 (11.1%) 276 (10.7%) 0.099
R0 resection   3025 (96.6%) 8063 (96.6%) 2463 (97.0%)
Irradical resectiona 107 (3.4%) 283 (3.4%) 77 (3.0%) 0.647
Any complication 1079 (33.8%) 3141 (36.6%) 1018 (38.1%) 0.009
    Respiratory complication 116 (4.0%) 349 (4.4%) 110 (4.5%) 0.547
    Cardiac complication 81 (2.1%) 217 (2.8%) 66 (2.7%) 0.985
Reinterventionb 308 (11.5%) 886 (12.6%) 315 (14.8%) 0.002
(re)laparotomy 170 (7.0%) 420 (6.6%) 168 (8.6%) 0.001
    Anastomotic leakage 78 (5.4%) 300 (8.1%) 96 (8.6%) 0.001
    Other intra-abdominal 
abscess
59 (2.2%) 141 (2.0%) 55 (2.6%) 0.257
    Ileus 44 (1.6%) 117 (1.7%) 22 (1.0%) 0.110
30-day or in-hospital mortality 62 (1.9%) 173 (2.0%) 49 (1.8%) 0.107
Length of stay (d) 8 (IR 7) 8 (IR 7) 7 (IR 8) <0.001
a Irradical resection includes both R1 and R2 resections (microscopically and macroscopically positive resection 
margins). 
b Reintervention includes both radiologic as surgical reintervention.
68











Age (y) 67.1±11.0 65.2±12.0 63.3±11.1 <0.001
Male gender 376 (49.5%) 179 (53.3%) 231 (55.5%) 0.126
BMI 25.6±4.6 25.1±4.2 25.2±4.5 0.076
Medical history
   Cardiac 117 (22.8%) 51 (22.0%) 62 (23.8%) 0.885
   Vascular 272 (52.7%) 112 (47.7%) 130 (49.8%) 0.290
   Pulmonal 97 (18.9%) 43 (18.6%) 43 (16.5%) 0.802
   Diabetes 117 (22.8%) 49 (21.2%) 57 (21.9%) 0.889
   Neurologic 92 (17.9%) 36 (15.6%) 29 (11.1%) 0.048
ASA class 3 or 4 149 (19.8%) 58 (17.3%) 58 (13.9%) 0.042
MDT meeting preoperative 734 (96.7%) 329 (97.9%) 414 (99.5%) 0.033
Neoadjuvant therapy 674 (89.4%) 294 (88.0%) 349 (84.3%) 0.040
   Short-course (5x5 Gy) 127 (17.1%) 52 (15.8%) 31 (7.5%)
   Long-course 43 (5.8%) 23 (7.0%) 31 (7.5%)
   Chemoradiotherapy 494 (66.4%) 214 (65.0%) 285 (69.2%) <0.001
Tumour characteristics
   cN0 202 (28.8%) 46 (14.5%) 73 (18.0%)
   cN1 278 (39.7%) 83 (26.2%) 135 (33.3%)
   cN2 221 (31.5%) 188 (59.3%) 197 (48.6%) <0.001
   cM1 89 (11.8%) 57 (17.4%) 76 (18.4%) <0.001
Distance to anal verge (cm) 6.1±4.7 5.7±4.6 6.2±4.6 0.268
Surgical procedures
   LAR 223 (29.4%) 68 (20.3%) 118 (28.4%)
   Low Hartmann 176 (23.2%) 66 (19.7%) 48 (11.5%)
   APR 355 (46.8%) 197 (58.8%) 247 (59.4%)
   Different 5 (0.7%) 4 (1.2%) 3 (0.7%) <0.001
Laparoscopic 396 (52.2%) 109 (32.7%) 1 (0.2%) <0.001
Intraoperative radiotherapy 0 (0.0%) 4 (1.4%) 56 (24.9%) <0.001
Additional resection tumour involvementa <0.001
   None 523 (71.0%) 195 (58.2%) 138 (34.0%)
   Limited resection 100 (13.6%) 55 (16.4%) 62 (15.7%)
   Extensive resection 114 (15.5%) 85 (25.4%) 195 (49.4%) <0.001
Additional resection metastasis 23 (3.0%) 48 (14.4%) 73 (17.5%) <0.001
Blood transfusion needed 111 (14.8%) 87 (26.6%) 212 (51.0%) <0.001
BMI: body mass index; ASA: American Society of Anaesthesiologists; MDT meeting: multidisciplinary tumour board 
meeting; LAR: low anterior resection; low Hartmann: LAR with end-colostomy; APR: abdominoperineal resection. 
Different surgical procedures included local resection procedures and proctocolectomy. 
a Extensive additional resection of tumour involvement included typically total or partial exenterative procedures, while 





Pathologic tumour stage 4 was more often found in high volume hospitals (32.6% vs. 
21.3% and 25.9% in low and medium hospitals, respectively, p < 0.001), while the overall 
rate of a radical resection did not differ between groups (Table 4). In a sub-analysis of pT4 
patients, irradical resections were seen in 33.8% in low volume hospitals, as compared to 
22.5% and 20.8% in medium and high volume hospitals (p = 0.031). 
A complicated course after resection of cT4 rectal cancer occurred in 50.8% in high 
volume hospitals, as compared to 44.9% in medium volume hospitals and 21.3% in low 












    pT0 66 (9.0%) 24 (7.4%) 35 (8.6%)
    pT1 29 (4.0%) 8 (2.5%) 10 (2.5%)
    pT2 159 (21.7%) 58 (17.9%) 43 (10.6%)
    pT3 323 (44.1%) 150 (46.3%) 185 (45.7%)
    pT4 156 (21.3%) 84 (25.9%) 132 (32.6%) <0.001
Pathologic lymph node stage
    pN0 480 (65.3%) 196 (60.3%) 936 (64.0%)
    pN1 160 (21.8%) 77 (23.7%) 99 (24.6%)
    pN2 95 (12.9%) 52 (16.0%) 44 (10.9%) 0.243
pM1 94 (13.3%) 57 (18.2%) 76 (19.6%) 0.014
Overall R0 resection 659 (89.1%) 292 (89.3%) 365 (88.4%)
Overall irradical resectiona 81 (10.9%) 35 (10.7%) 48 (11.6%) 0.912
     pT4 R0 resection 100 (66.2%) 62 (77.5%) 103 (79.2%)
     pT4 irradical resection 51 (33.8%) 18 (22.5%) 27 (20.8%) 0.031
Any complication 294 (38.9%) 151 (44.9%) 211 (50.8%) 0.002
    Respiratory complication 42 (6.0%) 10 (3.4%) 32 (8.5%) 0.026
    Cardiac complication 12 (1.7%) 10 (3.4%) 15 (4.0%) 0.068
Reinterventionb 88 (14.1%) 26 (10.5%) 41 (13.4%) 0.364
(re)laparotomy 39 (7.1%) 15 (7.1%) 22 (9.0%) 0.492
    Anastomotic leakage 12 (6.6%) 1 (1.9%) 3 (3.2%) 0.258
    Other intra-abdominal abscess 31 (5.0%) 7 (2.8%) 14 (4.6%) 0.378
    Ileus 10 (1.6%) 4 (1.6%) 1 (0.3%) 0.230
30-day or in-hospital mortality 12 (1.6%) 2 (0.6%) 9 (2.2%) 0.214
Length of stay (d) 8 (IR 8) 9 (IR 8) 10 (IR 8) <0.001
a Irradical resection includes both R1 and R2 resections (microscopically and macroscopically positive resection 
margins). 
b Reintervention includes both radiologic as surgical reintervention.
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volume hospitals (p = 0.002). The 30-day mortality rate was 1.6% in low volume hospitals, 
0.6% in medium volume hospitals and 2.2% in high volume hospitals (p = 0.214), and 
reintervention did not differ significantly between groups as well. 
In multivariate analysis, ASA class 3 or 4, extensive resection of tumour involvement, and 
abdominoperineal resection were associated with increased risks of complications, while 
female gender was associated with lower risk of complications. Hospital volume did not 
significantly affect the risk of complications (Table 5).
disCussion
In this nationwide analysis, perioperative outcomes of cT1-3 rectal cancer surgery were 
not superior in high volume hospitals as compared to medium or low volume hospitals. 
With regards to cT4 rectal cancer, high volume hospitals performed more extensive surgical 
treatment of primary tumour and metastases, with similar perioperative outcomes. In case 
of pT4 rectal cancer, low volume was associated with increased rates of irradical resection.
Approximately 90% of rectal cancer resections in the Netherlands were performed for cT1-
3 tumours, which usually can be treated by standard TME procedures or even local excision 
in selected cases.(7) Risks of complications, anastomotic leakage, and reintervention were 
slightly decreased in lower volume hospitals after surgery for cT1-3 rectal cancer, while 
Table 5. Predictors of a complicated course after resection of cT4 rectal cancer in multivariate analysis
Variable Odds ratio 95%CI P value
Female gender 0.60 0.46-0.79 <0.001
Cardiac co-morbidity 1.31 0.95-1.82 0.105
ASA class 3 or 4 1.47 1.07-2.02 0.019
pT4 1.36 0.98-1.88 0.070
Laparoscopic approach 0.92 0.67-1.27 0.598
APRa 1.40 1.07-1.84 0.015
Extensive resection of tumour involvement 1.60 1.14-2.26 0.007
Additional resection metastasis 1.31 0.82-2.08 0.253
Hospital volumeb
    Low volume (0-19) 1.00 - -
    Medium volume (20-50) 1.09 0.77-1.54 0.618
    High volume (>51) 1.30 0.89-1.90 0.169
ASA: American Society of Anaesthesiologists.
a APR: abdominoperineal resection; low anterior resection or low Hartmann procedure was used as reference 
category. 




the rate of irradical resection and 30-day mortality were similar for the different volume 
groups. Therefore, it appears that further centralizing the care by increasing the minimal 
numbers to treat per centre may not be needed for patients without locally advanced 
disease in case of proper protocols, MDT meetings and regional networks. 
In patients with tumour invasion through the mesorectal fascia (cT4), more radical pro-
cedures than standard TME surgery is needed in order to achieve R0-resections. These 
surgical procedures beyond the TME planes are less straightforward and more technically 
demanding compared to cT1-3 rectal cancer.(8) In addition, the advanced stages of rectal 
cancer have the greatest benefit of a multimodality treatment, including neoadjuvant 
chemoradiotherapy, to facilitate complete resections and reduce local recurrence rates.(5, 
6) Accurate staging of the rectal tumour by a dedicated MDT is essential to select those 
patients who should be treated with neoadjuvant therapy, and to assess what kind of 
surgical approach is needed. 
We observed that in high cT4 volume hospitals, patients were more often discussed pre-
operatively in a MDT meeting and rates of neoadjuvant chemoradiotherapy were higher. It 
remains unclear why preoperative chemoradiotherapy was less frequently adopted for cT4 
rectal cancer in low and medium volume hospitals, possibly this was related to inadequate 
preoperative staging. Generally, in order to facilitate adequate preoperative staging and 
optimal neoadjuvant treatment, all rectal cancer patients should be discussed preopera-
tively in a MDT meeting. Patients in medium or high cT4 volume hospitals underwent more 
abdominoperineal resections, and additional resection of tumour involvement outside 
of the mesorectal fascia was more often needed, as compared to low volume hospitals. 
Intraoperative radiotherapy and resection of metastasis were performed more frequently 
as well. High volume hospitals performed less laparoscopic cT4 resections, which may 
suggest more advanced tumour stages in these hospitals. Pathologic examination revealed 
more frequently pT4 in high volume hospitals, while R0 rates were similar between low, 
medium and high volume hospitals. In a sub-analysis of pT4 patients, the rate of irradical 
resection was significantly increased in low volume hospitals (34%). To our knowledge, this 
is the first study evaluating pathologic outcomes stratified for hospital volume and tumour 
stage. Gietelink and collagues(14) did show that a low overall hospital volume defined as < 
20 rectal cancer resections per year, was associated with a higher risk of CRM involvement, 
but they did not perform sub-analysis for different tumour stages.(14) 
The extensive surgical treatment offered for cT4 rectal cancer in high volume hospitals 
was associated with increased rates of overall postoperative complications. However, after 
adjusting for confounding factors in multivariable analysis, including the type of surgery 
(APR) and extensive additional resection, hospital volume did not significantly affect the 
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complication rate anymore. Postoperative mortality rates were similar for low, medium and 
high volume hospitals as well. These findings may suggest that for true cT4 rectal cancer, 
high volume hospitals may offer a better multimodality treatment, eventually resulting in 
lower positive resection margins. 
Obviously, data regarding overall and local recurrence-free survival, stratified for hospital 
volume, is needed in order to assess if centralized care for locally advanced rectal cancer 
translates in a better long-term outcome. Unfortunately, the DSCA registry only contains 
data regarding perioperative outcomes. Regarding long-term outcomes of colorectal 
cancer, there appears to be a volume-outcome relationship as suggested in a Cochrane 
review; however, this was not stratified for tumour stage.(15) Most individual studies 
suggest similar overall survival rates at 5 years after cT1-4 rectal cancer surgery for low, 
medium and high volume hospitals.(10, 16-18) Hodgson and colleagues(19) did demon-
strate higher survival 2 years after surgery in high volume hospitals (84%) as compared 
to low volume hospitals (77%), however, their study did not differentiate either between 
cT1-3 and cT4 rectal cancer. In addition, patients were operated between 1994 and 1997 
and neoadjuvant treatment has improved considerably since then.(19) 
Since positive circumferential resection margins are associated with increased local recur-
rence rates and poorer survival in the literature, long-term outcomes of (true) cT4 patients 
operated in low volume hospitals may be inferior as compared to medium or high cT4 
volume hospitals.(3, 4) Future research should investigate whether higher hospital volume 
does indeed lead to improved survival, in order to confirm if centralized care for locally 
advanced rectal cancer is warranted.
Large population-based cohort studies, such as the present data from the DSCA, provide 
proper insights regarding the influence of hospital volume on perioperative outcomes 
of rectal cancer. However, limitations of the present study design should be taken into 
account, such as incompleteness of data. The hospital volume was based on the num-
ber of cases enrolled, which could theoretically differ from the actual hospital volume. 
Furthermore, we did not have details regarding exact additional resections performed for 
tumour involvement. Although registration bias cannot be excluded fully since data are 
self-reported, recent validation of the DSCA against the Dutch National Cancer Registry 
showed high accuracy and completeness of the data.(12) In addition, patient of more 
advanced stages of rectal cancer may have caused some bias in the present evaluation. 
Finally, long-term outcomes were not available for this evaluation, which are essential for 




In conclusion, perioperative outcomes of cT1-3 rectal cancer surgery were not superior in 
high volume hospitals as compared to medium or low volume hospitals, so there appears 
no benefit for centralization. With regards to cT4 rectal cancer, high volume hospitals 
performed more extensive surgical treatment with similar perioperative results. In case 
of pT4 rectal cancer, low hospital volume was associated with increased rates of irradical 
resection. For true cT4 rectal cancer, high volume hospitals may offer better multimodality 
treatment; however, long-term oncologic outcomes of rectal cancer surgery stratified for 
hospital volume and tumour stage are needed.
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Inguinal lymph node metastases (ILNM) from rectal adenocarcinoma are rare and staged 
as systemic disease. The aim of this study is to provide insight into the treatment and 
prognosis of ILNM from rectal adenocarcinoma.
Methods
All patients with a diagnosis of synchronous or metachronous ILNM from rectal adenocar-
cinoma between January 2005 and March 2017 were retrospectively reviewed.
Results
The study identified 27 patients with ILNM (15 with synchronous and 12 with metachronous 
disease). After discussion by a multidisciplinary tumour board, 19 patients were treated 
with curative intent, 17 of whom underwent inguinal lymph node dissection. Of the 17 
patients, 12 had locally advanced rectal cancer (LARC) with isolated ILNM, 3 had LARC 
and metastases elsewhere and 2 had locally recurrent rectal cancer (LRRC). The median 
overall survival (OS) for all the patients treated with curative intent was 27 months [95% 
confidence interval (CI) 11.6 - 42.4], with a 5-year OS rate of 34%. The median OS for 
the patients with LARC and isolated ILNM (n = 12) was 74 months [95% CI 18.0 - 130.0], 
with a 5-year OS rate of 52%. All the patients with metastases elsewhere (n = 3) or LRRC 
(n = 2) experienced recurrent systemic disease. Eight patients were treated with palliative 
intent. The median OS for this group was 13 months [95% CI 1.9 - 24.1] with a 3-year OS 
rate of 0%. 
Conclusions 
Clinicians should not consider ILNM as an incurable systemic disease. Patients with primary 
rectal cancer and solitary ILNM who are eligible for curative surgical treatment had a 5-year 
survival rate of 52%. The prognosis for patients with additional systemic metastases or 





Locally advanced rectal cancer is associated with pelvic lymph node metastases inside and 
sometimes outside the mesorectum. Besides these locoregional lymph node metastases, 
inguinal lymph node metastases (ILNM) may occur, particularly in lower rectal cancer, due 
to the lymphatic drainage by inguinal lymph nodes.(1) These ILNMs are relatively rare and 
the number of patients described in the literature is low.(2-7) The American Joint Com-
mittee on Cancer (AJCC) Cancer Staging Manual considers ILNM from rectal cancer as a 
systemic disease.(8) Whether ILNM should be treated with palliative or curative intent is 
unclear.(9-11) Obviously, patients with ILNM have a worse prognosis than patients with-
out ILNM, but even patients with lung or liver metastases are not always restrained from 
curative treatment.(12) The evidence in literature whether patients with ILNM from rectal 
adenocarcinoma can possibly be cured is scarce and few studies described treatment for 
ILNM of rectal cancer.(2,4-6) At our hospital, ILNM has been treated by inguinal lymph 
node dissection (ILND), with and without neoadjuvant chemotherapy, in case there were 
no other metastases, or when limited metastases were present elsewhere. This report 
presents the results for patients treated with both curative and palliative intent for ILNM 
from rectal cancer.
MeThods
All consecutive patients with ILNM from rectal adenocarcinoma treated at the Erasmus MC 
Cancer Institute, a tertiary referral centre in the Netherlands, between January 2005 and 
March 2017, were retrospectively identified by a search in the local pathology and rectal 
cancer database. All patients with synchronous or metachronous ILNM were included. 
Patients with deep/iliac groin nodes were not included. 
Patient characteristics, collected from medical records, included tumour characteristics, 
treatment, surgical variables, short- and long-term outcomes and postoperative mortality 
and morbidity. All the patients were followed up in our institution, and the last update 
of follow-up was 24 April 2018. Approval for this study was granted by the local medical 
ethics committee (Registration No. MEC-2017-448). 
Synchronous ILNMs were defined as all ILNMs diagnosed before surgery for the primary 
rectal tumour. Metachronous ILNMs were defined as all ILNMs diagnosed after surgery. All 
the patients with suspicious ILNMs during physical examination or on imaging [computed 
tomography (CT) of the abdomen or magnetic resonance imaging (MRI) of the pelvis] 
underwent lymph node biopsy. All the patients were screened for disseminated disease 
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by CT of the thorax and abdomen. All the patients were discussed by a multidisciplinary 
tumour board before treatment and were assessed for eligibility to receive treatment with 
curative or palliative intent. 
Neoadjuvant (chemo)radiotherapy usually comprised a cumulative dose of 50 Gy for 
primary rectal cancer and a cumulative dose of 30 Gy for LRRC in fractions of 1.8 - 2 
Gy, both with concomitant oral chemotherapy (Capecitabine 825 - 1000 mg/m2 for 5-7 
days a week). The target volume (95% of the radiation dose) mainly was the rectum, but 
inguinal nodes often received a substantial percentage (~ 30-50%) of the radiation dose. 
Neoadjuvant induction chemotherapy for ILNM was incidentally given.
For the patients with synchronous ILNM who underwent surgical treatment, an inguinal 
lymph node dissection (ILND) was performed either simultaneously with surgery for the 
rectal tumour or upfront before the start of neoadjuvant treatment for the rectal tumour. In 
case of metachronous metastases, an ILND was performed, in some cases simultaneously 
with surgical removal of a local recurrence. Notably, only superficial groin dissections were 
performed. 
statistical analysis
Data are reported as median [interquartile range (IQR) or 95% confidence interval] or mean 
± standard deviation as appropriate. Categorical data were reported as count (%). The 
Kaplan-Meier method was used for survival analysis and a log rank test was performed 
for comparison. The median follow up was calculated with the reversed Kaplan-Meier 
method. Overall survival was calculated from the day ILNM was diagnosed until death or 
the date of last follow up visit. Statistical analysis was performed using IBM SPSS Statistics 
version 24.0.0 for Windows (IBM Corp, Armonk, New York, USA). 
ResulTs
A flowchart of study patients is shown in Figure 1. Patient and primary tumour character-
istics are listed in Table 1. The characteristics of ILNM and follow up evaluation are shown 
in Table 2. The study identified 27 patients with ILNM from rectal adenocarcinoma. The 
majority of the ILNMs were from low rectal cancer (82%). The median age at diagnosis 
of ILNM was 63 years (IQR 44 – 69 years). The median interval between diagnosis of the 
primary tumour and diagnosis of ILNM was 6 months (IQR 1 – 30 months). All the patients 
were discussed by a multidisciplinary tumour board, after which 19 patients were treated 





For 10 of the 19 patients treated with curative intent, neoadjuvant chemotherapy for ILNM 
was administered, and all the patients received (chemo) radiotherapy for the rectal tumour. 
For two patients, the target volume included the ILNM. In all the remaining patients, the 
inguinal nodes received a lower percentage (30-50%) of the total radiation dose. Two 
patients with primary rectal cancer had progression of disease during neoadjuvant chemo-
therapy and were then treated palliatively, as depicted in Figure 1. Subsequently, ILND was 
performed for 17 patients, of these 17 patients, 12 had primary locally advanced rectal 
cancer and solitary ILNM, 3 patients had metastases elsewhere (liver, n = 2; peritoneal, n = 
1) and 2 patients had locally recurrent rectal cancer. 
Palliative intent
Eight patients were treated with palliative intent for disseminated disease or unresectable 
LRRC using either chemotherapy, radiotherapy or terminal care, as displayed in Figure 1. 
Five of these patients had received neoadjuvant radiotherapy for the rectal tumour, and 
figure 1. Flowchart included patients
ILNM = Inguinal lymph node metastases; ILND = Inguinal lymph node dissection; LRRC = Locally re-
current rectal cancer; CTx = Chemotherapy; RTx = Radiotherapy; Upfront = upfront dissection before 
resection of rectal tumour; Simultaneous = simultaneous resection with rectal tumour; Metachronous 
= resection during follow up rectal tumour; * Reason palliative treatment; †Died of respiratory failure 
before treatment
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the ILNMs were outside the target volume but still received a lower percentage (30-50%) 
of the total radiation dose. Two patients had received palliative radiotherapy with ILNM 
receiving the target volume, with a dose of 32 and 45 Gy, respectively.













n (%)  
n=8
n (%)
Gender Male 12 (44%) 7 (73%) 3 (38%)
Female 15 (56%) 12 (63%) 5 (63%)
Age at diagnosis ILNM Median (IQR)
63 (44-
69) 60 (40-69) 64 (57-67)
ASA ASA I-II 25 (93%) 18 (95%) 7 (78%)
ASA > II 2 (7%) 1 (5%) 1 (13%)
Rectal tumour at diagnosis 
ILNM
Primary 21 (78%)
17 (90%) 4 (50%)
LRRC 6 (22%) 2 (11%) 4 (50%)
Distance from anal verge 
(cm)
Median (IQR) 2 (1-3)
1 (0-7) 2 (1-3)
Location of rectal tumour Low rectal (<5 cm) 22 (82%) 14 (74%) 8 (100%)
Mid rectal (5-10 cm) 3 (11%) 3 (16%) 0 (0%)
High rectal (>10 cm) 2 (7%) 2 (11%) 0 (0%)
Neoadjuvant therapy rectal 
tumour
CTxRTx 18 (67%)
14 (74%) 4 (50%)
RTx 4 (15%) 3 (11%) 1 (13%)




2 (11%) 3 (38%)
Surgical procedure primary 
tumour
No resection† 2 (5%)
2 (11%) 0 (0%)
LAR 7 (26%) 4 (21%) 3 (38%)
APR 9 (33%) 5 (26%) 4 (50%)








4 (21%) 0 (0%)
Tumour stage primary 
tumour
No resection 2 (8%)
2 (11%) 0 (0%)
T2 3 (11%) 2 (11%) 1 (13%)
T3 11 (41%) 7 (37%) 4 (50%)






None of the patients died within 30 days of surgery, and 6 (35%) of the 17 patients experi-
enced postoperative complications. Four patients experienced inguinal seroma despite the 
standard use of postoperative suction drainage, which required percutaneous drainage in 
all cases. Two patients used antibiotics to treat superficial wound infections. Two patients 
experienced lymphedema during follow-up period and required elastic compression gar-
ments. Of all patients with inguinal complications, one patient had received neoadjuvant 
radiotherapy specifically on the inguinal nodes, in all the remaining patients inguinal nodes 
were outside the target area but still partly inside the radiotherapy field. 
Palliative intent
Half of the patients who received palliative treatment had ILNM-related morbidity. Four 
patients experienced severe pain requiring intravenous pain medication and three of these 
patients also had lymphedema. One patient experienced lymphedema without complaints. 
Four patients with lymphedema had received radiotherapy for the rectal tumour, with 
inguinal nodes partly in the radiation field. Two of these patients also had received a high-
dose palliative radiotherapy specifically on the inguinal nodes, but already had experienced 
lymphedema before palliative radiotherapy.













n (%)  
n=8
n (%)
Nodal stage primary 
tumour
No resection 2 (7%)
2 (11%) 0 (0%)
N0 10 (37%) 5 (26%) 5 (63%)
N1 8 (30%) 6 (32%) 2 (25%)
 N2  7 (26%)  6 (32%)  1 (13%)
ILNM = Inguinal lymph node metastases; LRRC = Locally recurrent rectal cancer; CTxRTx = Chemora-
diotherapy; CTx = Chemotherapy; RTx = Radiotherapy; LAR = Low anterior resection; APR = Abdomi-
noperineal resection; HIPEC = Hyperthermic intraperitoneal chemotherapy; † No resection due to 
progressive disease
Numbers do not add up due to rounding
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Time from Dx rectal cancer 
until ILNM
Months median (IQR) 6 (1-30)
4 (0-4) 24 (4-56)
Onset ILNM Synchronous 15 (56%) 13 (68%) 2 (25%)
Metachronous 12 (44%) 6 (32%) 6 (75%)
Location ILNM Unilateral 19 (70%) 14 (74%) 5 (63%)
Bilateral 8 (30%) 5 (26%) 3 (38%)
Solitary ILNM No 8 (30%) 3 (16%) 5 (63%)
Yes 19 (70%) 16 (84%) 3 (38%)
Distant metastases elsewhere Liver 1 (4%) 1 (5%) 0 (%)
Lung 1 (4%) 0 (%) 1 (13%)
Peritoneal 2 (7%) 1 (5%) 1 (13%)
Iliac lymph nodes and para aortic 1 (4%) 0 (%) 1 (13%)
Lung and spinal bone 1 (4%) 0 (%) 0 (%)
Liver and iliac lymph nodes 2 (7%) 1 (5%) 1 (13%)
Lung and iliac lymph nodes 2 (7%) 0 (%) 1 (13%)
Neoadjuvant CTx ILNM No 17 (63%) 9 (47%) N/A
Yes 10 (27%) 10 (53%) N/A
ILND No dissection 10 (37%) 2 (11%) 8 (100%)
Upfront 7 (26%) 7 (37%) 0 (0%)
Simultaneous with rectal tumour 4 (15%) 4 (21%) 0 (0%)
Metachronous during FU rectal 
cancer
6 (22%)
6 (37%) 0 (0%)
Histopathology Inguinal lymph nodes specimen¥ 
Positive lymph nodes No N/A 4 (24%) N/A
Yes N/A 13 (76%) N/A
Total number of harvested 
nodes
Median (range)
N/A 12 (3 -16) N/A
Total number of positive nodes Median (range) N/A 1 (0 – 11) N/A
follow up after surgical 
treatment
disease status at last follow up No evidence of disease N/A 5 (29%) N/A
Distant metastases N/A 7 (41%) N/A
 
Local recurrence rectal cancer 
and N/A 7 (41%) N/A
distant metastases
Inguinal lymph node recurrence± N/A 2 (12%) N/A
Dx = diagnosis; ILNM = Inguinal lymph node metastases;  ILND = Inguinal lymph node dissection; CTx 
= Chemotherapy; FU = follow up; † No resection due to progressive disease;  ¥ 17 patients and 22 dis-
section specimens, due to five bilateral ILN;  ± Nodal recurrence in dissected site. Numbers do not add 




hisToPaTholoGiCal ResulTs afTeR ilnd
Histopathologic evaluation was performed for 22 dissection specimens from 17 patients. 
The median number of lymph nodes found was 12 (range 3 – 26) and the median number 
of positive lymph nodes was 1 (range 0 – 11). In four patients treated with curative intent, 
no positive lymph nodes were found. Three of these four patients had received neoad-
juvant chemotherapy and were considered complete responders. In one patient without 
neoadjuvant therapy, three negative nodes were recovered, but four tumour deposits in 
the specimen were found, and this patient experienced local and distant recurrence during 
the follow-up period. In the remaining 13 patients, positive lymph nodes were found. Of 
these 13 patients, 5 had received neoadjuvant chemotherapy for ILNM. 
follow uP, ReCuRRenCe and suRvival
The median follow up period for survivors in the total cohort of 27 patients was 79 months 
(95% CI 46.9 - 111.1) during which 20 patients died. The median overall survival for the 
total cohort was 19 months (95% CI 5.8 - 32.2). There was no significant difference in 
survival between synchronous or metachronous ILNM (p = 0.86) and bilateral or unilateral 
ILNM (p = 0.05). 
Curative intent
Of 19 patients treated with curative intent, 2 had progressive disease under neoadjuvant 
therapy and experienced distant metastases, whereas the primary rectal tumour and the 
ILNM remained in situ. At last follow-up visit, 5 of the 17 patients who underwent ILND 
had no evidence of disease. Of these 17 patients, 2 experienced a local ILNM recurrence, 
accompanied by local recurrence of the rectal tumour and systemic metastases. Another 
five patients experienced local recurrence of the rectal tumour with distant metastases, and 
five patients experienced distant metastases only. 
At last follow-up visit, seven patients were alive, and all these patients had undergone 
ILND. Three patients were alive with local rectal tumour recurrence and distant metastases, 
including one patient with ILNM recurrence. Four patients were alive with no evidence of 
disease, and one patient had died with no evidence of disease. 
Survival curves are shown in Figure 2. The median overall survival for all 19 patients treated 
with curative intent after diagnosis was 27 months (95% CI 11.6 - 42.4). The 1- and 5-year 






































































































































































































































































Three patients underwent ILND with resection of the primary rectal tumour and resection 
of metastases elsewhere (liver, n = 2 and peritoneal, n = 1). Two of these patients died 
of systemic disease at 13 and 26 months of follow-up evaluation and one patient, who 
underwent ILND and surgery for primary rectal cancer with liver metastases only, at this 
writing is still alive after 14 months of follow-up evaluation with locally recurrent rectal 
cancer and recurrent liver metastases. The two patients that underwent ILND with simulta-
neous resection of locally recurrent rectal cancer died of systemic disease with respectively 
12 and 13 months of follow-up evaluation. 
Palliative treatment intent
At last follow-up visit, all eight patients treated with palliative intent had died of the dis-
ease. The median overall survival was 13 months (95% CI 1.9 - 24.1), with 1- and 3-year 
estimated overall survival rates of 63% and 0% respectively. 
disCussion
In this study, a 5-year survival rate of 52% was achieved after surgical treatment of pa-
tients with primary rectal cancer and isolated ILNM. Prognosis for patients with additional 
systemic metastases is worse and the benefit of surgery is unclear. Patients treated with 
curative surgery mostly experienced lymphedema and palliatively treated patients mostly 
had severe pain. 
In 1990 Graham et al.(7) was one of the first to describe management of ILNM. Their 
study identified 40 patients with ILNM from rectal cancer divided into three groups: (1) 
unresectable primary tumours, (2) recurrent disease after abdominoperineal resection 
with palliative treatment, and (3) solitary ILNM treated with ILND. None of the patients 
survived 5 years, but the median survival was highest in the solitary ILNM group (inguinal 
metastases only), with two patients having no evidence of disease at the last follow-up 
visit (one patient died of myocardial infarction, and one patient was alive with 15 months 
of follow-up evaluation). These authors concluded that only in case of solitary ILNM, the 
situation for eight patients in their study, a resection may be warranted. Tocchi et al. (4) 
reported a mean, not median, survival of 14.8 months in 21 patients with ILNM from rectal 
cancer, and none of the patients reached 5-year survival. Their study included five patients 
with ILNM only and supported the suggestion that ILND can be beneficial, although not 
curative, because a prolonged survival was achieved for these patients. They concluded 
that ILNM is frequently associated with distant metastases (in 16 of 21 patients of their 
series), and in these cases, systemic therapy is the treatment of choice. Luna-Pérez et al.(6) 
described a 5-year survival of 0% for 32 patients with ILNM from rectal adenocarcinoma, 
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27 of whom also had systemic metastases. They concluded that surgery for isolated ILNM 
may prolong survival, but that ILNM should be considered as systemic disease and treated 
palliatively as indicated. 
More recent studies by Bardia et al.(2) and Adachi et al.(5) retrospectively reviewed small 
groups of patients with ILNM and concluded that patients with isolated ILNM are a dif-
ferent subset of patients. Bardia et al.(2) studied six patients with solitary ILNM and the 
mean survival for these patients was 40 months. Adachi et al.(5) studied 10 patients with 
ILNM, 8 of whom had solitary ILNM and underwent ILND. They reported a 5-year overall 
survival rate of 75% in these patients. Adachi et al.(5) also reported a better prognosis 
for patients with metachronous metastases, but our study did not find any difference in 
survival for metachronous compared to synchronous metastases. This may be explained 
by the definitions Adachi et al.(5) used for synchronous (up to 1 year after diagnosis of 
the primary rectal cancer) and metachronous metastases (> 1 year after diagnosis of the 
primary rectal cancer) or by the small number of patients in both studies.
The current study presents the largest group of patients with ILNM caused by rectal cancer 
who were treated with curative intent since the study by Luna-Pérez et al.(6) in 1999. 
However, the majority of the patients in the latter study had distant metastases as well and 
may not be considered candidates for curative treatment. The results of previous studies 
presenting smaller groups of patients are confirmed: ILNM caused by rectal cancer should 
not necessarily be considered an incurable disease, especially in case of primary rectal 
cancer and the absence of other systemic metastases. In this study a median OS of 74 
months with 1- and 5-year estimated overall survival rates of 83% and 52%, respectively, 
was reached for this group.
In line with all other previously published studies, our study showed a poor prognosis for 
the patients with ILNM and distant metastases to other sites.(2,4-7) These results suggest 
that these patients should be treated with palliative intent. The current study included 
three patients who underwent resection of ILNM combined with resection of additional 
metastases. Only one patient, who underwent ILND and liver metastases resection, at this 
writing is still alive at 14 months follow-up evaluation, with systemic recurrence. In addi-
tion, both patients with locally recurrent rectal cancer who underwent resection of the 
rectal tumour with ILND died within 13 months. Due to small numbers, no conclusions can 
be drawn, and it is unclear whether surgery was at all beneficial for these patients. Cur-
rently, in the Netherlands, the ORCHESTRA trial is being performed to assess the beneficial 
effects of added local treatment with systemic treatment in case of systemic disease and 




The mortality and morbidity associated with ILND have been described for ILNM caused 
by melanoma and anal cancer, but few described morbidity after ILND for rectal cancer.
(14-16) The mortality is low, but the morbidity associated with this procedure is high. 
Short-term wound complications such as dehiscence, infection, and seroma are reported 
to reach 60%, and lymphedema can occur. (14-16) In our study, 6 (35%) of 17 patients 
experienced postoperative complications. All the patients with inguinal complications had 
received (partial) prior irradiation on inguinal nodes. The numbers were small in the current 
study, but the negative impact of radiation therapy is well known. Radiation therapy impairs 
wound healing and can increase the incidence of lymphedema.(17) Recent series indicate 
that routine inguinal lymph node radiation is not necessary.(17,18) The optimal balance 
between inguinal radiotherapy and the extent of surgery is unclear, but the morbidity of 
the combined procedure should not be underestimated. 
In the current study only ILND (i.e., superficial groin dissections) were performed and no 
deep groin dissection. In 12 of the 17 patients who underwent ILND, distant metastases 
occurred outside the pelvic region, including four patient with simultaneous iliac node 
recurrence. This could imply that a formal deep groin dissection in all these patients for a 
superficial ILNM would have been overtreatment with considerable morbidity. 
Our study was limited by its small numbers, referral bias from other centres and its retrospec-
tive nature. Inguinal lymph node metastases from rectal adenocarcinoma are relatively rare, 
and most previous studies contain small and heterogeneous groups of patients, collected 
before the era of total mesorectal excision (TME) surgery and before neoadjuvant therapy 
was widely accepted. Although the current study presents a small cohort, it provides proof 
that solitary ILNM from rectal adenocarcinoma does not equal incurable disease. This is 
supported by previous reports.
Conclusions
Surgical treatment of ILNM from rectal adenocarcinoma may result in prolonged survival 
and possibly in cure. Inguinal lymph node metastases should not be considered as an 
incurable disease, especially in patients with primary rectal cancer and solitary ILNM. The 
prognosis for patients with ILNM and distant metastases elsewhere or recurrent rectal 
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Abdominoperineal resection (APR) carries a high risk of perineal wound morbidity. Perineal 
wound closure using autologous tissue flaps has been shown to be advantageous, but 
there is no consensus as to the optimal method. The aim of this study was to evaluate 
the feasibility of a novel gluteal turnover flap (GT-flap) without donor site scar for perineal 
closure after APR. 
Methods
Ten patients who underwent APR for primary or recurrent rectal cancer were included in a 
prospective non-randomised pilot study in two academic centres. Perineal reconstruction 
consisted of a unilateral subcutaneous GT-flap, followed by midline closure. Feasibility was 
defined as uncomplicated perineal wound healing at 30 days in at least five patients, and 
a maximum of two flap failures. 
Results
Out of 17 potentially eligible patients, 10 patients underwent APR with GT-flap assisted 
perineal wound closure. Seven patients had pre-operative radiotherapy. Median added 
theatre time was 38 minutes (range 35-44). Two patients developed perineal dehiscence, 
likely because of too large width of the skin island. Two other patients developed purulent 
discharge and excessive haemoserous discharge, respectively, resulting in four complicated 
wounds at 30 days. No flap failure occurred, and no radiological or surgical re-interventions 
were performed. Median length of hospital stay was 10 days.
Conclusions
The GT-flap for routine perineal wound closure after APR seems feasible with limited ad-
ditional theatre time, but success seems to depend on correct planning of the width of the 






To date, abdominoperineal resection (APR) for low rectal cancer still carries a significant risk 
of perineal wound problems (1). A recent randomised controlled trial on perineal wound 
closure after APR reported an incidence of complicated perineal wound healing of 34-37% 
at 30 days postoperatively (2), but incidence of perineal complications have even been 
reported to occur in up to 66% after APR and primary closure (3). In addition, patients 
may experience persisting perineal pain, or develop a chronic perineal sinus or perineal 
hernia (4-6). 
The high risk of perineal morbidity after APR is related to the creation of a large pelvic 
dead space with bacterial contamination, making the surgical-site susceptible for infection. 
Furthermore, use of pre-operative radiotherapy significantly impairs the healing capacity 
of this dead space – secondary to the decreased angiogenesis. To prevent these wound 
problems, immediate soft tissue reconstruction has been advocated (7). The rationale 
is that by obliterating the surgical dead space with well-vascularised tissues, the risk of 
wound breakdown and infection is reduced. Another reason is related to the concept 
that autologous tissue may add strength to the (partially) excised pelvic floor muscles, 
which may potentially reduce the risk of perineal hernia formation. There is however no 
consensus on the optimal method for perineal wound closure after APR.
Several techniques are used to improve perineal wound healing, including reconstruction 
using a V-Y fasciocutaneous flap, a vertical rectus abdominis myocutaneous (VRAM) flap, 
a gluteal or a gracilis flap (8-11). However, there are potential disadvantages to these 
techniques. These include the need for a plastic surgeon, a substantially increased theatre 
time and the potential for donor site and recipient site complications, while often sacrific-
ing the benefits of laparoscopy (12-17). Moreover, as a large percentage of patients will 
not develop healing difficulties, immediate reconstruction with large muscle flaps might 
be an unnecessary risk and expense. An optimal harm-benefit ratio of reconstructive 
techniques is especially important in relatively low-risk patients undergoing non-extensive 
resections without pre-operative radiotherapy. There is an urgent need for a simple and 
minimally-invasive technique for routine perineal wound closure after APR. We propose a 
novel unilateral subcutaneous gluteal turnover flap (GT-flap) without additional scarring or 
donor site morbidity. 
The aim of this pilot study was to determine the feasibility of this procedure in patients 




A prospective longitudinal multicentre interventional cohort study was performed in 10 
consecutive patients at two academic medical centres. All patients scheduled for extraleva-
tory APR were pre-operatively informed on the study at the outpatient clinics. Written 
informed consent was obtained for all participants. Inclusion criteria were adult patients 
(age ≥ 18 years) and planned for APR for primary or recurrent rectal cancer. Exclusion 
criteria were need for total pelvic exenteration, sacral resection above S4/S5, severe 
concomitant diseases affecting wound healing (i.e. renal failure requiring dialysis, liver 
cirrhosis, peripheral vascular disease with Fontaine grade 3 or higher), or enrolment in 
other trials expected to influence perineal wound healing. 
On day seven and day 30 after surgery, the perineal wound was evaluated by residents 
or surgeons using the Southampton wound score (supplementary table 1). Postoperative 
pain was assessed using the visual analogue scale (VAS) which ranged from 0 (no pain) 
to 10 (worst pain). In addition, photographs were taken, and all appointed wound scores 
were centrally reviewed by the trial coordinators (RDB and PJT). Patient demographics, 
neo-adjuvant treatment, tumour characteristics and surgical details were intra-operatively 
collected. Postoperatively, type and extent of any wound event or any other adverse event, 
and all medical, radiological and surgical interventions were recorded to the last day of 
follow-up. The study protocol has been approved by the Institutional Review Board of the 
Amsterdam UMC, University of Amsterdam, and the Erasmus MC (NL58380.018.16). 
surgical procedure
APR started with skin incision close to the anus with subsequent dissection along the 
external sphincter, in order to preserve as much perineal skin and subcutaneous fat as 
possible without compromising oncologically safety. 
Perineal reconstruction is then performed using a unilateral, semilunar, de-epithelialized, 
subcutaneous GT-flap (figure 1). Creation of the GT-flap starts with drawing of a semi-
circular incision adjacent to the surgical defect of approximately two-and-a-half centimetre 
in width. Success of the flap is contingent upon obtaining tension-free closure at the 
midline. For this reason, the flap can only be a few centimetres in width. Pre-operative 
mapping of the perforators is not deemed necessary due to the broad base of the turnover 
flap and its robust blood supply. Furthermore, due to the design of the flap, there is no 
need to elevate the flap on a single perforator. The flap is de-epithelialized followed by 
incision through the skin and slightly lateral dissection towards the gluteus muscle. It is 




easier. The fl ap is then hinged into the defect, and the dermis is anchored to the contra-
lateral remnants of the levator muscles. Next, a vacuum drain is positioned on top of the 
fl ap and the subcutaneous fat and perineal skin are closed in a layered fashion in the 
midline over the fl ap.
fig. 1 Reconstruction of an abdominoperineal defect using a gluteal turnover fl ap. a) marking of the 
fl ap, b) de-epithelialisation of the dermis, c) fl ap after having transected onto the gluteal fascia, d) rota-
tion of the fl ap e) fi xation of fl ap to the contra-lateral remnants of pelvic fl oor muscles, f) midline scar 
following layered closure of the ischio-rectal and perineal tissues over the fl ap.
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Patients were allowed to mobilise on the first postoperative day, but were instructed not to 
sit directly on the perineal wound the first few days. The drain was removed after at least 
3 days according to the surgeons’ judgement. 
feasibility criteria and secondary outcome measures 
The procedure was deemed feasible if 1) no more than five patients had a complicated 
wound healing at 30 days postoperatively, 2) including no more than two flap failures. 
Complicated wound healing was defined as a Southampton wound score equal or greater 
than II (supplementary table 1). We hypothesised that, since the flap is covered and not 
visually accessible for evaluation of flap perfusion, flap failure would eventually result in 
wound breakdown. Therefore, flap failure was defined as a Southampton wound score of 
V. 
Secondary endpoints were median length of the procedure, hospital stay duration, number 
of specific complications, and number of re-interventions and re-admissions.
statistical analysis
Categorical data were expressed as absolute numbers with corresponding proportions, 
and continuous data according to distribution as means with standard deviation (SD) or 
medians with interquartile range (IQR). The treatment effect was determined based on a 
per-protocol analysis. All analyses were performed with IBM SPSS statistics, version 24.0.0 
(IBM Corp., Armonk, NY, United States). 
ResulTs
Among 17 eligible patients, 11 were willing to participate and signed informed consent. 
Patient characteristics are demonstrated in table 1. Mean age was 64 years, and seven 
were male. Indications for APR were primary rectal cancer (n=8), recurrent rectal cancer 
(n=2), and one patient that had a clinical diagnosis of rectal cancer, but appeared to have 
recurrent prostate cancer on postoperative pathological examination. Pre-operative radio-
therapy was given in eight patients.
Surgical details are shown in table 2. In one patient, it was considered unfeasible to ob-
tain tension-free midline closure using a GT-flap due to the large size of the perineal skin 
defect after resection. A GT-flap with midline perineal closure could be performed in the 
remaining 10 patients. Median total theatre time was 305 minutes (IQR 249-370 minutes), 
and median time taken for flap harvesting and insertion into the neo-pelvic floor was 38 



















































































































































































































































































































































































































































































































































































































































































































































Median follow-up duration was 33 days (IQR 27-35 days). Postoperative outcome is dis-
played in table 3. Median length of hospital stay was 10 days (IQR 8-12 days). In total, 
four patients had a complicated perineal wound healing at 30 days (Southampton wound 
score ≥ II). Two patients developed a superficial dehiscence of a few centimetres in depth, 
of whom one had concomitant pus discharge. The underlying GT-flaps were unaffected 
(figure 2). Retrospective evaluation of these two patients revealed that the design of the 
flap was too wide, resulting in tension on the perineal wound after midline closure. Both 
patients needed no further treatment besides irrigation with saline. One patient developed 
perineal infection with a small pus pocket necessitating manual drainage and antibiotic 
therapy for seven days. The last patient with a complicated wound healing at 30 days 
developed perineal pain secondary to a non-infected perineal seroma, which required 
manual drainage at the outpatient clinic. There were no cases of flap necrosis. With a total 
of four complicated perineal wounds at 30 days and no flap failures, predefined feasibility 
criteria were met.
Two more patients had perineal seroma, but both resolved within 30 days and without 
further treatment. In the remaining four patients, the perineal wound healed uneventful. 
Perineal pain at seven days was reported for seven patients with a median VAS score of 0. 
Perineal pain at thirty days was reported for six patients with a median VAS score of 1. Dur-
ing follow-up, there were no re-admissions, and no radiological or surgical re-interventions. 
Table 2. Surgical details and intra-operative outcome


















1 Extralevator Lithotomy Open Open None No Yes Yes Plastic Left Yes Transcutaneous 42 207
2 Extralevator Lithotomy Open Open None No Yes Yes Plastic Left Yes Transcutaneous 55 510
3 Extralevator Lithotomy Open Open None No Yes Yes General Left Yes Transcutaneous 45 302
4 Extralevator Lithotomy Laparoscopic Open None No No Yes Plastic Left Yes Intracutaneous 35 151
5 Extralevator Lithotomy Open Open None No Yes Yes Plastic Right Yes Transcutaneous 38 305
6 NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb
7 Extralevator Lithotomy Open Open None No Yes Yes General Left Yes Transcutaneous 36 327
8 Extralevator Prone Laparoscopic Open None No No Yes Plastic Right Yes Intracutaneous Missing Missing
9 Extralevator Lithotomy Laparoscopic TAMISc None No No Yes Plastic Left Yes Intracutaneous 35 310
10 Extralevator Lithotomy Laparoscopic TAMISc
Posterior 
vaginectomy No No No General Left Yes Intracutaneous 31 291
11 Extralevator Lithotomy Open Open Left pelvic sidewall Yes Yes Yes Plastic Right No Transcutaneous 40 412
aAbdominoperineal resection
bNot applicable
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1 Extralevator Lithotomy Open Open None No Yes Yes Plastic Left Yes Transcutaneous 42 207
2 Extralevator Lithotomy Open Open None No Yes Yes Plastic Left Yes Transcutaneous 55 510
3 Extralevator Lithotomy Open Open None No Yes Yes General Left Yes Transcutaneous 45 302
4 Extralevator Lithotomy Laparoscopic Open None No No Yes Plastic Left Yes Intracutaneous 35 151
5 Extralevator Lithotomy Open Open None No Yes Yes Plastic Right Yes Transcutaneous 38 305
6 NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb NAb
7 Extralevator Lithotomy Open Open None No Yes Yes General Left Yes Transcutaneous 36 327
8 Extralevator Prone Laparoscopic Open None No No Yes Plastic Right Yes Intracutaneous Missing Missing
9 Extralevator Lithotomy Laparoscopic TAMISc None No No Yes Plastic Left Yes Intracutaneous 35 310
10 Extralevator Lithotomy Laparoscopic TAMISc
Posterior 
vaginectomy No No No General Left Yes Intracutaneous 31 291
11 Extralevator Lithotomy Open Open Left pelvic sidewall Yes Yes Yes Plastic Right No Transcutaneous 40 412
aAbdominoperineal resection
bNot applicable
cTransperineal minimally invasive surgery using GelPOINT path and Airsea
dIntra-operative radiotherapy
eTime in minutes
fig. 2 Perineal wound dehiscence of 2,5 centimetre in depth with mild infl ammation following abdomi-
noperineal resection with insertion of gluteal turnover fl ap. The underlying sub cutis of the fl ap is still 




























































































































































































































































































































































































































































































































































































































































































































































































































Additional postoperative complications included ileus (n=3), unrelated abscess on buttock 
(n=1), urinary retention (n=4), urinary tract infection (n=2), pneumonia (n=1), and delirium 
(n=1). 
disCussion
This pilot study aimed to determine the feasibility of the GT-flap in routine perineal recon-
struction after APR. The GT-flap was technically feasible with midline closure in all patients, 
except for one patient in whom more perineal skin had to be excised for oncological 
reasons. The flap added only limited additional theatre time. The majority of patients had 
uncomplicated perineal wound healing at 30 days postoperatively without any flap failure, 
thereby fulfilling our predefined feasibility criteria. Retrospective analysis of two cases of 
wound dehiscence revealed the critical part of the procedure, namely planning the ap-
propriate width of the skin island that still allows for tension-free closure in the midline. 
The GT-flap displays a favourable profile, compared to existing literature on flap-repair (7, 
9). The flap seems to exhibit no partial necrosis or total flap loss as can be observed after 
muscle flaps, although the sample size is still small (18). The procedure can be combined 
with laparoscopy, contrary to conventional VRAM flaps for example. In addition, median 
additive theatre time was only 38 minutes, which included a learning curve and time 
needed for photographing the procedure. This is likely to decline in the future with increas-
ing experience. Another benefit is the ease of flap harvesting, not necessarily requiring a 
plastic surgeon. Nonetheless, the procedure should preferably be performed by a surgeon 
already familiar with harvesting perforator flaps, or after initially being proctored by a 
plastic surgeon. Injury to the perforators can have serious consequences. If the flap is 
raised too large, this will lead to undue tension of the perineal skin, which can result in a 
major dehiscence. However, these basic principles of the technique are quite simple and 
easy to learn. 
Another advantage of the GT-flap over other options is the symmetrical midline scarring, 
thereby preserving the gluteal cleft and restoring normal perineal aesthetics (figure 3). 
This is a major advantage compared to the VRAM or conventional gluteal flaps (e.g. V-Y 
transposition, SGAP, IGAP), which leave both large and visible scarring. Furthermore, no 
dissection of muscle is performed. Patients are allowed to mobilise directly. The GT-flap 
seems to avoid problems with balance, sitting or walking secondary to muscle weakness or 
pain that is often seen after gluteal muscle transpositions. Considering these benefits, the 
GT-flap may be very attractive for routine perineal wound closure after APR. 
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The GT-fl ap is only a valuable option if the perineal skin and subcutaneous fat can be maxi-
mally preserved from an oncological point of view. Therefore, distal rectal cancer without 
involvement of the perineal skin and subcutaneous fat requiring APR with a certain extent 
of resection of the levator muscles seems to be the optimal indication. If additional perineal 
skin has to be excised, for example in case of advanced anal cancer or radiation-induced 
skin fi brosis, there is a need for fl ap assisted closure that adds a skin island, such as the 
VRAM fl ap. 
Due to the design of this pilot study of small sample size and with relatively short follow-
up, it was not possible to assess the impact of the GT-fl ap on the risk of long-term perineal 
complications. A recent publication by Chasapi et al. reported on a similar reconstructive 
procedure in 14 patients undergoing APR for anorectal cancer (19). The type of fl ap used 
differed from the presently described technique by the fact that the fl ap was detached from 
the gluteal fascia with one remaining perforator for blood supply. They showed favourable 
outcome with only one patient suffering from superfi cial skin dehiscence, and one devel-
oping a perineal hernia 7 months after surgery. These fi ndings support our feeling that in 
selected patients, adjacent gluteal skin and subcutaneous fat can be relatively easily used 
for perineal closure after APR, with the potential advantages of reduced perineal morbidity 
by fi lling the space of the resected anal sphincter complex. The next step is conducting a 
randomised controlled trial to determine the effectiveness of this intervention in reducing 
perineal morbidity after APR, both short-term and long-term.
Conclusions
The GT-fl ap is a technically feasible and safe method for perineal wound closure after APR 
in patients with primary or recurrent rectal cancer if no additional perineal skin has to be 
sacrifi ced. The procedure is relatively quick and easily applicable, and seems associated 
with no apparent donor site morbidity or scarring. Further research is warranted to assess 
fig. 3 Healed perineal wound with symmetrical midline scarring a) on day 7, and b) day 30 after abdomino-
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The objective of this systematic review and meta-analysis was to examine the effects of 
omentoplasty on pelviperineal morbidity following abdominoperineal resection (APR) in 
patients with cancer.
background
Recent studies have questioned the use of omentoplasty for the prevention of perineal 
wound complications. 
Methods
A systematic review of published literature since 2000 on the use of omentoplasty during 
APR for cancer was undertaken. Authors were requested to share their source patient data. 
Meta-analyses were conducted using a random-effects model. 
Results
Fourteen studies comprising 1894 patients (n=839 omentoplasty) were included. The 
majority had APR for rectal cancer (87%). Omentoplasty was not significantly associated 
with the risk of pre-sacral abscess formation in the overall population (RR 1.11; 95% 
CI 0.79-1.56), nor in planned subgroup analysis (n=758) of APR with primary perineal 
closure for non-locally advanced rectal cancer (RR 1.06; 95% CI 0.68-1.64). No overall 
differences were found for complicated perineal wound healing within 30 days (RR 1.30; 
95% CI 0.92-1.82), chronic perineal sinus (RR 1.08; 95% CI 0.53-2.20) and pelviperineal 
complication necessitating reoperation (RR 1.06; 95% CI 0.80-1.42) as well. An increased 
risk of developing a perineal hernia was found for patients submitted to omentoplasty 
(RR 1.85; 95% CI 1.26-2.72). Complications related to the omentoplasty were reported in 
4.6% (95% CI 2.5-8.6%).
Conclusions
This meta-analysis revealed no beneficial effect of omentoplasty on pre-sacral abscess 
formation and perineal wound healing after APR, while it increases the likelihood of de-
veloping a perineal hernia. These findings do not support the routine use of omentoplasty 





The pelvic wound bed after abdominoperineal resection (APR) carries a high risk of 
morbidity.(1-3) This is likely related to the contaminated operative field and dead space 
formation with fluid accumulation, and may be further increased by extended resections 
and compromised perfusion post-radiotherapy. A randomized controlled trial showed that 
perineal complications within one year after APR with primary perineal closure may occur 
in up to 48%.(4) Patients frequently develop perineal wound dehiscence and infection, 
and often endure delayed healing. Secondary wound healing can take several months and 
may eventually result in a chronic perineal sinus.(5) Furthermore, patients may develop 
perineal pain and sitting problems, as well as a perineal hernia.(6, 7) 
To improve perineal wound healing after APR, various reconstructive methods have been 
proposed. These include the use of a biological mesh and several tissue flaps, such as a 
pedicled omentoplasty (OP) or a vertical rectus abdominis muscle flap (VRAM).(8-10) The 
flaps serve to obliterate the often non-collapsible defect with healthy and well perfused 
tissue, which has been associated with reduced abscess formation and improved wound 
healing.(11, 12) 
The omentum is supposedly an ideal option to prevent dead space formation after APR. It 
has a rich blood supply, expresses anti-inflammatory cytokines, often provides for abundant 
bulk and appears relatively easy to release.(13-16) Many surgeons therefore perform an OP 
as part of the APR procedure. In a recent nationwide study with variability in practice of 
applying OP, no improvement in perineal wound healing was observed, and the OP particu-
larly seemed to increase the risk of perineal herniation.(6) These results challenge the value 
of OP for closure of the pelvic defect after APR. Therefore, the aim of this systematic review 
and meta-analysis was to assess the effects of OP following APR on pelviperineal morbidity 
and related problems in patients treated for cancer in the published literature since 2000. 
MeThods
The study protocol was prospectively registered at PROSPERO (registration number: 
CRD42017073573) and followed Preferred Reporting Items for Systematic Reviews and 
Meta-analysis (PRISMA) guidance.(17) 
search
The literature was systematically reviewed by searching in the PubMed-library for studies 
published between January 2000 and March 2017. The search was limited to publication 
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since 2000 to limit the influence of historical changes in surgical and peri-operative care, 
which better ties in to current practices. The search was rerun in June 2018 (Supplementary 
Digital Content 1). The search strategy only included terms relating to or describing neo-
plasms, surgical outcome and APR. Since most studies do not explicitly mention the use of 
OP in the title or abstract, this was not included as a search term. Additional articles were 
manually selected from the reference lists of the retrieved papers.
Eligibility
Original studies including patients undergoing APR for cancer and reporting on use of OP 
and perineal wound outcome were potentially eligible. Articles were restricted to the Eng-
lish language. Exclusion criteria were studies with no original data, individual case reports 
(<10 patients with OP), studies that did not report on at least one predefined outcome of 
interest, and studies that exclusively pertained to pelvic exenteration or benign disease. 
Outcome parameters
The primary endpoint was incidence of pre-sacral abscess formation, as this was expected 
to be most consistently reported. Secondary endpoints were the rate of overall pelviperineal 
wound complications within 30 days, one year, and the total study period, wound healing 
time, specific pelviperineal morbidity (i.e. wound dehiscence, superficial wound infection, 
haemorrhage, perineal sinus), ileus (overall, and proportion requiring reoperation), perineal 
hernia (not specified), OP-related morbidity, operative time, and surgical perineal re-inter-
vention. Pelviperineal complication included any pelvic or perineal wound event (including 
perineal hernia), and surgical perineal re-intervention any pelvic or perineal wound-related 
reoperation (including hernia repair). Perineal infection was categorized into superficial 
wound infection (including perineal abscess), and deep wound infection (i.e. pre-sacral 
abscess). Perineal haemorrhage included active perineal bleeding or hematoma (regardless 
of need for re-intervention). There was no definition given for pre-sacral abscess, perineal 
sinus and perineal hernia. Perineal hernia was based on the reporting of the source studies, 
and could vary from asymptomatic incidental CT finding to symptomatic perineal bulge 
requiring surgical repair. 
Data collection and extraction
Two independent reviewers (RDB & CELK) scanned all abstracts identified by the search and 
cross-referencing. Full texts were retrieved for all studies that potentially met the inclusion 
criteria. Two reviewers (RDB & JAWH) further independently reviewed the eligibility of 
these studies in full text. Any disagreement on the eligibility of particular studies was 
resolved through consensus discussion with a third reviewer (PJT). Papers not meeting the 




were contacted on three separate occasions to share either the source individual patient 
data or aggregate data, reported separately for OP and non-OP.
Data extraction included general study information, participant demographics, operative 
details, perineal wound outcome, length of follow-up, and information for assessment of 
the risk of bias. Any disagreement was solved by consensus discussion, if necessary with a 
third reviewer (PJT). In case of missing data, the study authors were contacted to request 
additional information. 
figure 1. PRISMA fl ow diagram depicting the search strategy and study selection process. 
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The received source patient data was preferably used, and may slightly differ from the 
original publication. If this was not available, data from the original publication was used. 
The cohort of Musters et al. was updated using original patient files.(5) From the initial 104 
patients of the BIOPEX study, 99 were entered in the analyses because of missing outcome 
data due to study exclusions.(4) 
Assessment of risk of bias in included studies
Two reviewers (RDB & JAWH) independently assessed the risk of bias in the included stud-
ies using the Newcastle-Ottawa Scale (NOS) for non-randomized studies.(18, 19) 
Data synthesis
All outcome measures were quantitatively summarized. If at least three comparative stud-
ies (≥10 cases in both groups) provided data on a study parameter, data were pooled in 
meta-analysis using Review Manager (RevMan 5; Cochrane Collaboration). Studies without 
a control (<10 cases of non-OP) were pooled in proportional meta-analysis using RStudio 
(version 3.5.1). Pooled estimates of effect were calculated along with corresponding 95% 
confidence interval (CI), using a random-effects model. The method as proposed by Wan 
et al. was used to approximate the estimation of the sample mean and standard deviation 
in case the median and interquartile range was given.(20) Dichotomous data were sum-
marized by risk ratios (RR), and continuous data were presented as mean differences (MD). 
Heterogeneity between studies was perceived considerable when I2≥75%.(21) Two-sided 
p-values <0.05 were considered statistically significant. Funnel plots were generated to as-
sess for publication bias. The evidence along with the quality of the data were summarized 
in a GRADE summary of findings table. 
Analysis of subgroups
In order to decrease potential bias introduced by diverse indication and surgical methods, 
a planned subgroup analysis was performed for patients that underwent APR with primary 
perineal closure for non-locally advanced rectal cancer. The additional exclusion criteria 
for the purpose of this subgroup analysis were reconstructions using a mesh and/or flap, 
other pelvic malignancies, pT4 stage, and adjacent organ resection. We also performed a 
planned subgroup analysis only in patients who received pre-operative radiotherapy. 
ResulTs
literature search and selection
The results of the literature search are displayed in Figure 1. After deduplication, the 




After contacting the authors, individual patient data were provided in six(4-6, 22-24) and 
aggregate data in four.(25-28) An additional of four studies with full text of the original 
paper only were included.(9, 10, 29, 30) Eleven studies without separate data for OP(31-
41), and one study that eventually appeared to have included only one patient with OP(42) 
were excluded. 
Study characteristics
General study descriptions are demonstrated in Table 1. Eleven studies had a control group 
(i.e. ≥10 cases of non-OP).(2, 4, 6, 9, 10, 22-24, 26, 28, 30) The quality of the included 
studies was moderate to good (range 5-9; Supplementary Table 2; Supplemental Digital 
Content 2). The 14 included studies covered a total of 1894 patients, of whom 839 un-
derwent OP.
Table 1.  Study descriptions of the included studies.
study 
(author)









































































































Pooled baseline characteristics of the two groups are demonstrated in Table 2. The indica-
tion for APR was predominantly rectal cancer (87.2%). The number of patients receiving 
neo-adjuvant radiotherapy was 82.5% in the OP group and 74.4% in the non-OP group. 
Similar proportions of adjacent organ resection were performed (21.4 % versus 18.2%) 
with slightly less additional reconstructive procedures in the OP group (17.8 % versus 
27.5%). Median operative time was median 19 minutes longer for APR with OP, but not 
significantly different from the non-OP group. Median follow-up duration of the included 
studies ranged from 12-62 months (overall weighted mean 36.6 months). Supplementary 
Table 3 (Supplemental Digital Content 3) shows the baseline characteristics and operative 
details for each of the included studies. 
Study endpoints
Supplementary Table 4 (Supplemental Digital Content 4) shows the outcomes for each 
of the included studies. The main findings of the study are summarized in Table 3. Visual 
inspection of the funnel plots for the main outcomes of interest did not suggest presence 
of significant publication bias (Supplementary Figure 1; Supplemental Digital Content 5). 
Pre-sacral abscess
Twelve studies recorded the incidence of pre-sacral abscess formation.(4-6, 10, 22-29) The 
overall weighted mean proportion of pre-sacral abscess formation following OP was 8.7% 
(95% CI 6.1-12.3%). Considering nine comparative studies(4-6, 10, 22-24, 26, 28), pre-
sacral abscesses similarly occurred after OP and non-OP (RR 1.11; 95% CI 0.79-1.56; I2 = 0%)
(Figure 2.A). The risk of pre-sacral abscess was also similar in the predefined subgroup of APR 
with primary perineal closure for non-locally advanced rectal cancer (RR 1.06; 95% CI 0.68-
1.64; I2 = 0%)(Figure 2.B).(4-6, 23, 24) Similarly, there was no reduced risk of developing 
Table 1.  Study descriptions of the included studies. (continued)
study 
(author)


































* Newcastle-Ottawa Quality Assesment Scale; OP: Omentoplasty a: randomized controlled trial of 





pre-sacral abscesses after OP when only analysing the patients who have been treated with 
pre-operative radiotherapy (RR 0.94; 95% CI 0.61-1.45; I2 = 0%).(2, 4, 6, 23, 24) 
Table 2. Pooled baseline characteristics of study population with (OP) and without omentoplasty (Non-
OP)
 all patients (n= 1894)
non-locally advanced rectal 














64.3 [61.9 - 
66.6]
64.0 [61.7 - 
66.2]
64.9 [62.5 - 
67.3]
66.2 [64.2 - 
68.1]
Gender Male 438 (52%) 659 (62%) 204 (73%) 321 (67%)
 Female 280 (33%) 355 (34%) 77 (27%) 156 (33%)
 NR 121 (14%) 178 (17%) 0 (0%) 0 (0%)
disease Rectal cancer 693 (83%) 959 (91%) 281 (100%) 477 (100%)
 Anal cancer 99 (12%) 52 (5%) 0 (0%) 0 (0%)
 
Other malignant 
disease 18 (2%) 3 (0%) 0 (0%) 0 (0%)
 NR 29 (3%) 66 (6%) 0 (0%) 0 (0%)
neoadjuvant 
therapy None 104 (12%) 174 (16%) 18 (6%) 50 (10%)
 
Short course RTx 
(25Gy) 93 (11%) 114 (11%) 86 (31%) 168 (35%)
 
Long course RTx 
(40-60Gy) 78 (9%) 34 (3%) 15 (5%) 22 (5%)
 CRTx 319 (38%) 360 (34%) 147 (52%) 220 (46%)
 NR 245 (29%) 373 (35%) 0 (0%) 0 (0%)
Type of 
resection APR 594 (71%) 793 (75%) 281 (100%) 477 (100%)
 APR with MVR 154 (18%) 175 (17%) 0 (0%) 0 (0%)
 
Total pelvic 
exenteration 8 (1%) 1 (0%) 0 (0%) 0 (0%)
 NR 83 (10%) 86 (8%) 0 (0%) 0 (0%)
Perineal closure Primary suturing 690 (82%) 765 (73%) 281 (100%) 477 (100%)
 
Muscle flap 
reconstruction 42 (5%) 127 (12%) 0 (0%) 0 (0%)
 Mesh closure 107 (13%) 163 (15%) 0 (0%) 0 (0%)




36.6 [24.6 - 
48.6]
36.6 [22.7 - 
50.5]
37.9 [19.3 - 
56.5]
36.8 [19.6 - 
53.8]
OP: Omentoplasty; IQR: Interquartile range; NR: Not reported; RTx: Radiotherapy; CRTx: Chemoradio-
therapy APR: Abdominoperineal resection; MVR: Multivisceral resection; Percentages might not add 
up due to rounding
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Perineal wound healing
Eight studies recorded the primary perineal wound healing.(2, 4, 24-29) The overall 
weighted mean cumulative proportion of complicated wound healing at 30 days following 
OP was 50.6% (95% CI 35.5-65.6%). In fi ve comparative studies(2, 4, 24, 26, 28), the 
rate of complicated wound healing within 30 days was not signifi cantly different after 
OP and non-OP (RR 1.30; 95% CI 0.92-1.82; I2 = 74%). In subgroup analysis of APR 
with primary perineal closure for non-locally advanced disease, the association of OP with 
30-day wound complications remained non-signifi cant (RR 1.28; 95% CI 0.64-2.56; I2 = 
73%).(2, 4, 24) There was no reduced risk of pelviperineal morbidity within one year (RR 
1.18; 95% CI 0.80-1.74; I2 = 80%)(2, 4, 22, 24, 28) or within the total study period (RR 
1.09; 95% CI 0.83-1.44; I2 = 69%)(2, 4, 9, 10, 22-24, 28, 30) for patients submitted to OP. 
figure 2. Meta-analyses comparing pre-sacral abscess formation between patients with and without omento-
plasty in a) all patients who underwent APR for malignancy, and b) patients who underwent APR with primary 




Time to complete healing was not uniformly reported with regard to patient population 
(e.g. all patients or only those with dehiscence) and measuring unit (e.g. days or weeks)
(Supplementary Table 4; Supplemental Digital Content 4). The included studies demon-
strated no significant difference in time to achieve perineal wound healing in terms of 
mean number of days (MD 24 days in favour of non-OP; 95% CI minus 11 to 59; I2 = 80%)
(23, 24, 26, 30), or the proportion of patients in whom the perineal wound was healed 
within 3 months (RR 1.01; 95% CI 0.92-1.10; I2 = 0%).(4, 6, 22, 23)
Specific pelviperineal complications
The pooled proportions of specific pelviperineal complications following OP are demon-
strated in Supplementary Figure 2 (Supplemental Digital Content 6). After OP, the overall 
weighted mean incidence of wound dehiscence was 32.2% (95% CI 22.6-43.5%)(2, 4, 6, 
Table 3. GRADE Summary of findings table of the effects of omentoplasty for filling of the pelvic cavity 
following abdominoperineal resection













healing < 30 days RR 1.30 0.92-1.82 74% 853 (5) ⊕⊕⊕⊕ High
any complicated wound
healing < follow-up RR 1.09 0.83-1.44 69% 1033 (9) ⊕⊕⊕⊕ High
superficial perineal
infection RR 0.85 0.45-1.62 78% 1100 (8) ⊕⊕⊕⊝ Moderate
Pre-sacral abscess RR 1.11 0.79-1.56 0% 1596 (9) ⊕⊕⊕⊕ High
Perineal dehiscence RR 1.21 0.96-1.53 54% 1621 (9) ⊕⊕⊕⊝ Moderate
Perineal haemorrhage RR 1.39 0.29-6.58 25% 307 (3) ⊕⊕⊝⊝ Low
Persistent perineal sinus RR 1.08 0.53-2.20 56% 1370 (8) ⊕⊕⊕⊝ Moderate
Perineal hernia RR 1.85 1.26-2.72 0% 1584 (9) ⊕⊕⊕⊝ Moderate
ileus RR 0.90 0.62-1.31 0% 789 (6) ⊕⊕⊕⊝ Moderate
Reoperation for
pelviperineal complication RR 1.06 0.80-1.42 0% 1401 (9) ⊕⊕⊕⊕ High
GRADE Working Group grades of evidence
High quality: further research is very unlikely to change our confidence in the estimate effect
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of 
effect and may change the estimate
Low quality: further research is very likely to have an important impact on our confidence in the estimate of 
effect and is likely to change the estimate
Very low quality: we are very uncertain about the estimate
RR: risk ratio; CI: confidence interval; I2: test for heterogeneity
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9, 22-24, 26-29), which was 20.0% (95% CI 11.4-32.9%) for superficial perineal infection 
(2, 4, 9, 10, 23-29), 4.1% (95% CI 1.6-10.5%) for haemorrhage(2, 9, 24), and 8.0% 
(95% CI 5.1-12.4%) for perineal sinus.(2, 4, 6, 9, 22-24, 28, 29) There were no statistically 
significant differences among patients with and without OP in terms of perineal wound 
dehiscence (RR 1.21; 95% CI 0.96-1.53; I2 = 54%)(2, 4, 6, 9, 22-24, 26, 28), superficial 
perineal infection (RR 0.85; 95% CI 0.45-1.62; I2 = 78%)(2, 4, 9, 10, 23, 24, 26, 28), 
pelviperineal haemorrhage (RR 1.39; 95% CI 0.29-6.58; I2 = 25%)(2, 9, 24), or chronic 
perineal sinus (RR 1.08; 95% CI 0.53-2.20; I2 = 56%)(2, 4, 6, 9, 22-24, 28) (Supplementary 
Figure 3, Supplemental Digital Content 7).
Ileus
Twelve studies recorded the incidence of ileus.(2, 4, 6, 9, 10, 23-29) In the OP-group, the 
overall weighted mean proportion of ileus was 7.8% (95% CI 4.2-14.2%)(2, 4, 9, 10, 
23-26, 29), and 3.8% (95% CI 2.3-6.2%) required reoperation for ileus.(2, 4, 6, 25, 27-
29) Considering eight comparative studies, overall incidence of ileus was not significantly 
different with or without OP (RR 0.90; 95% CI 0.62-1.31; I2 = 0%)(2, 4, 9, 23, 24, 26), 
nor the proportion of ileus requiring reoperation (RR 1.19; 95% CI 0.58-2.44; I2 = 0%).
(2, 4, 6, 28) 
Perineal hernia
Twelve studies evaluated the incidence of perineal hernia.(2, 4, 6, 9, 22, 24-30) The overall 
weighted mean proportion of perineal hernia was 8.9% (95% CI 5.7-13.7%) in those 
undergoing OP. Nine comparative studies recorded the incidence of perineal hernia.(2, 4, 
6, 9, 22, 24, 26, 28, 30) The risk of perineal hernia was significantly increased in those sub-
mitted to OP compared to non-OP (RR 1.85; 95% CI 1.26-2.72; I2 = 0%)(Figure 3.A). This 
association remained similar in those who underwent APR with primary perineal closure for 
non-locally advanced disease (RR 1.83; 95% CI 1.17-2.87; I2 = 0%)(Figure 3.B).(2, 4, 6, 24) 
Omental flap complications
Among eight studies, the weighted mean proportion of OP-related complications was 
4.6% (95% CI 2.5-8.6%).(2, 4, 9, 10, 25, 27-29) Specific complications of the OP included 
signs of inflammation of the omentum (n=1), partial omental necrosis (n=1), total omental 
infarction (n=1), perineal dehiscence with omental protrusion due to necrosis of the OP 
(n=4), haemorrhagic shock due to bleeding of the gastro-epiploic artery (n=1) and internal 
herniation of small bowel underneath the OP (n=1). 
Surgical re-intervention
In twelve studies on OP, the overall weighted mean proportion of pelviperineal complica-




6, 9, 10, 22, 23, 25, 27-30), without signifi cant difference between OP and non-OP (RR 
1.06; 95% CI 0.80-1.42; I2 = 0%).(2, 4, 6, 9, 10, 22, 23, 28, 30) Hernia repair tended 
to be more frequent in the OP group (RR 1.71; 95% CI 0.87-3.35; I2 = 0%).(2, 4, 6, 28) 
Problems related to the OP itself were reason for reoperation in 3.8% (95% CI 1.9-7.6%).
(2, 4, 9, 25, 27, 28)
disCussion
In the current literature review with mainly source patient data, we found no evidence to 
suggest that OP reduces pelviperineal abscess formation, nor that OP enhances perineal 
wound healing considering any other endpoint, or that OP reduces the risk of small bowel 
obstruction. Similarly, no benefi cial effect of OP was found in planned subgroup analysis of 
patients that underwent APR with primary perineal closure for non-locally advanced can-
figure 3. Meta-analyses comparing perineal hernia development between patients with and without omento-
plasty in a) all patients who underwent APR for malignancy, and b) patients who underwent APR with primary 
perineal closure for non-locally advanced rectal cancer.
122
cer, thereby likely reducing the risk of allocation bias. Furthermore, OP itself is associated 
with a small risk of complications and appears to be associated with perineal herniation.
The absence of any beneficial effects of OP as found in the present meta-analysis is in con-
trast to literature on autologous tissue flaps for perineal wound closure following APR.(11, 
43) In particular, the use of a VRAM flap is well established.(8, 30, 44) However, studies 
directly comparing muscle flaps and OP are scarce. A retrospective single institutional study 
by Lefevre et al.(30) which was included in the present review – found that VRAM flap 
closure was associated with less perineal morbidity, reduced healing time and no perineal 
herniation (0% vs 15.4%; P=0.0072) if compared to primary layered closure with OP. There 
are several potential explanations as to why OP is not associated with such favourable out-
comes. Probably, the omentum is more likely to leave residual dead space, especially with 
thin patients. Furthermore, OP might have less robust blood supply after full mobilization, 
and compromised perfusion of an OP is sometimes difficult to recognize intra-operatively. 
An OP with partial necrosis of the most distal parts, which are subsequently placed in the 
perineal wound, will likely counterbalance any beneficial effect in other patients. But in 
our opinion, the most crucial difference between OP and VRAM flap reconstruction is the 
filling of anal dead space. The muscle, fascia, subcutaneous fat and skin of a VRAM flap 
are perfectly suited for reconstruction of the pelvic floor and perineal defect, while an OP 
only consists of loose fatty tissue that does not provide any strength. OP mainly fills the 
pre-sacral space, but the excised anal canal and sphincter complex seems to be the critical 
wound bed. The small bowel can fill the pre-sacral space in the absence of an OP, as will 
occur after VRAM flap reconstruction. 
Incidence of perineal hernia was around 10%, and is likely to even be an underestimation 
of the true incidence because of the retrospective design of most included studies. In 
meta-analysis, perineal hernia correlated significantly with the use of OP. This finding has 
recently been demonstrated in a nationwide study(6), but was felt to be counterintuitive by 
some surgeons, and probably best explained by wider resections in the OP-group. But this 
phenomenon may also be explained by the properties of an OP. As previously mentioned, 
the fatty and non-fibrous omentum is not providing any strength to the neo-pelvic floor, 
and even puts continuous pressure on the perineal skin in a standing position. It is under-
standable that, in case of a bulky OP with a long vascular pedicle, such redundant bulk of 
fat is more likely to descend below the level of the pelvic floor than a few loops of small 
bowel that are often restricted by a certain mesenteric length. The omental fat is certainly 
more likely to result in perineal bulging than VRAM flap closure where muscle and fascia is 




Two systematic reviews on the value of OP after APR have been published previously, both 
in contradiction with the current meta-analysis.(45, 46) Compared to the review of Nilsson 
et al.(46), only one study(29) is overlapping, and only three(9, 10, 29) out of 14 studies 
are overlapping with the review by Killeen et al.(45) Most of the older studies that were 
included in both previous reviews, concern a small sample size and diversity regarding 
patient population and surgical methods, with only few comparative series. In addition, 
the rather historical studies have restricted generalizability, especially considering the less 
frequent use of pre-operative radiotherapy. Strengths of the current review are restricted 
inclusion of publication since 2000, more comparative studies, and the use of primary 
source patient data, even if the original publication was not intended to study the effect of 
OP. Furthermore, benign pathology such as IBD was excluded, in contrast to the previous 
reviews. This resulted in more homogeneous patient populations with higher internal and 
external validity than previous systematic reviews published on the subject.(45, 46) These 
methodological issues may explain the contradictory findings.
The main limitation of our study is the potential for a certain degree of allocation bias. In 
the absence of randomized controlled trials, it could be that surgeons selectively applied 
OP in those with a larger empty space after resection, and therefore an a priori greater risk 
of wound complications and hernia. To reduce potential confounding, a subgroup analysis 
was performed by excluding extended resections and additional reconstructive procedures. 
Even then, however, the potential for allocation bias cannot be excluded. A second limita-
tion is that the definition of outcome variables in the source studies may be variable. In 
particular, the lack of a clear definition for pre-sacral abscess and perineal hernia (i.e. 
symptomatic perineal bulge or asymptomatic radiological finding) could potentially have 
influenced our results. However, reporting of perineal hernia was predominantly based on 
retrospective analysis of patient records, most likely not including small and asymptomatic 
radiological hernias . Also, total number of events were used for meta-analysis of perineal 
hernia, not properly taking into account the development of perineal hernia over time and 
differences among studies regarding duration of follow-up.
Based on the available literature, OP does not seem indicated for decreasing perineal 
wound complications after APR for cancer, nor does biological mesh closure.(4) Tissue 
transfer seems to have the greatest potential, but high quality studies comparing muscle 
flap closure to other methods of perineal wound closure are warranted. Although VRAM 
flap closure has been effectively used in selective populations(8), there remains the issue 
of donor and recipient site morbidity.(43, 47) A smaller flap without donor site problems 
such as the perineal turnover flap(48) seems attractive. We are currently evaluating the 
effectiveness of a modified gluteal turnover flap(49) for routine use after APR, and we 
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consider larger fascio-cutaneous gluteal or VRAM flaps only for the wider perineal defects 
with a high risk of sinus formation. 
Conclusions
In this systematic review and meta-analysis, that is reflecting current surgical practice of 
patients who are submitted to APR for malignant disease, we found no evidence to sup-
port the use of an OP for reducing pelviperineal morbidity. Additionally, use of OP has an 
added risk of OP associated complications, and seems to be associated with the long-term 
likelihood of developing perineal hernia. 
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The majority of patients with locally recurrent rectal cancer (LRRC) present with extensive 
metastatic disease or an unresectable recurrence, and will be treated palliatively. Only a 
minority of patients will be eligible for potential cure by surgical treatment. The aim of 
this study is to evaluate the long-term outcome of surgical treatment and non-surgical 
treatment of patients with LRRC.
Methods
All patients with LRRC referred to our tertiary institute between 2000 and 2015 were 
retrospectively analysed. Patients were discussed in a multidisciplinary tumour board (MDT) 
and eventually received curative surgical or non-surgical treatment. Overall survival (OS) 
was compared by resection margin status and non-surgical treatment. 
Results
A total of 447 patients were discussed in our MDT of which 193 patients underwent surgi-
cal treatment and 254 patients received non-surgical treatment. Surgically treated patients 
were significantly younger, received less neoadjuvant therapy for the primary tumour, had 
less metastasis at diagnosis and more central recurrences. The 5-year OS was 51% for 
R0-resections and 34% for R1-resections. Although numbers with R2-resections were too 
small to implicate prognostic significance, there was no difference in 5-year OS between 
R2-resections and non-surgical treatment (10% vs. 4%, p=0.282). In a subgroup analysis 
the OS of R2-patients was even poorer compared to optimal palliative treated patients with 
combined chemotherapy and radiotherapy(22 vs 29 months, p=0.413).
Conclusions
R2-resections do not result in a survival benefit compared to non-surgical treatment in this 
non-randomized series. Patients with a high chance on a R2-resection could be offered 





The introduction of total mesorectal excision (TME) and neoadjuvant (chemo-) radiotherapy 
have drastically decreased local recurrence rates after surgery for rectal cancer over the 
last decades. Locally recurrent rectal cancer (LRRC) still occurs in 6-10% of the surgically 
treated patients.(1-5) The development of LRRC has a major impact on quality of life, 
mostly by the occurrence of severe pain, bleeding and fistulation.(6)
Most patients with LRRC present with extensive metastatic disease or an unresectable 
local recurrence.(7-10) These patients can be offered non-surgical treatment, consisting 
of external beam radiotherapy, chemotherapy, a combination of both or comfort care.(11) 
Palliative external beam radiotherapy may relief pelvic pain complaints and chemotherapy 
may delay disease progression and prolong survival.(7, 8, 11-13) A minority of patients pre-
senting with LRRC can potentially be cured by surgical resection. The long-term outcome 
of surgical treatment mainly depends on the ability to achieve a clear resection margin.(10, 
14, 15) Management of LRRC remains a challenge both for curative surgical treatment and 
non-surgical treatment. 
The aim of the current study is to evaluate the long-term outcome of a large cohort of 
patients with LRRC and determining the outcome of curative surgical treatment and non-
surgical treatment in these patients. 
Patients and Methods
All consecutive patients with confirmed LRRC discussed in the multidisciplinary tumour 
board (MDT) of the Erasmus MC Cancer Institute, a tertiary referral hospital, from 2000-
2015 were retrospectively analysed. LRRC was defined as local recurrence of rectal cancer 
in the pelvic area. This MDT included experienced surgeons, radiologists, radiation on-
cologists and medical oncologists. If needed, gynaecologists, urologists, pathologists and 
plastic surgeons were invited to join the meeting. 
Data was collected from all referring hospitals, general practitioners and obtained from 
hospital notes, operation notes, histopathological and imaging reports. The local medical 
ethics committee of our institution approved this study (MEC-2017-448).
Surgical treatment
Surgical treatment was considered feasible in patients with resectable metastatic disease 
and/or non-metastasized LRRC with a realistic chance of a R0/R1-resection, as discussed by 
the MDT. R0-resections were defined as any radical resection (no tumour invasion in the 
resection plane, tumour-free margin of >1 mm); R1-resections as microscopically involved 
136
margins (tumour invasion in resection plane on microscopic assessment, tumour-free mar-
gin of ≤1 mm); R2-resections as macroscopically involved margins or massive invasion into 
the resection surface on pathology report. 
Patients were usually scheduled for neoadjuvant (chemo) radiotherapy. Radiotherapy-naïve 
patients were planned for long course radiotherapy (44.6-52Gy) and previously irradiated 
patients received a short course re-irradiation (27-30Gy). From 2006 onwards, all patients 
received concurrent Capecitabine during radiotherapy as reported previously.(16) Induc-
tion chemotherapy was occasionally administered. After neoadjuvant therapy, patients 
were restaged (CT Thorax/Abdomen and Pelvic MRI) and discussed in the MDT to evaluate 
development of distant metastases, tumour response of the local recurrence and clinical 
condition, which may alter the decision for surgical treatment to palliative treatment.(17) 
Surgical planning was made by the MDT based on imaging after restaging after neoadju-
vant therapy.
Surgical procedures included low anterior resection (LAR), abdominoperineal resection 
(APR) with and without multivisceral resection (MVR), and both posterior exenteration and 
total pelvic exenteration. Surgery was usually performed at our institute and in some cases 
in the referring hospital. In our institute, the multimodality approach for LRRC included 
intra-operative brachytherapy (IOBT) with a single dose of 10Gy. Patients received IOBT 
in case of a positive circumferential resection margin (CRM) or a narrow margin (CRM ≤ 
2mm) on frozen sections taken preoperatively. In addition, patients received IOBT in case 
of peroperatively expected or uncertain achievement of radical margins, i.e. due to fibrosis 
and patient with an expected peroperative R2-resection.(18, 19) Surgical complications 
were scored according to the Clavien-Dindo classification.(20)
Non-surgical treatment
Patients receiving non-surgical treatment usually had extensive metastatic disease, unresect-
able local recurrence or a poor clinical condition. There was no standard policy regarding 
the choice of non-surgical treatment. Non-surgical treatment consisted of radiotherapy or 
chemotherapy, either with or without hyperthermia or a combination of both and comfort 
care. Generally, patients with symptomatic LRRC were treated with radiotherapy and those 
with asymptomatic metastasized or unresectable LRRC were treated with chemotherapy. 
Hyperthermia was usually administered to previously irradiated patients due to the limited 
radiation dose available for their local recurrence. The choice of dose and fractioning of 
radiotherapy was largely based on the clinical judgment of the radiation oncologists and 
this resulted in heterogeneity in the radiotherapy management. Comfort care was provided 






Continuous data were reported as median (interquartile range or 95% confidence interval) 
and categorical data were reported as count (percentage). Group comparisons were made 
using Chi-square or Mann-Whitney-U-test as appropriate. Survival and follow-up were 
calculated from the date of LRRC diagnosis until death or last follow-up. Survival rates 
and follow-up were calculated by the (reversed) method of Kaplan-Meier and comparisons 
by log-rank test. For all analyses, patients were divided into two groups: 1) patients who 
underwent surgery and 2) patients who received non-surgical treatment including those 
patients who were previously considered eligible for surgical treatment. Statistical analyses 
were performed using IBM SPSS Statistics v24.0.0 for Windows (IBM Corp, Armonk, New 
York, USA).
ResulTs
A total of 447 consecutive patients with LRRC were discussed in our MDT. A flowchart 
of included patients is displayed in figure 1. After discussion in the MDT, 244 patients 
(55%) were considered candidates for surgery. This decision was reversed in 51 patients 
after restaging after neoadjuvant therapy, as described in figure 1. In total, 193 patients 
underwent surgical treatment and 254 patients received non-surgical treatment. Patient, 
primary and recurrent tumour characteristics are outlined in table 1. Treatment and follow-
up are depicted in table 2. 
Time to recurrence after primary rectal cancer resection
The median time from primary tumour resection to the diagnosis of LRRC was 23 months 
(IQR 11 – 39 months). In more than half of the patients (55%) LRRC developed within 
2 years and in almost all patients within 5 years (88%). A total of 162 patients (36%) 
presented with synchronous metastases at diagnosis of LRRC: the predominant location 
was lung only (34%), followed by liver only (28%), other (24%) or liver and lung (14%). 
The median time to diagnosis of LRRC was significantly shorter in patients with incomplete 
primary tumour resections compared to patients with complete resections (10 vs. 24 
months, p<0.001) and in patients who had received neoadjuvant radiotherapy for the pri-
mary tumour compared to no radiotherapy (21 vs. 24 months, p=0.039). More advanced 
primary pathological T-stage (T3-4 vs. T1-2) did not influence the median time to LRRC (21 
vs. 24 months, p=0.172), nor lymph node positivity (21 vs. 23 months, p=0.776).
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surgical and non-surgical patients
There were significant baseline differences for patients who eventually underwent surgery 
(n=193) compared to all non-surgically treated patients (n=254) (Table 1). Surgically treated 
patients were significantly younger, less symptomatic at presentation of LRRC, received less 
radiotherapy for the primary tumour, had fewer incomplete primary tumour resections, 
had less frequent synchronous distant metastasis, more differences in terms of localization 
of the local recurrence and underwent different procedures for the primary rectal tumour. 
Patients with a central localization of the local recurrence were more likely to be scheduled 
for surgical treatment, whereas patients with a pre-sacral recurrence were more likely to 
receive non-surgical treatment. 













Gender Male 289 (65%) 125 (65%) 164 (65%) 0.965
Female 158 (35%) 68 (35%) 90 (35%)
Age at primary tumour 
resection
Median (IQR) 63 (56-70) 62 (54-67.5) 64 (56-72) 0.016*
Age at diagnosis LRRC Median (IQR) 66 (58-73) 65 (57-71) 67 (58-75) <0.001*
Neoadjuvant treatment 
primary tumour
None 256 (57%) 126 (65%) 130 (51%) 0.002**
Short course RTx 49 (11%) 18 (9%) 31 (12%)
Long course RTx 62 (14%) 14 (7%) 48 (19%)
Chemoradiotherapy 80 (18%) 35 (18%) 45 (18%)
Primary tumour resection LAR 244 (55%) 112 (58%) 132 (52%) <0.001**
APR 106 (24%) 30 (16%) 76 (30%)
Rectosigmoid 55 (12%) 32 (17%) 23 (9%)
Exenterative surgery 21 (5%) 4 (2%) 17 (7%)
TEM 21 (5%) 15 (8%) 6 (2%)
Primary tumour stage Stage I 52 (13%) 30 (16%) 22 (10%) 0.076
Stage II 139 (34%) 58 (31%) 81 (35%)
Stage III 186 (45%) 86 (46%) 100 (44%)
Stage IV 38 (9%) 12 (7%) 26 (11%)
Missing*** 32 7 25
Resection margin primary 
tumour
R0 381 (88%) 174 (96%) 207 (83%) <0.001**
R1 50 (12%) 8 (4%) 42 (17%)
Missing*** 16 11 5
Interval primary - LRRC Median (IQR) 23 (11-39) 24 (12-40) 21 (10-37) 0.154
Recurrence within 24 months 246 (55%) 99 (52%) 147 (58%)
5 years 393 (88%) 174 (90%) 219 (86%)
10 years 433 (97%) 191 (99%) 242 (95%)
Symptoms at diagnosis LRRC Yes 262 (55%) 86 (45%) 176 (69%) <0.001**
No 185 (45%) 107 (55%) 78 (31%)
Metastases at diagnosis LRRC None 285 (64%) 172 (89%) 113 (45%) <0.001**
Lung 55 (12%) 11 (6%) 44 (17%)
Liver 45 (10%) 7 (4%) 38 (15%)
Lung & Liver 23 (5%) 0 (0%) 23 (9%)
Other 39 (9%) 3 (2%) 36 (13%)
Location LRRC Central 74 (18%) 54 (29%) 20 (9%) <0.001**
Anterior 62 (15%) 31 (17%) 31 (14%)
Posterolateral 53 (13%) 24 (13%) 29 (13%)
Anterolateral 34 (8%) 14 (8%) 20 (9%)
Lateral 59 (14%) 29 (16%) 30 (13%)
Pre-sacral 133 (31%) 33 (18%) 100 (44%)
 Missing*** 32 8 24  
*Mann Whitney U test ** Chi squared test *** missing’s not included in group comparison, percentages-
might not add up due to rounding
LRRC: Locally recurrent rectal cancer; IQR: interquartile range; RTx: radiotherapy; LAR: low anterior resection;APR: 
abdominoperineal resection; TEM: transanal endoscopic microsurgery
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surgical treatment
The majority of surgically treated patients received neoadjuvant therapy (90%) and more 
than half of the patients received (re-)chemoradiotherapy (62%). Some patients received 
induction chemotherapy (n=13) or radiation (n=38) or re-irradiation (n=9) without concur-
rent Capecitabine and 7 patients received solely induction chemotherapy. In 175 patients 
(91%) the surgical procedure was performed at our institute, while 18 procedures (9%) 
were performed in the referring hospitals. Neoadjuvant therapy and surgical procedures 
are described in Table 2. 
Table 2. Treatment and follow up of LRRC in surgical and palliative treatment
 surgical (n=193) Palliative (n=254)
neoadjuvant therapy lRRC
None 19 (10%) 205 (81%)
Irradiation (50Gy) 38 (20%) 13 (5%)
Re-irradiation (30Gy) 9 (5%) 3 (1%)
Induction chemotherapy* 20 (10%) 9 (2%)
Chemoradiotherapy (50Gy) 61 (32%) 14 (6%)
Re-Chemoradiotherapy (30Gy) 59 (31%) 15 (6%)
surgical procedure
Total pelvic exenteration 43 (22%) N/A
Posterior pelvic exenteration 27 (14%) N/A
 APR with MVR 26 (14%) N/A
 LAR with MVR 18 (9%) N/A
Local resection with MVR 11 (5%) N/A
APR only 25 (13%) N/A
LAR only 26 (13%) N/A
Local resection only 17 (7%) N/A
IORT 86 (45%) N/A
follow up
Alive at last FU 65 (34%) 9 (4%)
No evidence of disease at last FU 47 (24%) N/A
Local re-recurrence 62 (32%) N/A
Metastases (any) 88 (46%) 186 (73%)
Metastases (synchronous) 14 (7%) 138 (54%)
Metastases (metachronous) 74 (38%) 48 (19%)
Lung** 47 (53%) 63 (34%)
Liver 15 (17%) 46 (25%)
Lung and liver 10 (11%) 26 (14%)
Peritoneal 6 (7%) 15 (8%)
Lymphogenic 7 (8%) 20 (11%)
Other 3 (3%) 16 (9%)
* Combined with (chemo-)radiotherapy in 13 patients for surgical patients and 5 non-surgical patients; ** 
Location of metastases are reported as percentage within metastases; N/A: not applicable; APR: abdominoperi-






R0-resections were achieved in 116 patients (60%), R1-resections in 56 patients (29%) 
and R2-resections in 21 patients (11%). The 30-day mortality and the in-hospital mortality 
rate were both 3% (n=5). Four patients died within 22 days and one patient died during 
admission at 67 days after surgery. Postoperative complications were registered in 176 out 
of 193 patients. A total of 59 (34%) patients experienced major complications (Clavien-
Dindo ≥ 3). Most common complications were wound complications (23%), pre-sacral 
abscesses (11%) and urinary tract infections (9%). Surgical re-intervention was required 
in 26 patients (13%) and abscess drainage (i.e. pre-sacral or abdominal abscess) in 25 
patients (13%). Complications for surgically treated patients are displayed in Table 3.
non-surgical treatment
A total of 254 patients received non-surgical treatment, including 51 patients who were 
first considered candidates for surgical treatment. These patients had received neoadjuvant 
therapy, but the aim of the treatment was altered as described previously. Patients were 
Table 3. Surgical complications
 Total (n=193)
Clavien-dindo
No complication 59 (34%)
Clavien-Dindo I 31 (18%)
Clavien-Dindo II 27 (15%)
Clavien-Dindo IIIA 21 (12%)
Clavien-Dindo IIIB 25 (14%)
Clavien-Dindo IVA 3 (2%)
Clavien-Dindo IVB 4 (2%)
Clavien-Dindo V 5 (3%)
Most common complications
Wound complication 45 (23%)
Pre-sacral abscess 22 (11%)




Cardiac complication 12 (6%)
Nephrostomy 12 (6%)
Reintervention stoma 3 (2%)
Anastomotic leakage 3 (2%)
Any surgical reintervention 26 (13%)
Any abscess drainage 25 (13%)
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treated by radiotherapy (n=100), by chemotherapy only (n=54), by combined radiotherapy 
and chemotherapy (n=51) or comfort care (n=49). 
In 63 previously irradiated patients, re-irradiation was administered in varying doses of 
15 to 48 Gy delivered in 3-15 fractions. Radiotherapy-naïve patients (n=88) received 
radiotherapy doses varying from 6-66Gy in 4-28 fractions. Almost half of the patients 
experienced pain (48%) of whom the majority (56%) needed pain consultation. 
follow-up and survival surgical and non-surgical treatment
The median follow-up time for the whole cohort was 26 months (IQR 11 – 45) and median 
follow-up for survivors was 120 months (IQR 68 – 142).
survival surgically treated patients
The median follow-up of the 193 surgically treated patients was 42 months (IQR 29 - 70) 
and the median follow-up for survivors was 117 months (IQR 67 - 140). The estimated 1-, 
3- and 5-year overall survival rates were 93%, 65% and 41%, respectively. The median 
overall survival was 47 months (IQR 29 – 156). The estimated 1-, 3- and 5-year local 
re-recurrence free survival rates were 81%, 64% and 63%, respectively. The median local 
re-recurrence free survival was not reached. At last follow-up 65 (34%) patients were 
alive, of whom 50 patients with no evidence of disease. Sixty-two patients developed a 
local re-recurrence and 74 patients developed metastases after surgery. Thirty-one patients 
were diagnosed with both. Recurrence patterns and death by resection margin are dem-
onstrated in Table 4. 
survival non-surgically treated patients
The median follow-up of the 254 non-surgically treated patients was 15 months (IQR 7 – 29) 
and the median follow-up for survivors was 145 months (IQR 142-162). The estimated 1-, 
3-, 5-year overall survival rates were 60%, 19%, 4%, respectively. The median survival was 
the highest for patients treated with combined radiotherapy and chemotherapy, followed 
by chemotherapy only, radiotherapy only and comfort care (29, 18, 14 and 7 months, 
respectively). There was no significant difference in median survival of metastasized and 
non-metastasized patients at diagnosis (14 vs. 18 months, p=0.293). Nine patients were 
alive at last follow-up. One patient, with a proven LRRC on imaging, had a complete 
radiologic response of the recurrence after treatment with radiotherapy and was alive at 
162 months follow-up. Two patients, with histologically confirmed LRRCs, were alive at 
145 and 142 months with stable systemic and local disease after an experimental chemo-
therapeutic treatment. Two patients, with histologically proven LRRC and systemic disease, 
were alive at 44- and 32-months follow-up, both receiving experimental chemotherapeutic 




elevated carcinoembryonic antigen were alive at 44 and 32 months with slowly progressive 
systemic and local disease without treatment. Another two patients with histologically 
proven LRRC and systemic disease were alive, but were lost to follow-up at 21 and 10 
months. Distant metastases were diagnosed in 186 patients. In 141 patients, distant 
metastases were diagnosed at presentation and 45 patients developed distant metastases 
during follow-up of non-surgical treatment. 
survival by resection margin vs. non-surgical treatment
Compared to patients treated non-surgically, there was a significant difference in 5-year 
overall survival in favour of patients with R0-resections (51% vs. 4%, p<0.001) and R1-
resections (34% vs. 4%, p<0.001). There was no difference in overall survival between 
R2-resections and non-surgical treatment (10% vs. 4%, p=0.282). This is shown in figure 
2. In a subgroup analysis, patients with a R2-resection had a prolonged median survival of 
29 months (IQR 16 – 41) compared to 22 months (IQR 14 – 37) of the patients who were 
treated with palliative radiotherapy and chemotherapy, although this difference was not 
significant (p=0.413). 
figure 2. Overall survival according to surgical resection margin and non-surgical treatment
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disCussion
This large cohort of patients with LRRC, treated by surgical or non-surgical treatment, have 
demonstrated that R0- and R1-resections result in a 5-year overall survival rate of 51% 
and 34%, respectively. These survival rates are significantly prolonged compared to non-
surgical treatment. Although numbers were too small to implicate prognostic significance, 
R2-resections did not result in a 5-year overall survival benefit compared to non-surgical 
treatment with a rate of 10% vs. 4%. Moreover, the overall survival of patients who un-
derwent a R2-resection was poorer compared to patients who were treated non-surgically 
with combined radiotherapy and chemotherapy. 
The 5-year overall survival rate for R0-resections in the present study is in line with previ-
ously reported outcomes of population-based studies and meta-analyses within a range of 
43%-60%. Additionally, the poorer overall survival rate of R1-resections (range 14-36%) 
and the dismal overall survival rate of R2-resections (range 0-16%) are in line with the 
overall survival rates reported by others.(7-11, 14, 15) This confirms that resection margin 
status after surgical treatment for LRRC is the most important prognostic factor for overall 
survival. Unfortunately, not all LRRC patients are eligible for curative surgery. 
The 5-year survival rate of 4% for all non-surgically treated patients in this study seems rela-
tive high compared to other series, which rarely exceeds 4%.(21, 22) However, a recently 
published study by Bhangu et al.(23) demonstrated a 3-year overall of approximately 35% 
for patients who did not undergo surgery, which is even higher compared to our 3-year 
overall survival of 19%. In line with our study, they reported an overall survival benefit in 
favour of R0- and R1-resections compared to non-operative management. In R2-resections, 
they were not able to find a survival benefit compared to non-operative management. 
Neither a large meta-analysis by their group was able to demonstrate a survival benefit 
for R2-resections compared to non-surgical treatment.(14, 23). These results are similar to 
our study, where we were not able to find a survival benefit of R2-resection compared to 
non-surgical treated patients. In a subgroup of patients who were treated by radiotherapy 
and systemic chemotherapy, a prolonged median survival was found compared to R2-
resections (29 vs 22 months). Nevertheless, in our study the results of R-resections our 
limited by the small number of patients and cannot implicate statistical significance.
The survival benefit of R0- and R1-resections compared to non-surgical treatment seems 
clear in the current study. However, it is important to realize that these results may be 
influenced by a selection bias. This study includes patients who are referred and discussed 
in our MDT, the number of patients not suitable for surgery, and not referred to our MDT, 




tion of patients with unfavourable characteristics compared to the surgically treated pa-
tients. Non-surgically treated patients had more synchronous distant metastases and more 
advanced local recurrences. These unfavourable characteristics may contribute to a poorer 
prognosis of the non-surgical group. In line with others, the overall survival of patients 
receiving only comfort care was poor with a median survival of 7 months. This median 
survival was poorer compared to R2-resections.(8, 10, 14, 23) However, it is important to 
realize these patients were generally in such poor clinical condition that they were not able 
to receive any form of treatment. 
Untreated LRRC can cause severe impairment in quality of life mainly due to severe pain, 
but also fistula, obstruction or bleeding.(6, 24) There may be a role for palliative surgery in 
these patients to reduce pain, and relief symptoms of obstruction by stenting or a divert-
ing stoma as reported by others.(11, 25, 26) However, surgery is accompanied by high 
morbidity and mortality rates, occurring mainly perioperative or in the first 3 months after 
surgical treatment. This impairment in quality of life persists until one year after surgery. 
Thereafter, surgically treated patients tends to have a better quality of life.(27) This fact 
and the lack of a survival benefit of R2-resections suggest that LRRC surgery with a high 
chance on R2-resections should be abandoned and should only be performed when the 
potential benefit is clear.
Regarding the secondary findings, this study identified several factors associated with 
resectability of LRRC. Obviously, age is a factor to be considered candidate for LRRC sur-
gery due to the high morbidity and mortality rates of LRRC surgery. Previous irradiation 
for the primary tumour was also associated with resectability. Presumably, neoadjuvant 
radiotherapy for the primary tumour is not able to prevent local recurrences in patients 
with unfavourable primary tumour characteristics, such as more residual disease or higher 
tumour load. These patients do also have a higher risk of developing distant metastases 
and were therefore disqualified for LRRC surgery.(28) Patients with a more extensive 
primary procedure had a lower chance to be considered candidates for LRRC surgery. 
Extensive primary surgery leads to local recurrences closely related to structures, which can-
not be resected completely, while low anterior resections or local excisions (TEM, transanal 
endoscopic microsurgery) may lead to central recurrences. This makes localization of the 
local recurrence also associated with resectability, because central recurrences results more 
often into R0-resections.(29)
A promising strategy to improve resectability of LRRC is induction chemotherapy. However, 
improved resectability does not automatically guarantee a survival benefit. Other factors, 
such as tumour behaviour, have more impact on overall survival as well. In our study few 
patients received induction chemotherapy, but a retrospective cohort study by van Zoggel et 
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al.(30) compared outcomes of resection of LRRC in patients with induction chemotherapy 
followed by chemoradiotherapy to patients who received solely chemoradiotherapy. The 
R0-resection rate did not differ significantly, but a higher rate of pathologic complete 
response was found in patients with combined treatment. Van Zoggel et al.(30) suggested 
that response rate to induction chemotherapy may be used as guidance to avoid overtreat-
ment in patients with progressive disease under induction chemotherapy. Otherwise, in 
a previous study, our institute showed a lower response to chemotherapy of the local 
recurrence compared to the response of distant metastases in a small cohort of previously 
irradiated rectal cancer patients.(31) Further research is warranted to evaluate the potential 
benefit of induction chemotherapy for treatment of LRRC. 
Due to the retrospective nature of this analysis, this study has drawbacks. There was 
no standard protocol for non-surgical treatment. The choice of non-surgical treatment 
consisting of radiotherapy, chemotherapy, or only comfort care was judged on clinical 
factors. This resulted in a heterogenetic group of patients from critical ill patients not able 
to receive any form of treatment, to patients in good clinical condition, refusing surgery. 
Follow-up data of patients treated non-surgically was limited, because treatment was usu-
ally performed in the referring hospitals. Therefore, data of complication rates and quality 
of life in non-surgically treated patients was limited. 
Furthermore, this study was only able to demonstrate survival differences. As mentioned 
above, quality of life may be even more important in the management of LRRC. Future 
research should focus on quality of life of surgical or palliative management of LRRC. 
In conclusion, R0- and R1-resections of LRRC resulted in 5-year overall survival rates of 
51% and 34%, respectively. Although numbers with R2-resections were too small to 
implicate prognostic significance, there was no significant difference between the 5-year 
overall survival for R2-resections and palliative treatment (10% vs. 4%). Moreover, the 
median survival may be poorer for surgically treated patients with a R2-resection compared 
to optimal palliatively treated patients. Patients with a high chance on a R2-resection could 
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Chapter 9
Pelvic exenteration for invasive rectal 












The incidence of rectal cancer is increasing worldwide.(1) At the time of diagnosis of pri-
mary rectal cancer, approximately 10% of the patients have locally advanced rectal cancer 
(LARC) and approximately 6-10% of patients treated for primary rectal cancer will develop 
locally recurrent rectal cancer (LRRC).(2-6) Over the past decades the development of 
multimodality treatment for LARC and LRRC, including TME-surgery, neoadjuvant (chemo-)
radiotherapy, surgical treatments and intraoperative radiation therapy (IORT), improved 
overall survival and local control after treatment.(3, 4, 7-10) The cornerstone of treatment 
for rectal cancer remains achievement of a clear resection margin.(11-13) Many studies over 
the last decades described a clear resection margin as the single most important prognostic 
factor for overall survival and local control in rectal cancer surgery.(5, 11, 13-19) Overall 
survival by resection margin status is significantly higher after R0 resection compared to R1 
or R2 resections.(14, 18, 20) This emphasizes the importance of a radical resection margin 
with surgery. Standard abdominoperineal excision (APE) and low anterior resection (LAR) 
for rectal cancer often achieve radical resection margins, but if there is invasion of adjacent 
organs, such as bladder, ureters or male and female reproductive organs, a more radical 
approach is indicated. 
Surgical procedures during which more than one organ is resected are generally referred 
to as “multivisceral resections”. Exenteration is derived from the Latin term ‘’exenterare’’ 
and is generally interpreted as “complete removal” of contents of a body cavity such as the 
pelvis. Complete en bloc removal of all organs of the pelvis is called “pelvic exenteration”, 
or “total pelvic exenteration”. In women, an anterior pelvic exenteration refers to removal 
of the bladder, uterus and ovaries, leaving the rectum in situ, posterior pelvic exenteration 
refers to removal of the rectum, uterus, ovaries and the posterior vaginal wall. Total pelvic 
exenteration refers to removal of the rectum, uterus, ovaries and bladder. In men, an 
anterior exenteration means removal of bladder, vesicles and prostate, but this procedure 
is more commonly referred to as a cystoprostatectomy. A total pelvic exenteration means 
removal of bladder, prostate, vesicles and rectum. For selective resections of organs or 
structures that do not result in a formal anterior, posterior or total pelvic exenteration, we 
use the term “modified exenteration”.
Pelvic exenteration for advanced pelvic malignancies was first described by Brunschwig 
et al.(21) in 1948 as a palliative treatment of gynaecological cancer. The first series de-
scribed had a high perioperative mortality and poor survival rates.(21, 22) Over time pelvic 
exenteration developed as a surgical technique for curative treatment for all pelvic malig-
nancies with invasion of adjacent organs including urogenital cancers, rectal cancer and 
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recurrent malignancies, which were often previously treated with surgery and/or (chemo) 
radiotherapy.(23-25)
This chapter focuses on the treatment of locally advanced rectal cancer or recurrent rectal 
cancer with invasion of the male and female urogenitary tract with pelvic exenteration of 
the anterior compartment.
diagnostics
Every patient should be discussed in a specialized multidisciplinary tumour board. The 
characteristics of different diagnostic modalities are discussed elsewhere. In case of locally 
advanced tumours and even more so in recurrent rectal cancer, accurate local staging is im-
perative. We use contrast enhanced MRI with diffusion weighted images. For this specific 
patient group, other modalities may have their use in detecting metastases, but they are 
not helpful in evaluating the local situation in the pelvis and preoperative decision-making. 
One diagnostic modality may have its specific use in this population though: the MAGIII 
scan. Quite often, obstruction of one of the ureters has led to deterioration of the function 
of the affected kidney. The anastomosis between ureter and bowel for an urinary diver-
sion may cause complications such as anastomotic leakage and pyelonephritis. Therefore, 
reanastomosing a kidney that has a little or no function should be considered a failure. 
A MAGIII scan can clarify the percentage of kidney function that is contributed by both 
kidneys. In case of a contribution of <15% we usually choose to either ligate the ureter or 
remove the kidney in case it is contaminated (usually by placement of a double J catheter 
following the discovery of a dilated pyelum).
neoadjuvant induction therapy 
Current guidelines advise neoadjuvant chemoradiotherapy for the treatment of advanced 
rectal cancer. Usually, a cumulative dose of 50 Gy in 25 fractions of 2 Gy combined with a 
chemotherapeutic regimen is administered.(26, 27) Neoadjuvant therapy could downsize 
the tumour and this may result in more radical resections and less local recurrence. For 
patients with locally recurrent rectal cancer the options for neoadjuvant therapy may be 
limited, because patients often received neoadjuvant therapy for the primary tumour. Cur-
rently, reirradiation with or without concomitant chemotherapy is standard, usually with a 
cumulative dose of 30 Gy delivered in 15 fractions of 2 Gy. There are promising strategies 
such as induction chemotherapy with 5-fluoracil and oxaliplatin with reirradiation in these 
patients, which may lead to a higher pathological complete response in these patients.
(28) Neoadjuvant reirradiation may be combined with intraoperative radiation therapy or 





The nature of the surgical procedure depends on the extent of the tumour. In case of 
limited ingrowth in other organs, a selective resection can be sufficient. Resection of the 
ureter, uterus and part of the bladder are examples of selective procedures that are rou-
tinely performed in specialized centres. More extensive tumours and locally recurrent rectal 
cancer often require formal posterior and total pelvic exenterations. 
Patients are under general anaesthesia and generally receive epidural anaesthesia and are 
placed in the lithotomy position. Patients with T4 rectal cancer or locally recurrent rectal 
cancer are generally not considered candidates for minimally invasive techniques, because 
tactile feedback is essential in achieving a radical resection. The procedure starts with a 
midline laparotomy. In our centre we routinely perform an omentoplasty and therefore, the 
midline incision may be advanced cranially further than strictly necessary for pelvic surgery. 
Since both locally advanced and locally recurrent rectal cancer are associated with a high 
incidence of systemic and peritoneal metastases, careful inspection of the whole abdomen 
is mandatory before continuing the procedure. After placement of an abdominal retractor, 
dissection is commenced depending on the nature of the tumour. In case of a primary 
tumour in situ, a normal TME approach is continued for as long as possible.
Ureter 
In case of involvement of the ureter, the ureter is identified just above the level of the 
promontory and freed in a cranial and caudal direction, while preventing damage to the 
vasculature of the ureter itself. This is achieved by leaving the ureteral adventitia in place, 
rather than dissecting the ureter clean. We cut the ureter approximately one centimetre 
above the level of the tumour and insert a single J catheter. Fibrosis and tumour are often 
difficult to differentiate during surgery and any fibrous tissue is considered tumour for 
the sake of achieving radical resections. Transection of the ureter opens up the lateral 
compartment of the pelvis and facilitates radical resection of disease in this compartment. 
Further resection of all tissues involved is performed, as identified by palpation, macros-
copy and guided by preoperative MRI. When the bladder is not involved, the distal ureter 
may be cut and ligated, although leaving the ureter open seldom causes leakage from the 
bladder, because of the ureterovesical valve. The ureter may be reinserted in the bladder 
using the so-called “psoas-hitch” technique. The bladder is mobilized on the contralateral 
and anterolateral side of the bladder. Ligation of the vesical artery and vein is usually not 
necessary. The bladder is incised transversely and fixed to the psoas muscle fascia just 
above the level of the anticipated anastomosis between ureter and bladder. The ureter is 
then inserted in the bladder through a small incision, spatulated and fixed with resorbable 
sutures. The transverse incision in the bladder is closed longitudinally, the single J catheter 
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is led out through the bladder wall, the abdominal wall and skin. We remove the single J 
splint 10 days after surgery when no signs of anastomotic leakage are present.
Lateral compartment 
In case of involvement of the pelvic sidewall, which occurs frequently in locally advanced 
and recurrent rectal cancer, the internal iliac artery and vein, may also be transected to 
facilitate more extensive resections up to the acetabulum. Reconstruction of the internal 
iliac artery and vein is generally not needed because of sufficient collateral blood supply. In 
seldom cases, in which the external or common iliac vessels are involved, radical resection 
can sometimes be achieved by complete resection of the external or common iliac vessels. 
In case of persistent lymph node metastases in the lateral compartment, a formal lymph 
node dissection of this area can be performed. The goal of lateral lymph node dissection is 
to resect all nodes in the pelvic side wall lateral from the internal iliac vessels after ligating 
these vessels while preserving the obturator nerve and sacral plexus. In some cases, en bloc 
resection with these structures is necessary for full clearance of all suspect lateral lymph 
nodes.(33-35) This procedure is associated with increased urinary and sexual dysfunction, 
prolonged operation time and possible increased blood loss.(36, 37) A recent meta-analysis 
showed no cancer specific advantages of extended lymphadenectomy for rectal cancer, 
but there is evidence suggesting that patients with persistent lateral lymph nodes after 
neoadjuvant (chemo) radiotherapy may benefit from mesorectal excision with lateral lymph 
node dissection. (36, 38-40) 
Often, neoadjuvant therapy, recurrence and advanced disease result in a situation in which 
formal node dissections may be difficult to achieve technically. In such cases, achieving a 
radical resection is the goal, which will prove challenging enough as it is.
Partial cystectomy
Successful partial bladder resections are usually performed for radical resection of T4 sig-
moidal cancer, because these tumours may involve the more cranial aspect of the bladder. 
It is important to identify the orifices of both ureters to prevent obstruction of the ureter 
while closing the defect. It is also important to consider whether the size of the remaining 
bladder, combined with the anticipated function after neoadjuvant therapy, may result in 
a functioning bladder. We strongly advise to have an urologist-oncologist present in the 
OR to assist in decision-making. When a small bladder remnant is unlikely to ever func-
tion properly a bladder resection and urinary diversion may be preferable. When partial 
resection is possible, we open the bladder cranially and choose the dissection planes on 
palpation and sight. We close the bladder with two layers of 3-0 slowly resorbable sutures. 




bladder wall resections at this level often result in a bladder remnant that is impossible 
to reconstruct in such a manner that both ureters can be reinserted into a functional 
remnant. Again, we advise to involve the urologist-oncologist in decision-making. When 
partial resection is not feasible, a total pelvic exenteration is indicated (see below: total 
pelvic exenteration)
Partial prostatectomy
In case of limited involvement of the prostate, without involvement of the urethra, a partial 
resection of the prostate may be attempted. It should be noted that the urethra is close to 
the posterior capsula of the prostate. We insert a large diameter silicone urinary catheter 
to palpate the urethra. Softer catheters are palpated less easily. Dissection of the capsula 
of the prostate should be performed through a perineal approach, usually as part of an 
abdominoperineal excision (APE) of the rectum. After performing the usual steps of an 
APE as described elsewhere, we leave the anterior dissection as long as possible. We then 
identify the urethra by palpation of the silicone catheter and approach the capsula of the 
prostate caudally and laterally after lateral transection of the pelvic floor. The surgeon may 
now open the capsula of the prostate and include a layer of prostate in the resection speci-
men. Continuous palpation may clarify whether the tumour is resected completely and the 
surgeon can then return to the normal plane with or without including the seminal vesicles 
in the specimen. When complete removal of the seminal vesicles is performed, the surgeon 
should be aware that he is approaching the distal ureters from below. It is noteworthy 
that this type of resection often results in R2 resections, because the extra amount of 
tissue that can be resected is limited, palpation is difficult, especially in case of extensive 
fibrosis, and most surgeons are not accustomed to this dissection plane. We would advise 
to be cautious and refer these patients to a specialized centre, where conversion to a total 
pelvic exenteration can be performed as needed when perioperative frozen sections show 
involved resection margins. In case of damage to the urethra, repair will not result in heal-
ing of the urethra. A permanent suprapubic catheter may temporarily alleviate symptoms 
of urine leakage, but urinary deviation is usually indicated to restore quality of life.
In case the prostate cannot be saved, which is common in case of T4 tumours invad-
ing the prostate or locally recurrent disease in men, the prostate is resected completely 
and the urethra cannot be re-anastomosed, as high dose radiotherapy (which almost all 
patients have received) impairs proper healing of a vesico-urethral anastomosis. Therefore, 
we routinely perform a total pelvic exenteration in these cases, resecting both prostate 
and bladder and create an urinary diversion. For further details, see below (total pelvic 
exenteration).
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Uterus and vaginal wall
Whereas in men, anterior T4 and recurrent rectal cancer may extend into bladder and 
prostate, in women, the uterus and posterior vaginal wall are the first to become involved 
in tumour extension. Tumour ingrowth into the body of the uterus is relatively rare, as 
the peritoneal reflection is located lower, at the level of the cervix. Tumour ingrowth at 
this level can easily be solved by resection of the uterus, as described for gynaecological 
cancer. The ovarian vessels and ligaments are ligated and the uterus mobilized. This can 
be done by opening the peritoneum and dissecting the bladder form the anterior aspect 
of the uterus. The vaginal wall is identified and cleared to the caudal aspect of the cervix. 
The ureters are identified up to their insertion in the bladder or at least up to the point that 
they are no longer at risk. We then identify the vasculature at the level of the cervix, isolate 
and either ligate it or use an energy device. When cutting of the many venous branches 
results in blood loss, it is imperative to be cautious with clamps, diathermy and energy 
devices, considering the proximity of the ureter. We then open the vagina anteriorly, below 
the palpated level of the cervix, using diathermy and cut the lateral and posterior aspect of 
the vaginal wall. The placement of clamps on the vaginal wall and lifting these facilitates 
separation of vagina and rectum. The rectum may be cut at the level desired. We close the 
vaginal wall with a slowly absorbable suture, taking care to not include the distal ureter in 
the sutures. 
Involvement of the cervix and posterior vaginal wall is more common. We follow the same 
procedure as described above. When the anterior vaginal wall is opened, we perform an 
inspection and palpation of the vaginal wall and choose our level of dissection. Findings on 
the preoperative MRI also guide decision-making. The posterior wall is transected and the 
vaginal wall freed from the rectum. The lateral wall may be transected with diathermy, or 
an energy device. The defect in the vaginal wall may be large and when closed primarily, 
the remnant of the vagina may be small. This may be solved by performing some type of 
plasty. We routinely use a VRAM flap, in which case either skin, fascia or peritoneum may 
be used to replace the vaginal wall resected.(41) The alternative is to close the vagina 
primarily and refer the patient to the gynaecologist for dilatation at an early stage. There 
are no data proving one technique superior to the other. In case the urethra is involved, a 
total pelvic exenteration is indicated. In such cases, near complete removal of the vagina 
(colpectomy) is often unavoidable. 
Total pelvic exenteration (TPE)
In case of extensive involvement of the bladder, the prostate in men or the urethra, a total 
pelvic exenteration is indicated for radical resection. In case of a primary rectal tumour, the 
rectosigmoid is mobilized and cut as usual. The ureters are identified and cut at the lowest 




and fibrosis. The ureters are mobilized and single J catheters are inserted. Posteriorly, the 
rectum is mobilized according to TME principles when possible, or including fascia and 
periosteum when needed. Now, the easiest step is to free the bladder form the pelvic 
wall anterolaterally with diathermy or an energy device. This then leaves the lower vesical, 
prostatic or uterine arteries and veins, which may be ligated, but can be safely transected 
with an energy device. Rectum and bladder have now been freed posteriorly and laterally. 
The bladder should now be freed on the anterior side. Here, one can easily cause profuse 
bleeding from venous branches contributing to the internal iliac vein and the venous 
plexus located posteriorly of the symphysis. Careful dissection, combining diathermy and 
ligatures, should prevent extensive blood loss. An energy device is helpful, but should be 
used cautiously in this area. Large bites and rough tissue handling will result in unnecessary 
blood loss. 
TPE in men: 
Posterior to the symphysis, the dissection is continued over the neck of the bladder and 
the prostate in men. The fascia of the pelvic floor is incised just lateral and anterolateral 
of the neck of the bladder, which frees the bladder neck. Now, only the rectum, prostate 
and urethra remain fixed. Following the contours of the prostate, the urethra is cut distally. 
We leave a Foley catheter inserted, so we can easily palpate the urethra in an area that is 
difficult to visualize. The Foley catheter does not need to be removed but may be cut along 
with the urethra. Now we come back to the ventral side of the lower rectum. Depending 
on the extension of the tumour, the lower rectum may be spared, or an APE may be per-
formed. In case of an APE, dissection anterior of the prostate can also be easily preformed 
from the perineum, in which case we choose a plain just posterior of the symphysis to 
include the prostate.
TPE in women:
Posterior to the symphysis, the dissection is continued over the neck of the bladder, after 
which the urethra may be cut and the anterior vaginal wall opened. The involved part of 
the vagina is included in the resection specimen, after which the rectum may be resected 
completely or transected at the desired level. 
Urinary diversion
The standard option for urinary diversion is Bricker’s diversion, as described elsewhere.(42) 
In case the descending colon or sigmoid is transected during the procedure, we prefer a 
colon conduit. The distal colon is cut leaving a segment of approximately 15-20 centimetre 
with an arterial pedicle. This may be the mesenteric inferior artery, the left colonic artery 
or in some cases, the left branch of the middle colic artery. After mobilization, both ureters 
may be anastomosed in exactly the same way as in Bricker’s diversion. The urinary stoma 
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often needs to be placed on the left side of the abdomen and after mobilization of the 
transverse colon, the stoma for stool is then placed on the right side of the abdomen. The 
advantage of this approach is that Bricker’s diversion results in an extra ileo-ileostomy with 
a risk of complications such as leakage, whereas diversion with a colon conduit does not 
require an extra anastomosis.
Intraoperative radiation therapy
When the lateral pelvic sidewall or dorsal structures are involved, achieving clear resection 
margins may be difficult despite extensive resections. In case of doubt, peroperative assess-
ment of the resection margin can be performed by frozen sections. In patients with narrow 
or involved margins, intraoperative radiation therapy reduces the local recurrence rate.(17, 
43) Therefore, we advocate intraoperative radiation therapy (IORT) in locally advanced rec-
tal cancer in patients with involved or narrow (< 1 mm) circumferential resection margins 
and locally recurrent rectal cancer.
Mortality and morbidity
Improved surgical techniques, perioperative care and patient selection have reduced 
mortality and morbidity, but pelvic exenteration remains a procedure with a high risk of 
complications. (14, 15, 23, 44) The most common complications are listed in table 1. Peri-
operative 30-day mortality rates are reported in a range of 0% - 10%.(14, 18, 20, 44, 45) 
Especially in frail and elderly patients high perioperative mortality rates have been reported; 
up to 14%.(46) The overall morbidity rate has been described to be anywhere between 
32-100%. (24, 44) Patients often have common complications such as (intraoperative) 
bleeding, wound infection, pneumonia and (pelvic) abscesses, but the removal of adjacent 
organs is associated with other complications than normally encountered in colorectal 
surgery. (25) Short term complications of urinary diversion are leakage or obstruction of 
the urinary enteric anastomosis. Long-term complications include urinary stenosis and 
fistulas.(47-49) These complications can sometimes be managed conservatively, but more 
often require reintervention by prolonged drainage, nephrostomy catheters or ureter re-
implantation.(48) Perineal wound problems after exenterative surgery are also common: 
besides wound infection and abscesses on the short term, perineal hernia or fistulas can 
occur on the long term.(14, 24) Muscle flap reconstructions may improve perineal wound 
outcome and pelvic floor dysfunction, but failure of perineal reconstructions often results 





Oncological outcomes after pelvic exenteration have improved over the last decades, since 
pelvic exenteration was first described by Brunschwig for advanced cervix cancer.(21, 23) 
A Summary of oncological results is displayed in table 2. Nowadays, 5-year survival rates 
after pelvic exenteration for locally advanced rectal cancer ranges between 22% to 66%. 
For pelvic exenteration for locally recurrent rectal cancer, 5-year survival rates are 0% to 
37%.(19, 20, 44, 45) The 5-year local recurrence free survival rate for primary locally ad-
vanced rectal cancer is reported to be 65%- 88%. For locally recurrent rectal cancer, this is 
reported within a range of 38% to 60%. (16, 20, 44) Notably, these numbers are described 
by several single centre cohort studies and recent meta-analyses with a heterogeneous 
study population.

























































































































































































































































































































































































































































































































































































































































Although pelvic exenteration is a more radical approach compared to abdominoperineal 
resection or low anterior resection, oncological outcomes are not significantly worse, even 
when tumours requiring exenteration are likely to be more advanced.(51) Achievement of 
clear resection margins in pelvic exenteration for locally advanced or locally recurrent rectal 
cancer leads to a significant increase in overall and disease free survival compared to posi-
tive resection margins by more than twofold advantage as described by a recent systematic 
review.(16) Three-year survival rates are reported up to 82% for R0 resections, compared 
to 55% for R1 and 0% for R2 resections for primary locally advanced rectal cancer.(20) 
Similar differences in 3-year overall survival rates were found for locally advanced rectal 
cancer (R0 56.4%, R1 29.6% and R2 8.1%) and locally recurrent rectal cancer (R0 48.1%, 
R1 33.9% and R2 15%). 
Quality of life
Pelvic exenteration may be unavoidable to achieve clear resection margins in advanced 
rectal cancer, but this type of surgery does have a profound impact on the quality of life.
(52, 53) Although standard procedures in rectal cancer surgery have a significant impact 
on physical and mental health, body image and sexual functioning, the impact of pelvic 
exenteration is often thought to be much higher. On the other hand, the prognosis of 
patients with locally advanced or recurrent rectal cancer without treatment is poor, with a 
median survival of 1 year and a 5-year survival rate of 4.4%. Moreover, untreated locally 
advanced or locally recurrent rectal cancer is associated with severe symptoms such as 
pain, incontinence, fistula and unmanageable wounds, even with palliative radiotherapy 
or chemotherapy aimed solely at reducing symptoms. (54-57) A study that compared the 
quality of life of patients undergoing pelvic exenteration and patients who refrained from 
surgery, showed that patients, who underwent pelvic exenteration had a sharp decline in 
quality of life directly after surgery. However, their quality of life improved quickly after 
surgery and after three months, patients who had undergone pelvic exenteration reported 
a higher quality of life than patients who did not have surgery. Thereafter, quality of life 
in the surgery group continued to improve, whereas quality of life in patients who did 
not undergo surgery deteriorated.(15, 58) At nine months after surgery, quality of life in 
the exenterative group was back at baseline.(15, 58) In addition, there appears to be no 
difference in quality of life when pelvic exenteration patients are compared to patients who 
underwent an abdominoperineal excision.(59) 
Surgery for rectal cancer invading in the anterior compartment of the pelvis often results 
in sexual dysfunction. Men may experience erectile or ejaculatory disorders and in women, 
lubrication disorder and dyspareunia are common, especially when parts of the vaginal wall 
are resected. Both men and women report deterioration in body image.(53, 60) 
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Patients may experience major physical and mental changes before, during and after the 
surgical procedure. Therefore, it is advised to give extended counselling about the possible 
life changing events that patients will experience pre- and post-surgery. 
Conclusions
In patients with locally advanced rectal cancer or recurrent rectal cancer with invasion of 
adjacent urogenitary organs pelvic exenteration is often the only potentially curative treat-
ment option. Patient selection and preoperative assessment in a multidisciplinary tumour 
board is mandatory. The cornerstone of treatment is achievement of radical resection mar-
gins by surgery, which is the most important prognostic factor for overall survival. Induction 
therapy should be considered in case of expected narrow surgical margins. Perioperative 
mortality and morbidity is reduced over the last decades but remains high and needs to 
be taken in consideration before surgery. After surgery, quality of life is decreased but 
improves rapidly and in the longer term, patients report a good quality of life, comparable 
to patients who underwent less invasive procedures. Therefore, patients should not be 
denied exenterative surgery based on perceived poor quality of life.
Key points
•	 Achievement	 of	 a	 clear	 resection	 margin	 is	 the	 most	 important	 prognostic	 factor	 for	
overall survival.
•	 Perioperative	mortality	and	morbidity	is	high	after	pelvic	exenteration	with	a	wide	range	
of complications related to multivisceral resection, especially in frail and elderly patients. 
•	 5-year	overall	survival	after	pelvic	exenteration	for	locally	advanced	rectal	cancer	ranges	
from 22% - 66% and for locally recurrent rectal cancer from 0% - 37%. 
•	 Quality	of	 life	decreases	shortly	after	surgery	but	 increases	rapidly	after	surgery	and	 is	
higher within 3 months after surgery compared to patients who did not undergo exen-
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Total pelvic exenteration (TPE) is a radical approach for locally advanced rectal cancer (LARC) 
and locally recurrent rectal cancer (LRRC) in case of tumour invasion into the urogenitary 
tract. The aim of this study is to assess surgical and oncological outcomes of TPE for LARC 
and LRRC in elderly patients compared to younger patients.
Methods
All patients who underwent TPE for LARC and LRRC between January 1990 and March 
2017 were retrospectively analysed. Patients aged < 70 years were classified as younger 
and ≥ 70 years as elderly patients.
Results
In total 126 patients underwent TPE, of whom 88 younger and 38 elderly patients. Elderly 
patients had a significantly higher number of ASA > II patients (p = 0.01). Indication for 
surgery LARC (n = 73) and LRRC (n = 53) did not differ significantly. The 30-day mortality 
rate was significantly higher (p = 0.01) in elderly (13%) compared to younger patients 
(3%). Elderly patients experienced more anastomotic leakage (p = 0.02). Median overall 
survival (OS) was 75 months [95%CI 37.1;112.9] for elderly and 45 months [95%CI 
22.4;67.8] for younger patients (p = 0.77), with 5-year OS rates of 51% for elderly and 
44% for younger patients. Median disease specific survival (DSS) was 78 months [95%CI 
69.1;86.9] for elderly and 60 months [95%CI 36.6;83.4] for younger patients (p = 0.34). 
The 5-year DSS rate was 67% and 49%, respectively.
Conclusions
TPE is an invasive treatment for rectal cancer with high 30-day mortality in elderly patients. 
Oncological outcomes are similar in elderly and younger patients. Therefore, TPE should 





The incidence of rectal cancer is increasing worldwide and increases with age.(1-3) At the 
time of diagnosis of primary rectal cancer approximately 10% of the patients have locally 
advanced rectal cancer (LARC) and approximately 6-10% of patients treated for primary 
rectal cancer will develop locally recurrent rectal cancer (LRRC).(4-8) Over the past decades 
the development of multimodality treatment for LARC and LRRC, including TME-surgery, 
neoadjuvant (chemo-)radiotherapy, surgical treatments and intra-operative radiotherapy 
(IORT), improved overall survival and local control after treatment.(5, 6, 9-12) Achievement 
of a radical resection margin in rectal surgery is a known important prognostic factor. 
Abdominoperineal resection (APR) and low anterior resection (LAR) for rectal cancer often 
achieve radical resection margins, but if there is invasion of adjacent organs, such as blad-
der, ureters or male and female reproductive organs, a more radical approach is indicated. 
Total pelvic exenteration (TPE) is an invasive radical treatment modality and it comes with 
considerable morbidity and mortality.(11, 13, 14) Treatment of LARC and LRRC with TPE 
is a challenge, especially in elderly patients. Although it is generally known that elderly 
patients often present with more comorbidities and that surgical outcomes are worse than 
in younger patients, there is controversy whether the cancer specific survival is also worse 
in elderly patients.(15-18) The question remains, with an increasing elderly population with 
rectal cancer, whether it is justified to withhold extensive surgery from the elderly patient 
because of high mortality and morbidity. The aim of this study is to compare mortality, 
morbidity, surgical and oncological outcomes between elderly and younger patients who 
underwent TPE for LARC or LRRC and to assess whether TPE is justified as a treatment for 
LARC and LRRC in the elderly patient. 
Patients and Methods
All patients with LARC or LRRC who had undergone TPE with curative intent at the Erasmus 
MC Cancer Institute, a tertiary referral centre in the southwest region of the Netherlands, 
between February 1990 and March 2017 were identified from a prospectively maintained 
rectal cancer database. We retrospectively reviewed all data on patient demographics, 
(neo) adjuvant treatment, tumour characteristics, perioperative variables and short- and 
long-term surgical and oncological outcomes. Data was obtained from medical records, 
municipality registers and general practitioners. All patients were followed up by our insti-
tute and last update of follow up was performed on 28 February 2018. The present study 
was approved by the Erasmus MC local medical ethics committee (registration number 
MEC-2017-448). 
Elderly patients were defined as patients aged ≥ 70 years at the time of operation and 
patients were defined as younger patients when aged < 70 years. All patients were dis-
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cussed in a multidisciplinary tumour (MDT) board prior to neoadjuvant therapy and after 
neoadjuvant therapy for restaging prior to surgery. Initial tumour stage was assessed by 
physical examination, colonoscopy, histology and radiologic imaging. The American Joint 
Committee on Cancer (AJCC) TNM-classification was used according to the edition valid at 
the time of diagnosis (4th edition before 1998, 5th edition for 1998-2003, 6th edition for 
2003-2010 and 7th edition from 2010 onwards).(19) Radiologic imaging usually consisted 
of CT-thorax and CT-abdomen and pelvic MRI. Additional diagnostics were performed 
when indicated, such as targeted echo, abdominal MRI, PET-CT, lymph node biopsy and 
tissue biopsy. Complications were scored according to the Clavien-Dindo classification.(20)
neoadjuvant treatment
Neoadjuvant treatment consisted of chemoradiotherapy, chemotherapy only or radiothera-
py only depending on tumour stage and patients comorbidities. Chemoradiotherapy usually 
consisted of a dose of 46 - 50 Gy delivered in fractions of 1.8 - 2 Gy with concomitant oral 
chemotherapy (Capecitabine 825 - 1000 mg/m2 for 5-7 days a week) during the whole 
course of neoadjuvant therapy. Patients treated with radiotherapy only usually received a 
short course with a total dose of 25 Gy delivered in 5 fractions of 5 Gy. Neoadjuvant treat-
ment by chemotherapy alone was incidentally given. In case of LRRC, neoadjuvant treat-
ment was determined by previous therapy for the primary tumour. In general, if patients 
were previously treated with (chemo) radiotherapy, patients received reirradiation with a 
dose of 30 Gy delivered in fractions of 2 Gy with concomitant Capecitabine. For patients 
who were not previously treated and with no contraindications for (chemo) radiotherapy, 
the same course for patients with LARC was administered. 
surgical procedures
Total pelvic exenteration was defined as en bloc resection of the rectum including complete 
removal of the bladder and additional resection of reproductive organs (prostate/seminal 
vesicles or uterus, ovaries and/or vagina) with or without sacrectomy. The anus and levatory 
muscles were usually resected, but were spared incidentally. Patients who had undergone 
anterior or posterior pelvic exenteration were excluded. Surgical approach for resection 
was either abdominal or abdominoperineal. In case of a possible microscopically involved 
positive resection margin, frozen sections were taken peroperatively and were instantly 
reviewed by a pathologist. In case of a narrow microscopically resection margin of < 2 
mm or a clinical high risk of involved resection margins, intraoperative brachytherapy was 
administered with a dose of 10 Gy as previously described.(21) When possible, omento-
plasty was performed to fill the pelvis. When feasible, primary perineal wound closure was 
performed. If this was not feasible, muscle flap reconstruction of the perineal defect was 
performed by the plastic surgeon with a vertical rectus abdominis myocutaneous (VRAM) 




ureterocutaneostomy or colon conduit was performed as an urinary diversion. Ileo-ileal 
anastomosis was performed in patients with an ileal conduit and in patients with a colon 
conduit, an anastomosis is not necessary, with the exception of patients who underwent 
an additional bowel resection.
statistical analysis
Continuous data were reported as median (interquartile range or 95% confidence interval) 
and categorical data were reported as count (percentage). The method of Kaplan-Meier 
was used for survival analysis and comparisons were made using log rank test. Overall 
survival was calculated from the day of TPE until death or last follow up date and disease 
specific survival was calculated until cancer related death or last follow up date. Mann-
Whitney U and Chi-squared test were performed as appropriate. Two-sided p-values < 
0.05 were considered statistically significant. Statistical analysis were performed using IBM 
SPSS Statistics version 24.0.0 for Windows (IBM Corp, Armonk, New York, USA). 
ResulTs
A total of 126 patients underwent TPE for rectal cancer between January 1990 and March 
2017. Patient characteristics are depicted in Table 1. Eighty-eight patients (70%) were 
younger than 70 years and 38 patients (30%) were aged 70 years or older at the time of 
surgery. The median age in the elderly was 72.5 years [IQR 71–75.3] and 60.5 years [IQR 
51–65.8] in the younger group. The elderly had a significantly higher number of patients 
with ASA score > II (p = 0.01) and cardiac comorbidities (p < 0.01). All but seven patients 
received neoadjuvant therapy and the majority (55%) received chemoradiotherapy. 
surgical results
Surgical results are shown in Table 1. Indications for surgery were LARC (n = 73) and 
LRRC (n = 53) and did not differ significantly (p = 0.44). There was no statistical difference 
between the surgical approach in both age groups (p = 0.09). The duration of surgery was 
significantly less (p < 0.01) in elderly patients with a median of 426 min (IQR 379 - 507) 
compared to younger patients with a median of 514 min (IQR 441 - 619). A muscle flap 
reconstruction was performed significantly more often (p = 0.04) in younger patients than 
in elderly patients: 17 patients (19%) versus two patients (5%), respectively. IORT was 
admitted in 37 younger patients (42%) and in seven elderly patients (18%) which was 
statistically significantly different (p = 0.01). 
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histopathological results
Histopathological results are displayed in Table 1. In the younger patients, a clear resection 
margin (> 0 mm) was achieved in 74 patients (84%). Intra-operative radiotherapy (IORT) 
was administered to 27 patients with a resection margin of > 0 mm and < 2 mm. In the 
elderly patients, a clear resection margin was achieved in 36 patients (95%). IORT was 
administered to five patients with a resection margin of > 0 - 2 mm. The difference in 
the number of clear resection margins between younger and elderly patients was not 
statistically significant (p = 0.10). 
Table 1. Patient characteristics, surgical and histopathological results
  
Total 
age < 70 
years 
age ≥ 70 
years P-value
(n = 126) (n = 88) (n = 38)
Gender Male 107 (85%) 73 (83%) 34 (89%) 0.35
Female 19 (15%) 15 (17%) 4 (11%)
Age Median (IQR) 65 (56-70) 60.5 (51-65.8) 72.5 (71-75.3) n/a
ASA ASA I-II 108 (86%) 78 (94%) 30 (79%) 0.01a




No 104 (83%) 71 (88%) 33 (87%) 0.90
Yes 15 (12%) 10 (12%) 5 (13%)
Missing 7 (6%)
Cardiac comorbidity No 97 (77%) 74 (91%) 23 (61%) <0.01a
Yes 22 (18%) 7 (9%) 15 (39%)
Missing 7 (6%)
Type of rectal cancer LARC 73 (58%) 49 (56%) 24 (63%) 0.44
LRRC 53 (42%) 39 (44%) 14 (37%)
Neoadjuvant CTRTxc 70 (56%) 50 (57%) 20 (53%) 0.08
therapy RTxd 47 (37%) 34 (39%) 13 (34%)
CTxe 2 (2%) 2 (2%) 0 (0%)
None 7 (6%) 2 (2%) 5 (13%)
Radiotherapy dose Median (IQR) 50 (30-50) 50 (30-50) 50 (30-50) 0.15
Previous surgery No 52 (41%) 30 (34%) 22 (58%) 0.03a
Yes without 
anastomosis
44 (35%) 36 (41%) 8 (21%)
Yes with anastomosis 30 (24%) 22 (25%) 8 (21%)
surgical results
Surgical approach Abdominoperineal 74 (58%) 56 (64%) 18 (47%) 0.09
Abdominal 52 (41%) 32 (36%) 20 (53%)
Operation time Median (IQR) 490 (415-580) 514 (441-619) 426 (379-507) <0.01b










No 99 (79%) 70 (80%) 29 (76%) 0.69
Yes 27 (21%) 18 (20%) 9 (24%)




Postoperative mortality and morbidity
Mortality is shown in Table 2, complications in Table 3 and Clavien-Dindo scores are depicted 
in Table 4. In the elderly group five patients (13%) died within 30 days of surgery compared 
to two patients (2%) in the younger group, which was a statistically significant difference (p 
= 0.01). The 3, 6 and 12 months mortality rates were not significantly different. Three elderly 
Table 1. Patient characteristics, surgical and histopathological results (continued)
  
Total 
age < 70 
years 
age ≥ 70 
years P-value
(n = 126) (n = 88) (n = 38)
Yes 19 (15%) 17 (19%) 2 (5%)
Urinary diversion Ileal conduit 90 (71%) 66 (75%) 24 (63%) 0.16
Colon conduit 35 (28%) 22 (25%) 13 (34%)
Ureterocutaneostomy 1 (1%) 0 (0%) 1 (3%)
Anastomosis No 33 (26%) 20 (23%) 13 (34%) 0.18
Yes 93 (74%) 68 (77%) 25 (66%)
Omentoplasty No 18 (14%) 12 (14%) 6 (16%) 0.75
Yes 108 (86%) 76 (86%) 32 (84%)
IORTg No 82 (65%) 51 (58%) 31 (82%) 0.01a
Yes 44 (35%) 37 (42%) 7 (18%)
Hospital stay (days) Median (IQR) 14 (11-21.5) 15 (11-23) 14 (11-17.3) 0.58
ICU stay (days) Median (IQR) 2 (1-3) 1 (1-3) 2 (1-3.3) 0.81
histopathological 
results
Tumour size (cm) Median (IQR) 4.0 (2.7-6.0) 4.0 (3.0-7.0) 4.0 (2.7-5.9) 0.39
Nodal status N0 68 (73%) 46 (73%) 22 (73%) 0.97




No 16 (13%) 14 (16%) 2 (5%) 0.10
Yes 110 (87%) 74 (84%) 36 (95%)
Resection margins
Clear margin > 2 mm 88 (70%) 57 (65%) 31 (82%) 0.22
Microscopically clear > 0 mm & < 2 mm 22 (17%) 17 (19%) 5 (13%)
Microscopically 
involved
< 0 mm 12 (10%) 10 (11%) 2 (5%)
Macroscopically 
involved
4 (3%) 4 (5%) 0 (0%)
Pathologic complete 
response
No 122 (97%) 85 (97%) 37 (97%) 0.82
Yes 4 (3%) 3 (3%) 1 (3%)
follow up
Local recurrence No 94 (75%) 62 (70%) 32 (84%) 0.10
Yes 32 (25%) 26 (30%) 6 (16%)
Metastases No 68 (54%) 48 (55%) 20 (53%) 0.84
 Yes 58 (46%) 40 (45%) 18 (47%)  
a Chi squared test b Mann-Whitney U test c: Chemoradiotherapy d: Radiotherapy e: Chemotherapy f: Muscle flap 
reconstruction g: Intra-operative radiotherapy
Percentages do not add up due to rounding
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patients died of aspiration pneumonia, one patient died of sepsis after anastomotic leakage 
and one cause of death is unknown. In the younger group two patients ,died of intra-
abdominal sepsis based on a necrotic urostoma in one patient and interloop abscesses in the 
other patient. There was a significant higher rate of anastomotic leakage in the elderly group 
(in case an anastomosis was performed); five patients (20%) compared to three patients 
(4%) in the younger group (p = 0.02). In all eight patients with anastomotic leakage, all 
leakages were related to the ileo-ileal anastomosis, which was performed in seven patients 
for an ileal conduit and in one patient for additional small bowel resection. Three elderly 
patients with anastomotic leakage had received previous surgery for primary rectal cancer, 
but an anastomosis was not performed at that time. All five other patients with anastomotic 
leakage did not undergo surgery before and had no anastomosis from previous surgery. 
There was no significant difference in median length of hospital stay, 15 days for elderly (IQR 
11 - 23) and 14 days for younger patients (IQR 11 - 17), respectively, (p = 0.58). 
follow up and survival
The median follow up time was 48 months [95% CI 41.5;54.5] for elderly patients and 
145 months [95% CI 69.0;221.0] for younger patients. At last follow up 17 patients (45%) 
were alive in the elderly group and 32 patients (36%) in the younger group. In the elderly 
group, local recurrence occurred in six patients (16%) and distant metastases in 18 patients 
(47%). In the younger group, 26 patients (30%) were diagnosed with a local recurrence 
and 40 patients (46%) with distant metastases. 
Table 2. Mortality rates
  
Total age < 70 years age ≥ 70 years 
P-value
(n = 126) (n = 88) (n = 38)
In hospital mortality No 120 (95%) 86 (98%) 34 (89%) 0.05a†
Yes 6 (5%) 2 (2%) 4 (11%)
Died within 30 days No 119 (94%) 86 (98%) 33 (87%) 0.01a
Yes 7 (6%) 2 (2%) 5 (13%)
Died within 60 days No 116 (92%) 84 (95%) 33 (87%) 0.09
Yes 10 (8%) 4 (5%) 5 (13%)
Died within 90 days No 115 (91%) 83 (94%) 33 (87%) 0.15
Yes 11 (9%) 5 (6%) 5 (13%)
Died within 6 months No 112 (89%) 80 (91%) 32 (84%) 0.34
Yes 13 (10%) 7 (8%) 6 (16%)
Lost to follow-upb 1 (1%) 1 (1%) 0 (0%)
Died within 1 year No 101 (80%) 73 (83%) 28 (74%) 0.44
 Yes 21 (17%) 13 (15%) 8 (21%)  
Lost to follow-upb 4 (3%) 2 (2%) 2 (5%)






Total age < 70 years age ≥ 70 years 
P-value
(n = 126) (n = 88) (n = 38)
Anastomotic leakagea No 85 (91%) 65 (96%) 20 (80%) 0.02b
Yes 8 (9%) 3 (4%) 5 (20%)
Urinary tract infection No 111 (88%) 76 (86%) 35 (87%) 0.36
Yes 15 (12%) 12 (14%) 3 (13%)
Relaparotomy No 99 (79%) 69 (78%) 30 (79%) 0.95
Yes 27 (21%) 19 (22%) 8 (21%)
Any surgical Reintervention No 79 (63%) 53 (60%) 26 (68%) 0.38
Yes 47 (37%) 35 (40%) 12 (32%)
Any Abscess drainage No 98 (78%) 67 (76%) 31 (82%) 0.50
Yes 28 (22%) 21 (24%) 7 (18%)
Pneumonia No 109 (87%) 78 (89%) 31 (82%) 0.29
Yes 17 (13%) 10 (11%) 7 (18%)
Presacral abscess No 101 (80%) 69 (78%) 32 (84%) 0.45
Yes 25 (20%) 19 (22%) 6 (16%)
Sepsis No 101 (80%) 69 (78%) 32 (84%) 0.45
Yes 25 (20%) 19 (22%) 6 (16%)
Wound complication No 73 (58%) 49 (56%) 24 (63%) 0.43
Yes 53 (42%) 39 (44%) 14 (37%)
Cardiac complication No 110 (87%) 80 (91%) 30 (79%) 0.06
Yes 16 (13%) 8 (9%) 8 (21%)
Reintervention stoma No 118 (94%) 82 (93%) 36 (95%) 0.74
Yes 8 (6%) 6 (7%) 2 (5%)
Urinoma No 120 (95%) 85 (97%) 35 (92%) 0.28
Yes 6 (5%) 3 (3%) 3 (8%)
Nephrostomy No 117 (93%) 82 (93%) 35 (92%) 0.83
Yes 9 (7%) 6 (7%) 3 (8%)
Clavien-Dindo ≥ 3 No 71 (56%) 49 (56%) 22 (58%) 0.82
Yes 55 (44%) 39 (44%) 16 (42%)
aIn patients with anastomosis performed during this episode of surgery bChi squared test
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overall survival
The estimated 3-year overall survival (OS) rate was 64% in elderly patients and 56% in 
younger patients. The estimated 5-year OS rate was 51% for elderly patients and 44% for 
younger patients. Median OS for elderly patients was 75 months [95% CI 37.1;112.9] and 
45 months [95% CI 22.4;67.8] for younger patients (Figure 1a), this was not significantly 
different (p = 0.77). 
Disease specific survival
The estimated 3-year disease specific survival (DSS) rate was 82% in elderly patients and 
62% in younger patients. The estimated 5-year DSS rate was 67% in elderly patients 
and 49% in younger patients. Median DSS for elderly patients was 78 months [95% CI 
69.1;86.9] and 60 months [95% CI 36.6;83.4] for younger patients (Figure 1b), this was 
not significantly different (p = 0.34). 
Local recurrence free survival
There was no significant difference in local recurrence free survival (LRFS) between both 
groups (p = 0.15). Median LRFS was not reached in both groups. The estimate 3-year 
and 5-year LRFS rates were both 78% in elderly patients and 68% and 65% in younger 
patients, respectively (Figure 1c). 
Table 4. Complications Clavien-Dindo
 
age < 70 years age ≥ 70 years 
(n = 88) (n = 38)
No complication 21 (24%) 5 (13%)
Clavien-Dindo I 13 (15%) 3 (8%)
Clavien-Dindo II 15 (17%) 14 (37%)
Clavien-Dindo IIIA 11 (13%) 3 (8%) 
Clavien-Dindo IIIB 19 (22%) 4 (11%)
Clavien-Dindo IVA 3 (3%) 4 (11%)
Clavien-Dindo IVB 2 (2%) 0 (0%)
Clavien-Dindo V 4 (5%) 5 (13%)




































































































This study compares the results of total pelvic exenteration (TPE) for locally advanced rectal 
cancer (LARC) and locally recurrent rectal cancer (LRRC) in younger and elderly patients. 
Oncological outcomes are similar, but perioperative mortality is higher among elderly 
patients during the first 30 days after surgery. 
Previous studies showed that colorectal cancer surgery in the elderly patient comes with 
high mortality and morbidity and overall survival is not always improved.(15, 18, 22) Rutten 
et al. (18) described a significantly higher mortality rate (14%) in elderly patients (age ≥ 75 
years) until six months after surgery for rectal cancer compared to younger patients (4%). 
In our study, the mortality rate was only significantly different at 30-days after surgery, and 
the significant difference disappeared after 30 days. Six months after surgery the mortality 
rate was still higher in the elderly patients, 16% compared to 8% in the younger group, 
although not significant. Other series, by Quyn et al. (23) and the PelvEx Collaborative (14), 
who performed TPE for LARC reported a 30-day mortality of 1 - 1.5 % and 10% one-year 
mortality, but median age was 62 and 63 years in these cohorts and a comparison between 
age groups was not made. Reduction of the mortality rate within the first year postop-
erative remains a challenge in elderly patients.(24) In our institute, age is not a factor for 
preoperative counselling whether to perform an anastomosis, but in the present study, 
there was a significantly higher rate of anastomotic leakage in elderly patients, which is in 
concordance with other studies.(25, 26) Teixeira et al. described more complications after 
performance of an ileal conduit in comparison with a colon conduit.(27) In our study, seven 
out of eight patients with anastomotic leakage received an ileal conduit with an ileo-ileal 
anastomosis. A colon conduit may be preferable to an ileal conduit to prevent anastomotic 
leakage. In our series, one elderly patient died of sepsis based on anastomotic leakage. 
Aspiration pneumonia caused three deaths in elderly patients, which emphasizes the 
seriousness of this complication, especially in elderly patients. In general, elderly patients 
experienced a higher percentage of overall complications than younger patients which is 
in concordance with a previous systematic review of rectal cancer surgery between elderly 
and non-elderly patients by Manceau et al.(17)
Achievement of a clear resection margin is one of the most important prognostic factors 
for overall survival and can be achieved, if necessary, with pelvic exenteration.(14, 23) 
In the present study, the number of clear resection margins was similar to the range of 
79% – 87% reported by others after TPE for rectal cancer.(13, 14, 23, 28) Notably, we 
found a difference in percentage of clear resection margins: 84% in younger patients 
and 95% in elderly patients. This difference was not statistically significant. In addition, 




operative radiotherapy (IORT) for surgical treatment of LARC and others described accept-
able survival of treatment with IORT for LARC.(29, 30) In our study IORT was administered 
significantly more often in younger patients compared to elderly patients (42% vs 18%, 
p = 0.01). In our institute, we generally perform intraoperative brachytherapy in case of 
resection margins < 2 mm. There was a higher percentage of resection margins < 2 mm in 
younger patients, which explains a higher rate of IORT in the younger group. Admission 
of intraoperative brachytherapy results in 2-3 hours extra operation time, it may be that 
surgeons are less willing to prolong the operation with such a long time in the elderly 
patient. In case of a doubtful resection margin, surgeons may be more willing to administer 
IORT in younger patients compared to elderly patients. The admission of intraoperative 
brachytherapy could also explain the significantly longer duration of surgery in younger 
patients compared to elderly patients. 
In our study overall survival and disease specific survival did not differ significantly, but this 
cohort suggests that elderly patients have a better DSS (5-year disease specific survival 
rate of 67% in elderly compared to 49% in younger patients, p = 0.34). Before surgery, 
patients are assessed in a multidisciplinary tumour (MDT) board whether they are eligible 
for TPE. Conceivably, the MDT board is more reluctant to select elderly patients unless 
good clinical outcome is expected considering their comorbidities. Furthermore, referring 
physicians may have also selected fit patients for referral to our hospital. Younger patients 
are likely to be more easily considered for invasive surgery, even when tumour character-
istics are unfavourable. Therefore, it could be that our results display a selection of better 
elderly patients and worse younger patients. Rutten et al.(18) described better oncological 
outcomes in elderly, but no improvement in overall survival. In their study, overall survival 
did not improve because of high perioperative mortality. To improve overall survival the 
challenge remains to reduce perioperative mortality and morbidity in the elderly by better 
patient selection and/or improving patients performance status prior to surgery.(31, 32) 
Perioperative chemotherapy may also help in selecting patients. Currently, in line with 
the national guideline, adjuvant chemotherapy in the treatment of rectal cancer is not 
standard of care in the Netherlands.(33-35) However, there may be a benefit of periopera-
tive chemotherapy in selected colorectal cancer patients; this should not be denied on the 
basis of high age alone, as described by Papamichael et al.(36) 
A recent study about pelvic exenteration by Radwan et al.(28) included patients, aged ≥ 70 
years, who had undergone total pelvic exenteration for primary rectal cancer. The 5-year 
survival rate of 47% for rectal cancer patients was similar to our results, but the 3% 30-day 
mortality compares well to our 30-day mortality rate of 13%. However, only 31 out of 
65 patients underwent total pelvic exenteration, while all other patients had undergone 
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posterior pelvic exenteration and no patients with locally recurrent rectal cancer were 
included. 
Despite high morbidity and mortality after total pelvic exenteration in the elderly, which af-
fects quality of life, the alternative outcome of no treatment is poor, with a reported 5-year 
survival rate of 4.4% for untreated rectal cancer.(37) Young et al.(38) described quality of 
life in patients following pelvic exenteration compared to patients who did not undergo 
exenteration for pelvic malignancies. Quality of life was decreased shortly after surgery, but 
improved rapidly within one month after surgery. At nine months after surgery, quality of 
life returned to baseline in the exenteration group and was similar to those patients who 
did not have surgery. After nine months, quality of life started to deteriorate in patients 
who did not have exenteration and was higher in patients who had undergone pelvic 
exenteration.(38) These results suggest that pelvic exenteration results in an acceptable 
quality of life and that quality of life actually starts decreasing within one year when TPE is 
not performed for this patient category.
Our data is collected over three decades and especially in the last two decades, our diag-
nostics (contrast enhanced MRI) and treatment (chemoradiotherapy, TME surgery, IORT) 
improved gradually. Exploratory assessment of our cohort divided over time showed no 
significant results. Although it seems that especially elderly patients benefit from improved 
treatment over time with increased survival and slightly decreased perioperative mortality, 
we have to conclude that these are very small subgroups of selected patients and that this 
should be assessed in larger cohorts.
Our study is limited by its retrospective nature and contains a selected group of patients. 
On the other hand, it contains a rather large homogenous group of patients who all un-
derwent TPE for LARC or LRRC. Despite the fact of selection bias and possible differences 
in outcomes between LARC and LRRC, this study provides useful insights for outcomes 
of total pelvic exenteration in the elderly patient for locally advanced and locally recur-
rent rectal cancer. Finally, direct comparison between studies is difficult because of large 
difference in subsets of patients, age, type of malignancy, type of surgery and variance in 
definitions for total pelvic exenteration. 
Conclusions
Total pelvic exenteration for locally advanced or locally recurrent rectal cancer is an invasive 
surgical approach, but should not be withheld from the elderly patient. Careful patient 
selection is needed to reduce perioperative mortality in elderly patients. If patients are 




gest that there is no significant difference in oncological outcome between younger and 
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Surgery for locally advanced rectal cancer (LARC) or locally recurrent rectal cancer (LRRC) 
may require total pelvic exenteration with the need for urinary diversion. The aim of this 
study was to describe outcomes for ileal and colon conduits after surgery for LARC and 
LRRC.
Methods
All consecutive patients from two tertiary referral centres who underwent total pelvic 
exenteration for LARC or LRRC between 2000 and 2018 with cystectomy and urinary 
reconstruction using an ileal or colon conduit were retrospectively analysed. Short- (≤30 
days) and long-term (>30 days) complications were described for an ileal and colon conduit. 
Results
259 patients with LARC (n =131) and LRRC (n =128) were included, of whom 214 patients 
received an ileal conduit and 45 patients a colon conduit. Anastomotic leakage of the 
ileo-ileal anastomosis occurred in 9 patients (4%) after performing an ileal conduit. Ileal 
conduit was associated with a higher rate of postoperative ileus (21% vs 7%, p = 0.024), 
but a lower proportion of wound infections than a colon conduit (14% vs 31%, p = 0.006). 
The latter did not remain significant in multivariate analysis. No difference was observed in 
the rate of uretero-enteric anastomotic leakage, urological complications, mortality rates, 
major complications (Clavien-Dindo ≥ 3), or hospital stay between both groups.
Conclusions
Performing a colon conduit in patients undergoing total pelvic exenteration for LARC or 
LRRC avoids the risks of ileo-ileal anastomotic leakage and may reduce the risk of a post-






In approximately 10% of all newly diagnosed patients with primary rectal cancer there 
is local invasion of the tumour in surrounding structures. In patients who develop a lo-
cal recurrence, which occurs in approximately 6-10% of all patients treated for primary 
rectal cancer, invasion in adjacent organs, such as the bladder and/or the organs of the 
reproductive system, is even more common.(1–3) Radical surgery is essential for cure and 
the achievement of a clear resection margin is the most important prognostic factor for 
overall survival in these patients.(4,5) To achieve a clear resection margin in patients with 
tumour invasion in the bladder, prostate or urethra, a radical approach is indicated, which 
often requires partial or complete cystectomy (i.e. pelvic exenteration). When a complete 
cystectomy is performed patients require a urinary diversion.(6,7) Historically there are 
several urinary diversions, but in current practice the most common urinary diversions are 
an ileal conduit (i.e. Bricker) or a colon conduit.(8–11) In both cases, an isolated bowel 
segment (ileum or colon) is used as a conduit for the ureters, which is deviated through 
the abdominal wall as a urostomy. Both surgical procedures slightly differ due to the use 
of different bowel segments. An ileal conduit requires an ileo-ileal anastomosis, whereas in 
colon conduits an extra anastomosis is usually not required because the terminal segment 
of the descending colon can be used. Both procedures are associated with general surgical 
and urological complications. In addition, conduit specific complications may occur, such 
as metabolic changes or intra-abdominal complications of the urinary diversion, such as 
leakage of the uretero-entero anastomosis and ileus.(8,12–14) 
The aim of this study was to describe the short- and long-term complications associated 
with an ileal and colon conduit after surgery for locally advanced rectal cancer (LARC) 
and locally recurrent rectal cancer (LRRC) in a pooled cohort of two large tertiary referral 
hospitals.
Patient and methods
All consecutive patients who underwent a total pelvic exenteration with complete cystec-
tomy for LARC or LRRC with formation of an ileal or colon conduit in the Catharina Hospital 
Eindhoven (CZE) or the Erasmus MC Cancer Institute (EMC) between January 2000 and 
November 2018, were identified from a prospectively maintained database. CZE and EMC 
are both tertiary referral hospitals in the Netherlands. Both centres have an experienced 
multidisciplinary tumour board (MDT) in which all patients diagnosed with rectal cancer are 
discussed and evaluated for optimal multimodality treatment. This tumour board includes 
dedicated surgeons, radiologists, radiation oncologists, medical oncologists and urologists. 
If indicated, gynaecologists, pathologists and plastic surgeons participate in this meeting. 
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Data collection
All data on patient and tumour characteristics, (neo) adjuvant treatment, surgical pro-
cedures, perioperative variables, short- and long-term surgical and urological outcomes 
were retrospectively reviewed. All included patients were followed up for at least 30 days 
after surgery. Thereafter, follow-up was conducted either in the hospital in which the 
surgery was performed or in the patients’ primary referring hospital. The present study was 
approved by both institutional local medical ethics committees (CZE; registration number: 
W19.031 and EMC registration number; MEC-2017-448).
Neoadjuvant treatment and surgical procedures
Patients were usually scheduled for neoadjuvant radiotherapy: short-course (25Gy) or 
long-course (50Gy) radiotherapy for LARC and re-irradiation (30Gy) or long course (50Gy) 
for LRRC, either with or without concurrent chemotherapy. Surgery was performed in 
collaboration with the surgical oncologist and urologist. Resection of the rectal tumour 
was performed by open abdominal or abdominoperineal approach. All patients underwent 
complete cystectomy and a urinary diversion was performed by ileal or colon conduit. The 
surgical procedures were similar in both CZE and EMC, except for the administration of 
intra-operative radiation therapy (IORT) that was delivered as intra-operative external beam 
radiotherapy (IOERT) in the CZE and as intra-operative brachytherapy (IOBT) in the EMC. 
In the EMC, the choice for either a colon conduit or an ileal conduit was made during 
surgery and was based on practical considerations; there were no reasons for choosing one 
technique or the other from an oncological perspective. A colon conduit was the preferred 
technique when this would avoid the need to make an extra anastomosis. In practice, this 
meant that patients who were to receive an end colostomy were selected for the colon 
conduit technique. In case a primary low anastomosis could be performed or a colon 
conduit could not prevent an extra anastomosis, an ileal conduit was routinely performed. 
In the CZE, the preferred method was to perform an ileal conduit.
An ileal conduit was performed as previously described by Bricker et al. In summary, an ileal 
segment of approximately 15 cm was isolated at 10 cm distance from the valve of Bauhin, 
and a hand sewed or stapled ileo-ileal anastomosis was performed.(9) Both ureters were 
spatulated and then separately hand sutured in one layer with PDS 4-0 side-to-end into 
the ileal segment. Subsequently, the distal end of the conduit was delivered through the 
abdominal wall and was matured. 
To create a colon conduit a colon segment of approximately 15 cm was isolated.(10) This 
segment was the distal segment of the descending colon that was already transected 
during a procedure in which the rectum was removed. Oxygenation of this segment was 




artery was performed for the rectal resection. The colon conduit was often placed in the 
left hemiabdomen and the transverse colon was then mobilized to create a right-sided 
end colostomy, although colon conduits are usually mobile enough to facilitate placement 
on either side of the abdomen (Figure 1). In some cases, the ureters were inserted in an 
already existing colostomy after which a new end colostomy was created for stool. Ureters 
were attached in the same way as described for Bricker’s diversion. In both ileal and colon 
conduits single J stents (EMC 7 French and CZE 8 French) were placed in both ureters to 
ensure sufficient flow during the first 10 days. Stents were fixed to the bowel wall with 4-0 
quickly absorbable braided sutures and led out through the ostomy. If no complications oc-
curred stents were removed at day 9 and day 10 after surgery under antibiotic prophylaxis.
Complications
Short-term complications were defined as any complication within 30 days after surgery, 
during the primary hospital admission or during a readmission within 30 days. Long-term 
complications were defined as any complication that occurred more than 30 days after sur-
gery, unless they occurred during the primary admission or a readmission within 30 days. 
Complications were graded according to the Clavien-Dindo classification.(15) Surgical 
and urological complications were identified from available data. Urological complications 
were defined as complications related to the urinary diversion or urogenitary tract or the 
ileo-ileal anastomosis performed for isolating the ileal conduit. Surgical complications were 
defined as any non-urological complication. A postoperative ileus was defined as two or 
more of the following: nausea/vomiting, inability to tolerate an oral diet, the absence of 
flatus, abdominal distention and/or radiological evidence of bowel distension without signs 
of a mechanical obstruction. During hospitalization, patients were daily observed for the 
occurrence of ileus. An anastomotic leakage was defined as a communication between the 
intra- and extraluminal compartments, determined by either clinical or radiologic evidence.
figure 1. Schematic presentation of performing a colon conduit
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Statistical analysis
Continuous data were reported as median (interquartile range or 95% confidence inter-
val) and categorical data were reported as count (percentage). Group comparisons were 
made using Chi-square or Mann-Whitney U test as appropriate. Long-term complication 
rates were calculated from the date of surgery until the last visit to the outpatient clinic. 
Two-sided p-values ≤ 0.05 were considered statistically significant. Multivariable logistic 
regression analysis was performed using all variables from table 1 and table 2 with a 
p-value <0.1. Nephrectomy was not used as a covariable in multivariable analysis due to 
low patient numbers. Statistical analyses were performed using SPSS version 24.0 (SPSS 
Inc., Chicago, IL) and R version 3.5.1 (http://www.r-project.org).








n (%) n (%) n (%)
hospital CZE 134 (52) 1 (2) 133 (62) <0.001
EMC 125 (48) 44 (98) 81 (38)
Type of rectal cancer LARC 131 (50) 28 (62) 103 (48) 0.086
LRRC 128 (50) 17 (38) 111 (52)
Gender Female 45 (17) 7 (16) 38 (18) 0.723
Male 214 (83) 38 (84) 176 (82)








asa I 42 (17) 7 (16) 35 (18) 0.944
II 164 (67) 31 (69) 133 (67)
III 37 (15) 7 (16) 30 (15)
Clinical tumour stagea cT3 12 (9) 2 (7) 10 (10) 0.676
cT4 119 (91) 26 (93) 93 (90)
Clinical nodal stage cN0 70 (46) 13 (37) 57 (48) 0.144
cN1 34 (22) 12 (34) 22 (19)
cN2 49 (32) 10 (29) 39 (33)
Clinical metastases cM0 229 (88) 38 (84) 191 (89) 0.360
cM1 30 (12) 7 (16) 23 (11)
neoadjuvant chemotherapy No 213 (82) 40 (89) 173 (81) 0.199
Yesb 46 (18) 5 (11) 41 (19)
neoadjuvant radiotherapy None 25 (9) 4 (9) 21 (10) 0.113
Radiotherapy 51 (20) 4 (9) 47 (22)
Chemoradiotherapy 182 (71) 37 (82) 145 (68)










CZE: Catharina Hospital Eindhoven; EMC: Erasmus Medical Centre; LARC: Locally advanced rectal cancer; LRRC: 
Locally recurrent rectal cancer
a Only applicable for LARC; b 35 out of 46 patients had received induction chemotherapy in addition to other 












 n (%) n (%) n (%)
approach Abdominal 109 (42) 19 (42) 90 (42) 0.984
Abdominoperineal 150 (58) 26 (58) 124 (58)
hiPeC Yes 5 (2) 0 (0) 5 (2) 0.300
synchronous 
metastases resectiona
Yes 8 (27) 3 (43) 5 (22) 0.269
ioRT IOBT 41 (16) 16 (36) 25 (12) <0.001
IOERT 105 (41) 1 (2) 104 (49)
No 113 (44) 28 (62) 85 (40)
ureter resection Yes 2 (1) 0 (0) 2 (1) NA
nephrectomy Yes 3 (2) 1 (1) 2 (1) 0.075
length conduit (cm) Median [IQR]
15.0 [15.0, 
20.0]
15.0 [15.0, 20.0] 15.0 [15.0, 20.0] 0.372
ileo-ileal anastomosis 
for ileal conduit
No NA NA 4 (2) NA
Yes NA NA 210 (98)
Colo-anal 
anastomosis
No 228 (88) 44 (98) 184 (86) 0.027
Yes 31 (12) 1 (2) 30 (14)
additional 
anastomosis
No 240 (93) 43 (96) 197 (92) 0.413
Yes 19 (7) 2 (4) 17 (8)
ostomy No ostomy 4 (2) 0 (0) 4 (2) 0.040
Pre-existing ostomy 101 (39) 13 (29) 88 (41)
Loop ostomy 29 (11) 2 (4) 27 (13)
End ostomy 125 (48) 30 (67) 95 (44)

















NA: Not applicable; HIPEC: Hyperthermic intraperitoneal chemotherapy; IORT: Intra-operative radiation therapy;
IOBT: intra-operative brachytherapy; IOERT: intra-operative external beam radiotherapy




Baseline characteristics are shown in Table 1. A total of 259 patients with locally advanced 
(n=131) or locally recurrent rectal cancer (n=128) were included for analyses. An ileal con-
duit was performed in 214 patients and more frequently in the CZE (CZE n=133, EMC=81) 
and a colon conduit in 45 patients and more frequently in the EMC (CZE n=1, EMC n=44) 
(p < 0.001). No other significant baseline differences were observed. 
surgical results
Surgical characteristics are shown in Table 2. All patients underwent pelvic exenteration 
with a cystectomy and resection of the (recurrent) rectal tumour. The length of the conduit 
was similar for both ileal and colon conduit (median 15 cm, IQR 15 – 20 cm). Patients with 
a colon conduit more often received an end colostomy, whereas patients with an ileal con-
duit more often had an ostomy from previous surgery (e.g. end colostomy after resection 
for the primary tumour)(p=0.040). Colo-anal anastomoses were more often performed 
in patients with an ileal conduit (p=0.027). The operation time was significantly shorter 
for patients receiving an ileal conduit than for those receiving a colon conduit with 420 
minutes [IQR 351 – 495 min] versus 510 minutes [IQR 439-620], respectively (p < 0.001).
anastomosis
In 210/214 patients with an ileal conduit an ileo-ileal anastomosis was performed, and in 
four patients no anastomosis was required because the pre-existing end ileostomy was 
used as a conduit (n=1) or a new end ileostomy was performed (n=3). In 30 patients with 
an ileal conduit, a colo-anal anastomosis was performed, and in 17 patients, an additional 
anastomosis was performed due to an additional bowel resection. In patients with a colon 
conduit, one colo-anal anastomosis was performed and two additional anastomoses due 
to additional bowel resection were performed.
short-term surgical and urological complications
Short-term surgical and urological complications are displayed in Table 3 and 4. There was 
no statistical difference in major complications (Clavien-Dindo ≥ 3) and mortality rates 
(30-day mortality or in-hospital mortality) for patients with an ileal conduit compared to 
a colon conduit. There was no difference between hospital stay, reintervention rates and 
readmission rates between both groups. A postoperative ileus occurred more often in 
patients with an ileal conduit compared to patients with a colon conduit (21 vs. 7%, 
p=0.024, respectively), which remained significant after multivariable analysis (p=0.025). 
In patients with a colon conduit a wound infection (perineal and/or abdominal) was ob-
served more often than in patients with an ileal conduit (31% vs. 16%, p=0.006), but this 




found when comparing the rate of urological complications or the reintervention rate for 
urologic complications between the two groups. Metabolic acidosis occurred in 6 patients 
(3%) with an ileal conduit, and did not occur in patients with a colon conduit (p=0.256).
Anastomotic leakage occurred in 6/210 patients (3%) with an ileo-ileal anastomosis. Anas-
tomotic leakage of the ureter anastomosis occurred in 14/214 patients (7%) with an ileal 
conduit and in 3/45 patients (7%) with a colon conduit (p=0.976). Anastomotic leakage 
of the colo-anal anastomosis occurred in 7/30 patients (23%) with an ileal conduit. In the 
colon conduit group, only one colo-anal anastomosis was performed without leakage. In 
both groups, no leakage of additional anastomoses was observed. 
When comparing only patients who underwent a resection through abdominoperineal 
approach, a postoperative ileus was still more often observed in patients who received an 
ileal conduit compared with a colon conduit (p=0.028). The wound infection rate did not 
differ. In a subanalysis comparing patients with LARC and LRRC, there were no significant 
differences in short-term surgical and urologic complications.







n (%) n (%) n (%)
30-day mortality 14 (5) 1 (2) 13 (6) 0.299
in-hospital mortality 26 (10) 3 (7) 23 (11) 0.408
Major complications (Clavien-
dindo ≥ 3)
101 (39) 14 (31) 87 (41) 0.233
any reintervention 90 (35) 11 (24) 79 (37) 0.110
ileus 48 (19) 3 (7) 45 (21) 0.024
wound infection (abdominal & 
perineal)
44 (17) 14 (31) 30 (14) 0.006
Pre-sacral abscess 47 (18) 7 (16) 40 (19) 0.620
abdominal abscess 31 (12) 4 (9) 27 (13) 0.484
ostomy complication 4 (2) 0 (0) 4 (2) 0.355
fistula 6 (2) 1 (2) 5 (2) 0.963
hospital stay in days (median 
[iQR])
14.0 [11.0, 18.5] 13.0 [11.0, 19.0] 14.0 [10.0, 18.0] 0.859
no readmission 217 (83) 36 (80) 179 (84) 0.230
urological readmission 11 (4) 4 (9) 7 (3)
non-urological readmission 33 (13) 5 (11) 28 (13)  
Percentages may not add up to 100% due to rounding
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long-term complications
Long-term complications are presented in Table 5. In 72% of the patients (186 patients, 
colon conduit n=44, ileal conduit n=142) long-term complications after 30 days were 
registered. The median follow-up for survivors for long-term complications was 55 months 
(95% CI 55-65 months). No significant differences in long-term complications between 
both groups were observed. One patient (2%) with a colon conduit and five patients (4%) 
with an ileal conduit experienced metabolic acidosis (p=0.582). Three (2%) out of 139 
patients with an ileal conduit presented with a late anastomotic leakage of the ileo-ileal 
anastomosis, 2/142 patients (1%) with uretero-ileal conduit leakage, and 2/21 patients 
(9%) with leakage of the colo-anal anastomosis. Patients with a colon conduit did not 








n (%) n (%) n (%)
urological complication 58 (22) 7 (16) 51 (24) 0.226
urological reintervention 35 (14) 4 (9) 31 (14) 0.318
urosepsis 9 (3) 1 (2) 8 (4) 0.614
Metabolic acidosis 6 (2) 0 (0) 6 (3) 0.256
urinoma 12 (5) 2 (4) 10 (5) 0.947
urinoma drainage 9 (3) 2 (4) 7 (3) 0.696
urostomy complication 4 (2) 1 (2) 3 (1) 0.685
hydronefrosis 22 (8) 1 (2) 21 (10) 0.097
ureter stenosis 7 (3) 0 (0) 7 (3) 0.609
urinary tract infection 16 (6) 3 (7) 13 (6) 0.881
leakage ileo-ileal anastomosis a     
No NA NA 204 (97) NA
Yes NA NA 6 (3)
leakage ureter - conduit 
anastomoses a
    
No 242 (93) 42 (93) 200 (93) 0.976
Yes 17 (7) 3 (7) 14 (7)
leakage colo-anal anastomosis a     
No 24 (77) 1 (100) 23 (77) 0.538
Yes 7 (23) 0 (0) 7 (23)
leakage other anastomosis a     
No 19 (100) 2 (100) 17 (100) NA
Yes 0 (0) 0 (0) 0 (0)  
a Percentage of anastomotic leakage is calculated of patients in which a specific anastomosis was performed 
NA: Not applicable




experience anastomotic leakage 30 days after surgery. Twelve patients (9%) with an ileal 
conduit developed a fistula (n=8 entero-cutaneous, n=4 uretero-enteric) compared to four 
(9%) patients with a colon conduit (p=0.895) (all entero-cutaneous). 
In a subanalysis, there were no significant differences in long-term surgical and urologic 
complications when comparing LARC with LRRC. 
disCussion
The present pooled retrospective cohort of 259 patients undergoing total pelvic exen-
teration with urinary diversion for LARC and LRRC describes few differences in surgical 
and urological complications between a colon conduit and an ileal conduit. However, the 








n (%) n (%) n (%)
urological complication 37 (20) 6 (14) 31 (22) 0.234
urological reintervention 22 (12) 5 (11) 17 (12) 0.913
urosepsis 4 (2) 1 (2) 3 (2) 0.949
Metabolic acidosis 6 (3) 1 (2) 5 (4) 0.682
hydronefrosis 19 (10) 3 (7) 16 (11) 0.394
Percutaneous nephrostomy drainage 14 (7) 2 (5) 12 (9) 0.319
urinary tract infection 19 (10) 4 (9) 15 (11) 0.778
urinoma 0 (0) 0 (0) 0 (0) NA
ureter stenosis 16 (9) 4 (9) 12 (9) 0.895
Revision ureter stenosis 3 (2) 2 (5) 1 (1) 0.076
Revision urostomy 4 (2) 2 (5) 2 (1) 0.207
fistula 16 (9) 4 (9) 12 (9) 0.895
leakage ileo-ileal anastomosisa     
No NA NA 136 (98) NA
Yes NA NA 3 (2)
leakage ureter - conduit 
anastomosisa     
No 184 (99) 44 (100) 140 (99) 0.429
Yes 2 (1) 0 (0) 2 (1)
leakage colo-anal anastomosisa     
No 20 (91) 1 (100) 19 (91) 0.746
Yes 2 (9) 0 (0) 2 (9)  
a Percentage of anastomotic leakage is calculated of patients in which a specific anastomosis was performed
NA: Not applicable. Percentages may not add up to 100% due to rounding
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formation of a colon conduit avoids the risk of ileo-ileal anastomotic leakage, which was 
4% in this cohort. In addition, an ileal conduit appears to be associated with a higher 
postoperative ileus rate. 
Several studies reported on outcomes after multivisceral surgery with cystectomy and the 
formation of a urinary diversion. However, complications are usually described for all types 
of pelvic cancer, and as outcomes may differ for different types of cancer this complicates 
comparison between studies. In the case of LARC and LRRC, a complete en bloc blad-
der removal with the rectal tumour is often performed, which makes it prone to other 
complications than after primary cystectomy alone.(16,17) A recent study by Bolmstrand et 
al. described complications after urinary tract reconstruction in colorectal and anal cancer 
after partial or complete cystectomy.(13) They reported a rate of 35% major complications 
(Clavien-Dindo≥3), which is comparable with the 39% in our series. The rate of intestinal 
anastomotic leakage was 9% in their series compared to 7% in our study. In the present 
study, we did not find a significant difference when comparing the anastomotic leakages 
separately between the two types of conduit. However, 9 patients with an ileal conduit had 
an anastomotic leakage of the ileo-ileal anastomosis, which is obviously ruled out when a 
colon conduit is performed.
Teixeira et al. compared outcomes in 74 patients who received an ileal or a colon conduit 
for different types of pelvic malignancies.(12) Their study did not find significant differences 
for complications assessed separately, such as urinary leaks, small bowel fistula, sepsis or 
drained collections. However, when all complications were combined, a significantly higher 
incidence of complications in patients with an ileal conduit compared to a colon conduit 
was found (40% vs. 19%, respectively, p<0.01).(12)
In the present study, a postoperative ileus was observed significantly more often in patients 
with an ileal conduit compared to patients with a colon conduit (21% vs 7%, p=0.024). 
Prolonged duration of ileus is a known complication after formation of an ileal conduit and 
may lead to a prolonged hospitalization.(8,18) In CZE, patients are frequently transferred 
to referring hospitals when they are clinically stable. This may have led to an underestima-
tion of hospital stay in CZE patients.
The proportion of patients with a wound infection (abdominal and/or perineal) was sig-
nificantly higher in patients with a colon conduit. Several factors may influence wound 
healing such as surgical approach, extent of surgery, perineal or abdominal reconstruction 
(i.e. muscle flap reconstruction, omentoplasty), patient characteristics or even bacterial 
load from the conduit. This could not be explained clearly with the available data and 




Despite the possible favourable outcomes in terms of complications, and the fact that pre-
vious studies showed a low tie can be safely performed regarding oncological outcomes, 
a colon conduit is not always technically possible to perform.(19,20) For example, in case 
of macroscopic lymph node metastasis above the level of the left colic artery a high tie 
must be performed and a colon conduit can only be created when the blood supply via the 
middle colic artery and Riolan’s arcade conduit is sufficient. Furthermore, in patients with 
LRRC a repeated resection of the descending colon can result in insufficient length and 
blood supply for the creation of a colon conduit.
In addition to an ileal or colon conduit, the formation of other types of urinary diversion 
such as an Indiana pouch, neobladder or double-barrelled wet colostomy are technically 
possible as well. However, in CZE and EMC reconstructions using an Indiana pouch or 
neobladder are not performed in patients with extensive colorectal malignancy as these 
reconstructions are associated with a higher complication rate in these patients.(17) The 
double-barrelled wet colostomy (DBWC) inherently has a benefit over the ileal or colon 
conduit, as it requires only one stoma. However, in our experience this type of diversion 
is unpleasant to take care of for patients and subsequently has a negative impact on the 
quality of life. Therefore, a DBWC is not performed in our institutions.
This study is limited by its retrospective nature. Improvement in multimodality treatment 
such as neoadjuvant therapies over the last decades may influence our results, but the 
majority of patients in our study were treated with neoadjuvant (chemo-)radiotherapy and 
there was no significant difference between both groups. Although treatment protocols 
are similar in both hospitals, there is an imbalance in the proportion of patients with an 
ileal or colon conduit, as CZE only performed one colon conduit. In addition, the admission 
of IORT is different in both hospitals; in CZE IOERT is administered whereas in EMC IOBT 
is administered. The significant difference in operation time between the ileal and colon 
conduit may be explained by the administration of mainly IOBT in the colon conduit group, 
as this is a more time-consuming procedure than IOERT. For the same reason, IOBT was 
only applied in case of positive fresh frozen sections, whereas IOERT was also administered 
in case of clinically threatened margins. Since a larger proportion of patients in this cohort 
was treated in the CZE where an ileal conduit was the preferred method, IORT was most 
frequently used in patients with an ileal conduit.
The use of an intestinal segment as urinary conduit may lead to metabolic changes, which 
may depend on the length and type of the conduit, ileal or colonic.(8,14,21) In the lit-
erature, a colon conduit is more often associated with metabolic acidosis than an ileal 
conduit. This study did not find a significant difference, although metabolic acidosis may 
be underreported. 
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Long-term follow-up was available in 70% of the patients with a wide range of follow-up 
time. Despite these limitations, this study still provides valuable information for the use of 
both an ileal and colon conduit. 
Conclusions
The formation of an ileal or colon conduit in patients undergoing total pelvic exenteration 
for LARC or LRRC has similar urologic complications. However, the formation of a colon 
conduit rules out ileo-ileal anastomotic leakage. Besides, an ileus was more frequently seen 
after the formation of an ileal conduit in this study. Therefore, the colon conduit may be a 







 1.  Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, et al. Preoperative 
radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: 
Results of FFCD 9203. J Clin Oncol. 2006;24(28):4620–5. 
 2.  van GW, Marijnen CAM, Nagtegaal ID, Kranenbarg EMK, Putter H, Wiggers T, et al. Preop-
erative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 
12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol [Internet]. 
2011;12(6):575–82. Available from: http://dx.doi.org/10.1016/S1470-2045(11)70097-
3%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/21596621
 3.  Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and 
trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683–91. 
 4.  PelvEx Collaborative. Surgical and Survival Outcomes Following Pelvic Exenteration for Locally 
Advanced Primary Rectal Cancer. Ann Surg. 2017; 
 5.  PelvEx Collaborative. Factors affecting outcomes following pelvic exenteration for locally recur-
rent rectal cancer. Br J Surg. 2018;105:650–7. 
 6.  Russo P, Ravindran B, Katz J, Paty P, Guillem J, Cohen AM. Urinary diversion after total pelvic 
exenteration for rectal cancer. Ann Surg Oncol. 1999;6(8):732–8. 
 7.  Fujisawa M, Nakamura T, Ohno M, Miyazaki J, Arakawa S, Haraguchi T, et al. Surgical man-
agement of the urinary tract in patients with locally advanced colorectal cancer. Urology. 
2002;60(6):650–7. 
 8.  Nieuwenhuijzen JA, de Vries RR, Bex A, van der Poel HG, Meinhardt W, Antonini N, et al. 
Urinary Diversions after Cystectomy: The Association of Clinical Factors, Complications and 
Functional Results of Four Different Diversions. Eur Urol. 2008;53(4):834–42. 
 9.  Bricker E. Bladder substitution after pelvic evisceration. Surg Clin N Amer. 1950;30:1511. 
 10.  Schmidt JD, Hawtrey CE, Buchsbaum HJ. Transverse colon conduit: a preferred method of 
urinary diversion for radiation treated pelvic malignancies. J Urol. 1975;113(3):308–13. 
 11.  Meijer RP, Mertens LS, Meinhardt W, Verwaal VJ, Dik P, Horenblas S. The colon shuffle: A 
modified urinary diversion. Eur J Surg Oncol. 2015;41(9):1264–8. 
 12.  Teixeira SC, Ferenschild FT, Solomon MJ, Rodwell L, Harrison JD, Young JM, et al. Urological 
leaks after pelvic exenterations comparing formation of colonic and ileal conduits. Eur J Surg 
Oncol. 2012;38(4):361–6. 
 13.  Bolmstrand B, Nilsson PJ, Holm T, Buchli C, Palmer G. Patterns of complications following 
urinary tract reconstruction after multivisceral surgery in colorectal and anal cancer. Eur J Surg 
Oncol. 2018;44(10):1513–7. 
 14.  Roth JD, Koch MO. Metabolic and Nutritional Consequences of Urinary Diversion Using Intes-
tinal Segments to Reconstruct the Urinary Tract. Urol Clin North Am. 2018;45(1):19–24. 
 15.  Dindo D, Demartines N, Clavien P-A. Classification of surgical complications: a new proposal with 
evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205–13. 
206
 16.  Brown KGM, Solomon MJ, Latif ER, Koh CE, Vasilaras A, Eisinger D, et al. Urological complica-
tions after cystectomy as part of pelvic exenteration are higher than that after cystectomy for 
primary bladder malignancy. J Surg Oncol. 2017;115(3):307–11. 
 17.  Stotland PK, Moozar K, Cardella JA, Fleshner NE, Sharir S, Smith AJ, et al. Urologic complica-
tions of composite resection following combined modality treatment of colorectal cancer. Ann 
Surg Oncol. 2009;16(10):2759–64. 
 18.  Lee DJ, Tyson MD, Chang SS. Conduit Urinary Diversion. Urol Clin North Am. 2018;45(1):25–36. 
 19.  Yang Y, Wang G, He J, et al. High Tie Versus Low Tie of the Inferior Mesenteric Artery in 
Colorectal Cancer: A Meta-Analysis. International Journal of Surgery. 2018; 52: 20-24.
 20.  Fujii S, Ishibe A, Ota M, et al. Randomized clinical trial of high versus low inferior mesenteric 
artery ligation during anterior resection for rectal cancer. BJS Open. 2018; 2(4): 195-202.
 21.  Van der Aa F, Joniau S, Van Den Branden M, Van Poppel H. Metabolic Changes after Urinary 










The aim of this thesis is to further improve the multimodality treatment for rectal cancer, 
locally advanced rectal cancer and locally recurrent rectal cancer. Further development of 
the multidisciplinary approach and ‘tailor made’ treatment strategies is ongoing and has 
rapidly improved since the early 90’s with neoadjuvant/induction therapy and periopera-
tive improvements.(1) Current research may cause a shift towards even more conservative 
therapies after preoperative treatment such as rectal sparing surgery or non-operative 
treatment with watchful waiting.(2) Although this is not the aim of this thesis, these new 
insights in future treatment of rectal cancer will also be discussed in this chapter. In the 
current thesis, the focus lies on different aspects and outcomes of treatment for primary 
rectal cancer, locally advanced rectal cancer and locally recurrent rectal cancer. 
The first part of this thesis focuses on treatment of rectal cancer and mainly on short- and 
long-term outcomes associated with hospital volumes in rectal cancer surgery. This associa-
tion is still a subject of debate. Since 2012 a minimal hospital volume of 20 rectal cancer 
resections annually per hospital is mandatory in the Netherlands, irrespective of tumour 
stage.(3) Centralization is recommended for patients with advanced stages of rectal cancer 
in specialized colorectal cancer hospitals. In the first Snapshot database study of this thesis, 
including 2095 patients treated in 71 Dutch hospitals in 2011, annual hospital volume 
was not significantly associated with any outcome measure after rectal cancer surgery 
in low (<20 resections/year), medium (20-50 resections) or high (>50 resections) volume 
hospitals, regardless of tumour stage. The differences that were observed among volume 
groups were related to clinical nodal staging and the use of minimally invasive surgery 
and diverting stoma. Overall complications seemed to be lower in low volume hospitals, 
although reintervention rates did not differ significantly. Three-year overall survival rates 
were similar for low (75.9%), medium (79.1%) and high volume (80.3%) hospitals. We 
did not find a significant difference between CRM-positivity rates, in contrast with a study 
of Gietelink et al.(4), where a significant higher incidence of CRM positivity was found 
in low-volume hospitals in 2011 and 2012 using DSCA data of all 94 Dutch hospitals.(4) 
This underlines the difficulty in interpretation of hospital volume as a single discrimina-
tor, because specific low-volume hospitals may actually be high performing.(5) In 2011, 
centralization for treatment of advanced stages was already recommended and it seems 
likely that a certain volume is needed to manage this complex care. Patients with cT4 
tumours are potentially more accurately assessed in experienced multidisciplinary tumour 
board (MDT) meetings and treated by specialized surgeons for ‘beyond TME’ surgery in 
centres for locally advanced disease. These centres may not necessarily be high-volume, 
because of their focus on referred patients with less use of their capacity for patients with 
cT1-3 tumours. These results suggest that hospital volume, as a single discriminator should 
be used with caution, although a certain unspecified volume is likely needed to gain and 
retain expertise in rectal cancer care with increasing complexity. 
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Treatment of rectal cancer is dependent on tumour stage. A majority of patients will pres-
ent with early stage rectal cancer (cT1-cT3) and may be treated with standard TME-surgery. 
Less patients will present with advanced rectal cancer (cT4) and a more multidisciplinary 
approach with preoperative (chemo-) radiotherapy and extensive resections beyond the 
standard TME-plane are mandatory. A recent population-based study revealed no differ-
ences in 5-year survival rates between hospital volumes for patients with colorectal cancer, 
but outcomes were not stratified for rectal cancer, nor for tumour stage.(6) Therefore, 
stratification for clinical tumour stage according to hospital volumes is important. Our 
study showed that patients with locally advanced (cT4) rectal cancer treated in high volume 
hospitals (≥ 10 resections/year) had a significantly improved 5-year overall survival of 63% 
compared to 53% in low volume (1 – 4 resections) and 54% in medium volume cT4 
hospitals (5 - 9 resections), when corrected for patient and tumour related confounders. 
This difference disappeared after adjustment for neoadjuvant therapy, but the omission 
of neoadjuvant treatment in cT4 rectal cancer may also reflect lower quality of care. This 
survival difference related to hospital volume was not found in cT1-3 rectal cancer. Further 
centralization of cT4 rectal cancer seems warranted to improve outcome for this difficult 
group of patients. Several studies in other malignancies, such as oesophagus, pancreas 
and bladder cancer have reported survival differences according to hospital volume in 
complex surgical procedures.(7-9) The hypothesis of this survival benefit is that more 
exposure and experience in the multimodality treatment (staging, induction therapy and 
surgical expertise) of these relatively rare malignancies results in an improved long-term 
outcome.(7-9) As described previously in an experienced MDT, cT4 tumours are potentially 
more accurately assessed and this may lead to superior selection for preoperative therapy 
and surgical treatment, which eventually results in better outcomes. CRM involvement 
did not differ significantly for cT4 tumours according to hospital volume, but even in an 
experienced high volume hospital radical resection of cT4 tumours is challenging. Referral 
of the most difficult cases to high volume hospitals may offer an explanation for similar 
CRM involvement in different volume hospitals for cT4 rectal cancer. 
In line with association between long-term oncological outcomes, short-term perioperative 
outcomes may be dependent on hospital volume and tumour stage. In our nationwide 
analysis, perioperative outcomes of cT1-3 rectal cancer surgery were not superior in high 
volume hospitals as compared to medium or low volume hospitals, so there appears no 
benefit for centralization regarding perioperative complications. With regard to cT4 rectal 
cancer, high volume hospitals performed more extensive surgical treatment with similar 
perioperative results. Pathologic examination revealed more frequently pT4 in high volume 
hospitals, while R0 rates were similar between low, medium and high volume hospitals. In 
a sub-analysis of pT4 patients, the rate of irradical resection was significantly increased in 




fined as < 20 rectal cancer resections per year, regardless of tumour stage, was associated 
with a higher risk of CRM involvement.(4) Unfortunately, they did not perform sub-analysis 
for different tumour stages, and results are not directly comparable to our study. However, 
these results indicate that centralization for advanced stage rectal cancer (cT4) may be 
beneficial regarding perioperative and oncological outcomes, and this beneficial effect may 
not apply to lower stage rectal cancer (cT1-cT3). 
Lymphatic drainage in the lower rectum is partly by inguinal lymph nodes.(10) Currently, 
the American Joint Committee on Cancer (AJCC) Cancer Staging Manual considers inguinal 
lymph node metastases (ILNM) from rectal cancer as a systemic disease.(11) ILNM caused 
by rectal cancer should not necessarily be considered as an incurable disease, especially in 
case of primary rectal cancer and the absence of other systemic metastases. In our study 
a median overall survival of 74 months with 1- and 5-year estimated overall survival rates 
of 83% and 52%, respectively, was reached for patients with solitary ILNM. Prognosis for 
patients with additional systemic metastases is worse and the benefit of surgery is unclear. 
Obviously, patients with ILNM have a worse prognosis than patients without ILNM, but 
even in patients with ILNM and lung or liver metastases curative treatment is sometimes 
considered.(12) Although, resection of ILNM may not be curative in these patients, it could 
still be beneficial. Currently, the ORCHESTRA-trial(13) is being performed in patients with 
multi-organ colorectal cancer metastases, to compare the added value of a combination of 
chemotherapy and maximal tumour debulking versus chemotherapy alone.(13) The mor-
bidity of surgical treatment in patients with curative or palliative resection of ILNM should 
not be underestimated, since most of these patients experience lymphedema. On the other 
hand, most patients who did not undergo resection of ILNM experienced severe groin pain.
For distal rectal cancer, surgical options are often resection by low anterior resection (LAR) 
or an abdominoperineal resection (APR). Abdominoperineal resection for low rectal cancer 
still carries a significant risk of perineal wound problems.(14) This is likely related to the 
contaminated operative field and dead space formation with fluid accumulation, and may 
be further increased by extended resections and compromised perfusion after preopera-
tive radiotherapy. A recent randomised controlled trial on perineal wound closure after 
APR reported an incidence of complicated perineal wound healing of 34-37% at 30 days 
postoperative and complications of primary perineal closure within one year up to 48%.
(15) In the long-term patients may experience persisting perineal pain, or develop a chronic 
perineal sinus or perineal hernia. (16-18) Several techniques are used to improve perineal 
wound healing, including reconstruction with mesh, using a V-Y fasciocutaneous flap, a 
vertical rectus abdominis myocutaneous (VRAM) flap, a gluteal or a gracilis flap.(15, 19-21) 
There are potential disadvantages to these techniques. These include the need for a plastic 
surgeon, increased theatre time and the potential for donor site and recipient site compli-
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cations, while often sacrificing the benefits of laparoscopy (22, 23). In our pilot study the 
feasibility of a new gluteal turnover flap (GT-flap) for routine perineal reconstruction after 
APR for (recurrent) rectal cancer was determined. The GT-flap was technically feasible with 
midline closure in all patients, except for one patient in whom more perineal skin had to 
be excised for oncological reasons. The flap added only limited additional theatre time, the 
majority of patients had uncomplicated perineal wound healing at 30 days postoperatively 
without any flap failure. A recent publication by Chasapi et al.(24) reported on a similar re-
constructive procedure in 14 patients undergoing APR for anorectal cancer.(24) The type of 
flap used differed from the technique described in this thesis. The flap was detached from 
the gluteal fascia with one remaining perforator for blood supply. These findings support 
that in selected patients, adjacent gluteal skin and subcutaneous fat can be relatively easily 
used for perineal closure after APR, with the potential advantages of reduced perineal 
morbidity by filling the space of the resected anal sphincter complex. The GT-flap seems a 
technically feasible and safe method for perineal wound closure after APR if no additional 
perineal skin has to be sacrificed. The procedure is relatively quick and easily applicable, 
and seems associated with no apparent donor site morbidity or scarring. Currently, the 
use of the GT-flap is investigated in a randomized controlled trial, the BIOPEX-2 study.(25)
Another procedure intended to improve perineal wound healing is the use of a pedicled 
omentoplasty (OP).(26) The omental flap serves to obliterate the non-collapsible defect 
in the smaller pelvis with healthy and well-perfused tissue. This has been associated with 
reduced abscess formation and improved perineal wound healing.(27) The omentum is 
supposedly an ideal option to prevent dead space formation after APR. It has a rich blood 
supply, expresses anti-inflammatory cytokines, often provides for abundant bulk and ap-
pears relatively easy to release.(28, 29) Many surgeons therefore perform an OP as part of 
the APR procedure. In a recent nationwide study with variability in practice of applying OP, 
no improvement in perineal wound healing was observed, and the OP seemed to increase 
the risk of perineal herniation.(17) In line with these results, our systematic review and 
meta-analysis found no evidence to support the use of an OP for reducing pelviperineal 
morbidity. Omentoplasty did not reduce pelviperineal abscess formation, nor enhanced 
perineal wound healing or reduced the risk of small bowel obstruction. Similarly, no benefi-
cial effect of OP was found in a planned subgroup analysis of patients that underwent APR 
with primary perineal closure for non-locally advanced cancer. Furthermore, OP appears to 
be associated with the long-term likelihood of developing perineal hernia. Two systematic 
reviews on the value of OP after APR have been published previously, both in contradic-
tion with the current meta-analysis.(30, 31) Reviews of Killeen et al.(30) and Nilsson et 
al.(31) concern studies with a small sample size and diverse patient population and surgical 
methods, with only few comparative series. However, in studies included in our systematic 




based on surgeon’s preference and surgical procedures where different, leading to larger 
or smaller defects and in some cases combined with muscle flaps. Therefore, results should 
be interpreted with care, but the standard use of OP may not be necessary after abdomi-
noperineal resection. Studies directly comparing muscle flaps and OP are scarce. Tissue 
transfer seems to have the greatest potential, but high quality studies comparing muscle 
flap closure to other methods of perineal wound closure are warranted. Although VRAM 
flap closure has been effectively used in selective populations, there remains the issue of 
donor and recipient site morbidity.(20) A smaller flap without donor site problems such as 
the earlier described GT-flap may have potential to reduce perineal morbidity in selected 
patients. 
Treatment of locally recurrent rectal cancer remains a challenge. The cornerstone of cura-
tive treatment and the long-term outcome of surgical treatment mainly depends on the 
ability to achieve a clear resection margin.(32, 33) In a large cohort of LRRC patients, 
treated surgically and non-surgically, we have demonstrated that R0- and R1-resections 
result in a 5-year overall survival rate of 51% and 34%, respectively. These survival rates are 
significantly prolonged compared to non-surgical palliative treatment. Although numbers 
were too small to implicate prognostic significance, R2-resections did not result in a 5-year 
overall survival benefit compared to non-surgical treatment with a rate of 10% vs. 4%. 
Moreover, the median survival may be poorer for surgically treated patients with a R2-
resection compared to optimal palliatively treated patients. Patients with a high chance of 
a R2-resection could be offered palliative treatment, without local resection. On the other 
hand, untreated LRRC can cause severe impairment in quality of life mainly due to severe 
pain, but also fistula, obstruction or bleeding.(34, 35) There may be a role for palliative 
surgery in these patients to reduce pain, and relief symptoms of obstruction by stenting or 
a diverting stoma as reported by others.(36, 37) However, surgery is accompanied by high 
morbidity and mortality rates, occurring mainly perioperative or in the first 3 months after 
surgical treatment. This impairment in quality of life persists until one year after surgery. 
Thereafter, surgically treated patients tends to have a better quality of life.(38) This fact 
and the lack of a survival benefit of R2-resections suggest that debulking surgery for LRRC 
resulting in planned R2-resections should be abandoned. 
A promising strategy to improve resectability of LRRC is induction chemotherapy. However, 
improved resectability does not always equal a survival benefit. Other factors, such as 
tumour behaviour, appear to have impact on overall survival as well. In our study few 
patients received induction chemotherapy, but a retrospective cohort study by van Zoggel 
et al.(39) compared outcomes of resection of LRRC in patients with induction chemo-
therapy followed by chemoradiotherapy to patients who received chemoradiotherapy 
alone. The R0-resection rate did not differ significantly, but a higher rate of pathologic 
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complete response was found in patients with combined treatment. Van Zoggel et al.(39) 
suggested that response rate to induction chemotherapy may be used as guidance to 
avoid overtreatment in patients with progressive disease under induction chemotherapy. 
In contrast with this study, our institute showed a lower response to chemotherapy of 
the local recurrence compared to the response of distant metastases in a small cohort of 
previously irradiated rectal cancer patients.(40) Because that study focussed on palliative 
patients this may reflect selection of patients with poor tumour biology. Careful evaluation 
of these patients individually in a MDT is mandatory to evaluate best possible outcome and 
treatment, whether to perform surgery or provide best non-surgical treatment.
For both primary rectal cancer and recurrent rectal cancer, achievement of a clear resection 
margin is described as an important prognostic factor for overall survival and local control.
(33, 41-44) This emphasizes the importance of a radical resection margin with surgery. 
Standard abdominoperineal resection (APR) and low anterior resection (LAR) for rectal 
cancer often achieve radical resection margins, but if there is invasion of adjacent organs, 
such as bladder, ureters or male and female reproductive organs, a more radical approach 
is indicated, such as total pelvic exenteration.(45) Our book chapter outlines the surgical 
procedure of total pelvic exenteration for locally advanced rectal cancer or recurrent rectal 
cancer with invasion of the anterior compartment. 
Five-year-survival rates after pelvic exenteration for locally advanced rectal cancer range 
between 22% to 66% and for locally recurrent rectal cancer between 0% to 37%.(33, 
43). Achievement of clear resection margins in pelvic exenteration for locally advanced 
or locally recurrent rectal cancer leads to a significant increase in overall and disease free 
survival compared to positive resection margins as described by Simillis et al.(44) in a 
recent systematic review. Perioperative 30-day mortality rates are reported in a range of 
0% - 10%.(33, 43, 46) Especially in frail and elderly patients high perioperative mortality 
rates have been reported; up to 14%.(47) The overall morbidity rate has been described 
to be anywhere between 32-100%. (33, 43, 48) Patients often have common complica-
tions such as (peroperative) bleeding, wound infection, pneumonia and (pelvic) abscesses, 
and the removal of adjacent organs is associated with other complications than normally 
encountered in colorectal surgery. Pelvic exenteration may be unavoidable to achieve clear 
resection margins in advanced rectal cancer, but this type of surgery does have a profound 
impact on the quality of life.(49, 50) On the other hand, the prognosis of patients with 
locally advanced or recurrent rectal cancer without treatment is poor and is associated with 
severe symptoms such as pain, incontinence, fistula and unmanageable wounds. Quyn et 
al.(51) showed that patients who underwent pelvic exenteration had a sharp decline in 
quality of life directly after surgery. However, their quality of life improved quickly after 




a higher quality of life than patients who did not have surgery. Thereafter, quality of life 
in the surgery group continued to improve, whereas quality of life in patients who did not 
undergo surgery deteriorated.(51) Therefore, patients should not be denied exenterative 
surgery based on perceived poor quality of life.
As previously described, total pelvic exenteration is an invasive procedure with consider-
able mortality and morbidity, especially in elderly patients. Although it is generally known 
that elderly patients often present with more comorbidities and that surgical outcomes are 
worse than in younger patients, there is controversy whether the cancer specific survival is 
also worse in elderly patients.(47, 52) The discussion remains whether patients should be 
withheld from surgery based on age. Our study showed that pelvic exenteration should 
not be withheld from the elderly patient. There is no significant difference in oncological 
outcome between younger (< 70 years) and elderly patients (≥ 70 years), but perioperative 
mortality is higher among elderly patients during the first 30 days after surgery. In line 
with our results Rutten et al. (47) described a significantly higher mortality rate (14%) in 
elderly patients (age ≥ 75 years) until six months after surgery for rectal cancer compared 
to younger patients (4%). In our study, the mortality rate was only significantly different 
at 30-days after surgery, and the significant difference disappeared after 30 days. Overall 
survival and disease specific survival did not differ significantly, but this cohort suggests 
that elderly patients have a better 5-year disease specific survival rate of 67% in elderly 
compared to 49% in younger patients. When patients are assessed in a MDT whether they 
are eligible for total pelvic exenteration, the MDT board is more reluctant to select elderly 
patients unless good clinical outcome is expected considering their comorbidities. This may 
be a bias. Nevertheless, Careful patient selection is needed to reduce perioperative mortal-
ity in elderly patients by better patient selection and/or improving patient’s performance 
status prior to surgery.
If total pelvic exenteration with a complete cystectomy is performed, patients require a 
urinary diversion. Historically there are several urinary diversion techniques, but in current 
practice, the most common urinary diversion is an ileal conduit (i.e. Bricker). The colon 
conduit technique was described by several authors, but is less well known.(53, 54) Both 
surgical procedures slightly differ due to the use of different bowel segments. An ileal 
conduit requires an ileo-ileal anastomosis, whereas in colon conduits an extra anastomosis 
is usually not required because the terminal segment of the descending colon can be used 
in patients receiving an end colostomy anyway. In our pooled retrospective cohort of 259 
patients undergoing total pelvic exenteration with urinary diversion for LARC and LRRC 
few differences in surgical and urological complications between a colon conduit and an 
ileal conduit were found. However, the formation of a colon conduit avoids the risk of 
ileo-ileal anastomotic leakage, which was 4% in this cohort. In addition, an ileal conduit 
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appears to be associated with a higher postoperative ileus rate. Prolonged duration of ileus 
is a known complication after formation of an ileal conduit and may lead to a prolonged 
hospitalization.(55, 56) Several studies reported on outcomes after multivisceral surgery 
with cystectomy and the formation of a urinary diversion for all types of pelvic cancer. A 
recent study by Bolmstrand and colleagues in colorectal and anal cancer patients, who 
underwent partial or complete cystectomy, reported a rate of 35% major complications 
(Clavien-Dindo≥3), comparable with the 39% in our cohort. The rate of overall intestinal 
anastomotic leakage was 9% in their series compared to 7% in our cohort.(57) Teixeira et 
al.(58) compared several outcomes in 74 patients who received an ileal or a colon conduit 
for all types of pelvic malignancies. Their study did not find significant differences for 
complications assessed separately, but a significantly higher incidence of complications in 
patients with an ileal conduit compared to a colon conduit was found if all complications 
were combined.(58) In line with the results found in this thesis, the colon conduit may be 
a feasible alternative for an ileal conduit in patients receiving an end colostomy.
fuTuRe PeRsPeCTives
The multidisciplinary treatment of (recurrent) rectal cancer has evolved over the past de-
cades and is still evolving in a high pace. Innovation in diagnostics and treatment may have 
a significant impact on current practice. The current standard diagnostics for (recurrent) 
rectal cancer staging are endoscopy, MRI-scan of the pelvic area and a CT-scan of the 
thorax and abdomen to search for signs of disseminated disease. This is also the standard 
for restaging after neoadjuvant therapy, to evaluate tumour response and in follow up to 
detect local or distant recurrence.
A promising new technique as a predictive or prognostic value to measure tumour re-
sponse or detect tumour recurrence is the use of liquid biopsies.(59) Circulating tumour 
DNA (ctDNA) is a promising biomarker considered to be an important diagnostic tool for 
the detection of minimal residual disease with liquid biopsies.(60-62) CtDNA is part of 
the total amount of small fragments of DNA in the blood, called cell-free DNA. These 
fragments are shed into the bloodstream from dying cells during cellular turnover or other 
forms of cell death.(60-62) Several studies demonstrated that mutations found in ctDNA 
correspond to mutations found in tumour tissue. Therefore, ctDNA can potentially be used 
for early detection of minimal residual disease or response to local or systemic therapy. The 
detection limit of ctDNA analysis approaches to detect tumour DNA in the total amount 
of cell-free DNA is below 0.05%.(60, 61) This very sensitive technique still has a specificity 
of >99.99%. In colorectal cancer, the majority of patients have detectable ctDNA in their 




62) CtDNA has a short half-life of approximately 2 hours, detection several days after surgi-
cal resection of the primary tumour is indicative for presence of minimal residual disease. 
Therefore, ctDNA analysis seems an accurate and reliable test to use in clinical practice and 
can be particularly useful in diagnosis, treatment and monitoring of rectal cancer patients.
As minimal residual disease is undetectable by imaging techniques, but may still be present 
after surgery in rectal cancer patients, they might have a high risk of recurrence. Tie and 
colleagues(63) studied ctDNA in colorectal cancer. They found a recurrence rate of 79% 
in stage II colon cancer patients with detectable ctDNA compared to 10% recurrence rate 
in patients without detectable ctDNA after surgery.(63) In locally advanced rectal cancer 
patients, 58% of the patients with detectable ctDNA had a recurrence within 2 years, in 
contrast to 8.6% in negative ctDNA patients.(64) These results show that postoperative 
ctDNA analysis stratifies patients with LARC into very high and low risk groups for recur-
rence.
In high-risk colorectal cancer patients, the positive effect of adjuvant chemotherapy is 
well established. In rectal cancer patients, the role of adjuvant chemotherapy is still under 
debate and it is not the standard of care in the Netherlands.(65-68) Several trials and 
reviews present contradicting results and could not demonstrate a beneficial role for 
adjuvant chemotherapy in rectal cancer. The EORTC-2291-(69), I-CTR-RT-(70), PROCTOR-
SCRIPT-(67) and CHRONICLE-trial(71), showed no benefit of adjuvant chemotherapy on 
overall survival and disease free survival. The QUASAR-trial(72) and a Cochrane review(65) 
did demonstrated benefit of adjuvant chemotherapy on overall survival and disease free 
survival. A more recent meta-analysis by Bujko et al.(66) and Breugom et al.(73) demon-
strated no improvement with adjuvant chemotherapy. None of the trials and meta-analyses 
could identify a specific group at high risk for recurrence who may benefit from adjuvant 
chemotherapy, which is the fact for high-risk colon cancer.(74, 75) In the study of Tie et 
al.(64) some patients received adjuvant chemotherapy and post-operative ctDNA detec-
tion was predictive of recurrence irrespective of administration of adjuvant chemotherapy. 
The negative impact of ctDNA seems more pronounced in patients without adjuvant 
chemotherapy. CtDNA may be a promising biomarker to predict tumour response and may 
identify patients at high risk for recurrence. Possibly the use of ctDNA can provide guidance 
in clinical decision making to treat rectal cancer patients with a high risk on recurrence with 
adjuvant chemotherapy. Besides identifying patients at high risk for recurrence, there also 
may be a role for ctDNA in measurement of tumour response after neoadjuvant therapy. 
These patients may be withheld from radical surgery in case of a ctDNA response and 
treated by local excision or even watchful waiting.(76) Implementing ctDNA as a predictive 
and prognostic marker in clinical practice is promising and may lead to better patient 
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selection and treatment, but the use of this new biomarker in clinical practice needs to be 
demonstrated. 
Implementation of a more ‘tailor made’ treatment for rectal cancer and improved neo-
adjuvant therapy have led to interesting research regarding organ preserving surgery and 
a ‘watch and wait (or watchful waiting)’ strategy. The role of chemoradiotherapy was 
previously limited to facilitating tumour shrinkage to perform radical surgery in advanced 
rectal cancer. In some patients, a pathologic complete response was observed after surgery. 
Even in lower stage rectal cancer, there may be a potential beneficial effect of chemora-
diotherapy to achieve a complete response and this may lead to less invasive and rectal 
sparing or surgery can even be omitted in selected patients. Rectal cancer patients with a 
pathologic complete response after neoadjuvant chemoradiotherapy have a significantly 
better outcome.(77, 78) To assess whether a patient has a complete pathological response 
with 100% certainty a surgical resection is required. Already in 2004, Habr-Gama and col-
leagues(79) were one of the firsts to omit surgery in patients with stage 0 distal rectal can-
cer and compared results of this strategy with operative treatment. They showed that both 
treatment strategies had good long-term outcomes, and the omission of surgery prevents 
patients from unnecessary morbidity and mortality.(79) Radical surgery by total mesorectal 
excision is associated with a perioperative mortality rate of 2-5%, anastomotic leakage 
in 3-11%, permanent colostomy in 10-30% and long-term bowel, bladder and sexual 
dysfunction.(80). Rectal cancer patients may be spared from this extensive radical surgery 
by organ sparing therapy (i.e. transanal endoscopic microsurgery) or even no surgery, thus 
watch and wait. A recent systematic review by Dossa et al.(81) with multiple series follow-
ing the pioneering research of Habr-Gama and colleagues showed promising results with 
this new strategy. They found no significant difference in overall survival between complete 
responders after a watch and wait strategy compared to surgical treatment for different 
stages of rectal cancer.(81) An international pooled cohort with individual patient data also 
described similar results and recurrence mostly occurred within 2 years, which emphasizes 
the need for close surveillance, but the vast majority of patients could still undergo salvage 
surgery.(82) In case of a partial response, patients can still possibly undergo organ sparing 
transanal endoscopic microsurgery (TEM), as shown in the CARTS study.(83) Appelt et 
al.(84) performed a prospective observational trial to assess the feasibility of high dose 
chemoradiotherapy and watchful waiting for rectal cancer and concluded that this might 
be a safe alternative to abdominoperineal TME-surgery. On the other hand, some patients 
with lower stage rectal cancer will receive chemoradiotherapy with possible morbidity not 
leading to a complete response. The current available literature seems promising for a 
watch and wait strategy or organ preserving surgery, but randomized trials need to be 
performed for further research as the results mainly depends on retrospective outcomes. 




ized comparison of standard radical surgery versus organ saving treatment using either 
short course radiotherapy or chemoradiotherapy with selective use of TEM based upon a 
radiotherapy response assessment. (87) This study may provide evidence in the future for 
this new treatment strategy.
The Prognosis of locally recurrent rectal cancer is still poor with a 5-year overall survival 
of 30-40% in optimally surgically treated patients.(88, 89) In the vast majority of patients 
with LRRC who did not and could not undergo surgery prognosis is worse with a 5-year 
survival of 4%, as described in chapter 8 of this thesis. Achievement of a radical resection 
margin is an important prognostic factor.(32, 33) This is challenging, because patients have 
often received previous radiotherapy and surgery in the TME-plane, and recurrent rectal 
cancer may invade other structures within the pelvic area. Tumour shrinkage preopera-
tively may achieve a higher rate of radical resections. Reirradiation with Capecitabine as 
radiosensitizer in LRRC is proven to be safe and effective.(90) Despite this treatment radical 
resections are only achieved in 60% of patients with LRRC.(89) Induction chemotherapy 
is widely used in several types of (primary) cancer or metastatic disease such as colorectal 
liver metastases, to induce tumour shrinkage and improve resectability. In LRRC, the role of 
induction chemotherapy is still limited. Few retrospective studies have been published on 
this topic. Kusters et al.(91) described a small cohort of patients with lateral node recur-
rences treated with induction chemotherapy follow by chemoradiotherapy and resection. 
This regimen resulted in an improved R0-resection rate of 85%.(91) A study by van Zoggel 
et al.(39) retrospectively compared a cohort of patients receiving induction chemotherapy 
with chemoradiotherapy versus matched patients who received chemoradiotherapy alone. 
They found a high complete pathological response rate of 17% compared to 4% in 
chemoradiotherapy alone group. Surprisingly, radical resection rates were similar.(39) 
Currently, a new study by Voogt and Burger et al. is being introduced to compare induc-
tion chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as 
neoadjuvant treatment for locally recurrent rectal cancer. A recent retrospective study by 
Voogt et al.(92) compared the effect and potential benefit of induction chemotherapy 
for LRRC in patients from 2010 and 2018. They found a 3-year overall survival of 92% in 
patients with a complete pathological response after induction chemotherapy. They also 
found a similar pathological complete response rate compared to van Zoggel et al.(39) A 
radical resection margin was achieved in 63% of all patients treated with induction che-
motherapy. In unpublished data, they observed a trend in higher R0-resection rates with 
increasing administration of induction chemotherapy overtime. These (preliminary) results 
seem promising to achieve a higher rate of pathologic complete response and maybe a 
higher rate of radical resections. Currently there is no hard evidence for the use of induc-
tion chemotherapy, but this new randomized controlled trial might give the answer and 
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alter standard treatment for LRRC in the future. This PelvEx-2 study has recently received 
funding and is expected to start accrual in the fall of 2020.
In summary, the goal of this thesis was to focus on several aspects of treatment and further 
improve treatment of primary rectal cancer, locally advanced rectal cancer and locally recur-
rent rectal cancer. For cT4 rectal cancer, centralization in high volume hospitals seems 
to improve outcome. In patients with ILNM from primary rectal cancer cure by surgical 
resection is still an option. The proposed gluteal turnover flap seem promising to reduce 
perineal morbidity after abdominoperineal resection but needs further clinical research 
and the standard use of an omentoplasty after APR may not be necessary. In patients with 
LRRC, achievement of a radical resection margin is important, patients with a high chance 
on R2-resection should maybe be withheld from surgery and receive non–surgical palliative 
treatment. Patients with LARC and LRRC undergoing total pelvic exenteration experience 
considerable morbidity but quality of life increases after surgery, and elderly should not 
be withheld from total pelvic exenteration on age only. In patients undergoing total pelvic 
exenteration, a colon conduit avoids the risk of ileo-ileal leakage and may be a feasible 
alternative for an ileal conduit in patients receiving an end colostomy. Future and current 
studies regarding organ preserving therapy and watchful waiting are promising as less 
invasive treatment strategies. In addition, the use of induction chemotherapy in LRRC may 
be important to achieve a higher rate pathologic complete response and R0-resections. The 
use of liquid biopsy and ctDNA as a predictive or prognostic marker may be of great value 
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Colorectal cancer is the third most common malignancy in the Western world and rectal 
cancer accounts for approximately one third of the colorectal cancer patients. In 2018, 
almost 4,000 patients were newly diagnosed with rectal cancer in the Netherlands and this 
number is stable over the last four years. Despite these stabilizing numbers, the burden of 
rectal cancer is high and treatment remains a challenge. At the time of diagnosis of primary 
rectal cancer, in approximately 10% of the rectal cancer patients, the tumour is close to 
the mesorectal fascia and may invade surrounding organs such as the bladder or male and 
female reproductive organs. These patients have locally advanced rectal cancer (LARC). 
After treatment for primary rectal cancer, the tumour may recur locally in the rectum or 
in surrounding structurers within the pelvic area in approximately 5-10% of the patients. 
These patients have locally recurrent rectal cancer (LRRC). Over the past decades treat-
ment of rectal cancer has evolved into a ‘’tailor made’’ multidisciplinary approach including 
neoadjuvant chemo- and radiotherapy, total mesorectal excision surgery, sometimes with 
surgery beyond the TME-plane, and intraoperative radiation therapy (IORT). The aim of this 
thesis is to further improve the multimodality treatment for rectal cancer, locally advanced 
rectal cancer and locally recurrent rectal cancer. 
Chapter 1 describes a general introduction and outline of this thesis. 
In chapter 2, the impact of hospital volume on short- and long-term outcomes of rectal 
cancer surgery was assessed in a population-based study of a Dutch cohort in 2011 pro-
vided by the Dutch Snapshot Research Group. According to the Dutch National Guidelines, 
hospitals require a minimum number of rectal cancer resections a year. In this study no 
impact of hospital volume on outcome after rectal cancer surgery could be demonstrated 
between hospitals with low volume (<20 resections/year), medium volume (20-50 resec-
tions/ year) or high volume (>50 resections/year) hospitals. 
In chapter 3, we analysed the long-term results of cT1-3 and cT4 rectal cancer according 
to hospital volume in the Netherlands between 2005 and 2013 from data of the National 
Cancer Registry, stratified by tumour stage. Hospital volume was not associated with over-
all survival after surgery for cT1-3 rectal cancer. The treatment of cT4 rectal cancer in high 
volume cT4 hospitals was associated with an improved survival compared to low volume 
cT4 hospitals when corrected for patient and tumour related confounders. This association 
was no longer statistically significant after correction for neoadjuvant treatment. Further 
centralization of cT4 rectal cancer may further improve outcome for this difficult group of 
patients.
Chapter 4 evaluates the impact of hospital volume on surgical resection and perioperative 
outcomes of cT1-3 rectal cancer and cT4 rectal cancer using data from a national registry. 
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Patients with early stage rectal cancer (cT1-cT3) may be treated with standard TME-surgery. 
For patients with advanced rectal cancer (cT4) a more multidisciplinary approach with pre-
operative (chemo-) radiotherapy and extensive resections beyond the standard TME-plane 
are mandatory. This study demonstrates that perioperative outcomes of cT1-3 rectal cancer 
surgery were not superior in high volume hospitals as compared to medium or low volume 
hospitals, so there appears no benefit for centralization regarding perioperative complica-
tions. With regard to cT4 rectal cancer, high volume hospitals performed more extensive 
surgical treatment with similar perioperative results. These results indicate that centraliza-
tion for advanced stage rectal cancer (cT4) may be beneficial regarding perioperative and 
oncological outcomes, and this beneficial effect may not apply to lower stage rectal cancer 
(cT1-cT3).
In chapter 5, a cohort of patients with inguinal lymph node metastasis (ILNM) from rectal 
cancer is presented. Currently, the American Joint Committee on Cancer (AJCC) Cancer 
Staging Manual considers ILNM from rectal cancer as a systemic disease. Obviously, patients 
with ILNM have a worse prognosis compared to patients without ILNM, but surgery may 
not be withheld in some patients. Our study demonstrated a 5-year survival rate of 52% 
after surgical treatment of patients with primary rectal cancer and isolated ILNM. Prognosis 
for patients with additional systemic metastases is worse and the benefit of surgery is 
unclear. Inguinal lymph node metastases should not be considered as an incurable disease, 
especially in patients with primary rectal cancer and solitary ILNM. 
In chapter 6, results of the BIOPEX II pilot study are presented. Abdominoperineal resection 
(APR) carries a high risk of perineal wound morbidity. In this study, the feasibility of a novel 
gluteal turnover flap (GT-flap) was assessed in a small cohort. The GT-flap was technically 
feasible with midline closure in all patients, except for one patient in whom more perineal 
skin had to be excised for oncological reasons. The flap added only limited additional the-
atre time, the majority of patients had uncomplicated perineal wound healing. The GT-flap 
seems a technically feasible and safe method for perineal wound closure. The procedure 
is relatively quick and easily applicable, and seems associated with no apparent donor site 
morbidity or scarring. Currently, the use of the GT-flap is investigated in a randomized 
controlled trial, the BIOPEX-2 study. 
In chapter 7 a systematic review and meta-analysis of the effects of omentoplasty on 
pelviperineal morbidity following abdominoperineal resection (APR) in mostly rectal pa-
tients is presented. Our study found no evidence to support the use of an OP for reducing 
pelviperineal morbidity. Omentoplasty did not reduce pelviperineal abscess formation, nor 
enhanced perineal wound healing or reduced the risk of small bowel obstruction. Similarly, 




derwent APR with primary perineal closure for non-locally advanced cancer. Furthermore, 
OP appears to be associated with the long-term likelihood of developing perineal hernia. 
Studies included in our systematic review had a certain degree of selection bias, therefore, 
results should be interpreted with care, but the standard use of OP may not be necessary 
after abdominoperineal resection.
In chapter 8, the long-term outcomes of a large cohort of patients with LRRC who 
underwent curative surgical treatment or non-surgical treatment are evaluated. In LRRC 
patients treated surgically and non-surgically R0- and R1-resections resulted in a 5-year 
overall survival rate of 51% and 34%, respectively. These survival rates are significantly 
prolonged compared to non-surgical palliative treatment. Although numbers were too 
small to implicate prognostic significance, R2-resections did not result in a 5-year overall 
survival benefit compared to non-surgical treatment with a rate of 10% vs. 4%. Moreover, 
the median survival may be poorer for surgically treated patients with a R2-resection com-
pared to optimal palliatively treated patients. This study suggest that debulking surgery for 
LRRC resulting in planned R2-resections should be abandoned.
In chapter 9, a book chapter is presented which outlines the surgical procedure and out-
comes of pelvic exenteration for locally advanced rectal cancer or recurrent rectal cancer 
with invasion of the anterior compartment. 
In chapter 10, a study is presented aiming to compare mortality, morbidity, surgical and 
oncological outcomes between elderly and younger patients who underwent total pelvic 
exenteration for LARC or LRRC. The discussion remains whether patients should be with-
held from surgery based on age. Our study showed that pelvic exenteration should not be 
withheld from the elderly patient. There is no significant difference in oncological outcome 
between younger (< 70 years) and elderly patients (≥ 70 years), but perioperative mortality 
is higher among elderly patients during the first 30 days after surgery. Careful patient 
selection is needed to reduce perioperative mortality in elderly patients by better patient 
selection and/or improving patients’ performance status prior to surgery.
In Chapter 11, short- and long-term complications of an ileal and colon conduit after 
surgery for LARC or LRRC are presented in cohort of two large tertiary referral hospitals. 
Our study demonstrated similar urological complications after the formation of an ileal or 
colon conduit. However, the formation of a colon conduit rules out ileo-ileal anastomotic 
leakage, which was 4% in this cohort. In addition, an ileus was more frequently seen 
after the formation of an ileal conduit in this study. Therefore, the colon conduit may be a 
feasible alternative for an ileal conduit in patients receiving an end colostomy.

Chapter 14






Het colorectaal carcinoom is de derde meest voorkomende maligniteit in de westerse 
wereld en het rectumcarcinoom treft ongeveer één derde van alle patiënten met een co-
lorectaal carcinoom. In Nederland zijn in 2018 ongeveer 4.000 patiënten gediagnostiseerd 
met een rectumcarcinoom. De behandeling van het rectumcarcinoom is de afgelopen 
decennia sterk verbeterd, maar de behandeling blijft uitdagend. Het doel van de behan-
deling is om de overleving te verbeteren en de kans op terugkeer te verminderen, en 
daarmee de kwaliteit van leven te verbeteren. Het primaire rectumcarcinoom kan vaak 
zonder voorbehandeling, in de vorm van chemotherapie of radiotherapie, worden behan-
deld door totaal mesorectale excisie. In gevallen dat het rectumcarcinoom is ingegroeid 
in omliggende structuren, zoals bij het lokaal voortgeschreden rectumcarcinoom of bij 
een lokaal recidief rectumcarcinoom, zal een uitgebreidere behandeling nodig zijn: een 
multimodaliteitsbehandeling met chemo- radiotherapie en een (uitgebreide) chirurgische 
resectie. Dit proefschrift heeft als doel om verschillende aspecten van het primaire, lokaal 
voortgeschreden en lokaal recidief rectumcarcinoom uiteen te zetten en aan te geven hoe 
de multimodaliteitsbehandeling is te verbeteren. 
In hoofdstuk 1 worden de verschillende onderzoeksvragen met onderbouwing beschre-
ven die beantwoord zullen worden in dit proefschrift. 
In hoofdstuk 2 wordt de invloed van ziekenhuisvolumes op de korte en lange termijn 
onderzocht in een groot cohort uit de Dutch Snapshot Research Group. Volgens de 
Nederlandse richtlijnen moeten ziekenhuizen een minimumaantal resecties van het rec-
tumcarcinoom per jaar verrichten om zo de kwaliteit te waarborgen. Er werd geen verschil 
gevonden in uitkomsten, zoals overleving en chirurgische uitkomsten, tussen ziekenhuizen 
met een laag volume (<20 resecties per jaar), gemiddeld volume (20-50 resecties per jaar) 
of een hoog volume (>50 resecties per jaar). 
In hoofdstuk 3 is ook onderzoek beschreven naar de invloed van ziekenhuisvolumes op 
overleving, echter nu in de grote nationale kankerregistratie-database met gegevens van 
2005 – 2013. In dit onderzoek is gestratificeerd voor het klinisch stadium voor een primaire 
tumor (cT1-3) of het lokaal voortgeschreden rectumcarcinoom (cT4). Deze studie liet zien 
dat patiënten met een cT4-rectumcarcinoom een verbeterde overlevingskans hadden wan-
neer zij behandeld werden in een hoogvolumeziekenhuis. Dit verschil verdwijnt echter na 
correctie voor neoadjuvante therapie. Centralisatie van deze cT4-tumoren lijkt een posi-
tieve invloed te hebben op de uitkomsten voor patiënten met deze uitgebreide tumoren. 
In hoofdstuk 4 is wederom onderzoek geanalyseerd naar de invloed van volumenormen, 
ditmaal naar de perioperatieve uitkomsten. In uitgebreide tumoren (cT4) is de multimo-
daliteitsbehandeling en chirurgie vaak technisch veeleisend in vergelijking met minder 
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uitgebreide tumoren (cT1-3). Voor cT1-3 tumoren waren de perioperatieve uitkomsten 
voor hoogvolumeziekenhuizen niet superieur aan die in laag- of gemiddeldvolumezieken-
huizen. Echter, voor patiënten met cT4-tumoren zien we dat er uitgebreidere chirurgie 
wordt verricht in hoogvolumeziekenhuizen met dezelfde perioperatieve resultaten. 
Hoogvolumeziekenhuizen bieden mogelijk een betere multimodaliteitsbehandeling, wat 
uiteindelijk kan leiden tot betere uitkomsten. Het lijkt dat centralisatie voor deze cT4-
tumoren een positieve invloed heeft. 
In hoofdstuk 5 onderzoeken we de behandeling van locoregionale metastasen naar de 
liesklieren van het rectumcarcinoom. Deze metastasen worden heden nog beschouwd als 
een systemische ziekte, maar er zijn aanwijzingen dat deze lokaal goed te behandelen zijn, 
door middel van chirurgie. In deze studie zien we dat patiënten met alleen metastasen 
naar de liesklieren en een primair rectumcarcinoom bij adequate behandeling een 5-jaars-
overleving van 52% hebben. Voor patiënten met metastasen elders of een lokaal recidief 
rectumcarcinoom zijn de uitkomsten slechter. Deze studie laat zien dat patiënten met 
metastasen alleen in de liesklieren en een primair rectumcarcinoom niet per se beschouwd 
moeten worden als patiënten met een systemische ziekte, en in opzet curatief behandeld 
kunnen worden. 
In hoofdstuk 6 beschrijven we een pilotstudie naar de bruikbaarheid van een nieuwe tech-
niek voor het sluiten van de perineale wond na een abdominoperineale rectumresectie. Na 
een abdominoperineale resectie is er een grote kans op wondgenezingsstoornissen. Vele 
verschillende manieren van wondsluiting zijn reeds bekend, zoals het gebruik van myocu-
tane flap. Deze hebben echter het nadeel dat elders een nieuwe wond gemaakt wordt. 
In de huidige studie onderzoeken we de bruikbaarheid van de gluteale turnover-flap, die 
direct na de operatie is te creëren zonder additionele schade aan te richten. In deze studie 
zien we dat de meerderheid van patiënten een ongecompliceerde wondgenezing had en 
de gluteale turnover-flap potentie heeft voor perineale wondsluiting. Dit zal echter moeten 
worden onderzocht in een grotere gerandomiseerde studie.
In hoofdstuk 7 verrichten we ook onderzoek naar perineale wondgenezing. Op dit mo-
ment wordt in veel gevallen gebruik gemaakt van een omentumplastiek ter bevordering 
van de wondgenezing. Het idee van een omentumplastiek is om het kleine bekken op te 
vullen met het omentum en de genezende of beschermende werking van het omentum 
te benutten ter bevordering van de wondgenezing. In dit systematische review en meta-
analyse zijn uit alle recente studies waar het gebruik van een omentumplastiek wordt 
toegepast gegevens opgevraagd. Een uitgebreide analyse van deze gegevens laat geen 
verbetering van de wondgenezing zien door het gebruik van een omentumplastiek. Het 




geeft op de langere termijn. Het gebruik van een omentumplastiek lijkt niet het gewenste 
effect te hebben om perineale wondgenezing te verbeteren. 
hoofdstuk 8 beschrijft een groot cohort van patiënten met het lokaal recidief rectumcar-
cinoom. Deze patiëntengroep vereist een speciale behandeling. Het recidief carcinoom zit 
in het kleine bekken met soms doorgroei in aanliggende structuren zoals het urogenitale 
stelsel, daarnaast presenteert de meerderheid van deze patiënten zich met afstandsme-
tastasen. Het belangrijkste van de behandeling is het bereiken van een radicale resectie-
marge. Als dit niet mogelijk is, dan is een behandeling met chemotherapie of radiotherapie 
een optie. Na een chirurgische behandeling, indien mogelijk, hebben patiënten met een 
R0- of R1-resectie een significant betere 5-jaarsoverleving van respectievelijk 51% en 34% 
dan patiënten met een R2-resectie (10%) of niet-chirurgische behandeling (4%). Patiënten 
met een R2-resectie hebben zelfs een slechtere overleving dan patiënten met optimale 
niet-chirurgische behandeling. Patiënten met een hoge kans op een R2-resectie kunnen in 
geselecteerde gevallen dus mogelijk niet chirurgisch behandeld worden, gezien de mor-
biditeit en mortaliteit van chirurgie. Niet chirurgisch behandelde patiënten kunnen echter 
veel lokale tumorklachten zoals pijn, fisteling en bloedingen ervaren. In beide gevallen 
dient rekening te worden gehouden met de kwaliteit van leven. 
hoofdstuk 9 toont een overzicht van de chirurgische behandeling van het lokaal voort-
geschreden of recidief rectumcarcinoom indien er sprake is van ingroei in aanliggende 
organen zoals de blaas. In deze gevallen dient een totaal-exenteratie te worden verricht. 
Dit is een ingreep waarbij door middel van chirurgie de tumor vaak enbloc met het uroge-
nitale stelsel bij de man of vrouw wordt verwijderd. Dit hoofdstuk beschrijft een overzicht 
van indicatie, procedure en uitkomsten op korte en lange termijn. De 5-jaarsoverleving 
varieert tussen 22% tot 66% voor het lokaal voortgeschreden rectumcarcinoom en 0% 
tot 37% voor het recidief rectumcarcinoom. De perioperatieve mortaliteit ligt tussen de 
0% en 10%. Een radicale resectie-marge is de belangrijkste prognostische factor. Kwaliteit 
van leven is kort na de chirurgie verminderd maar verbetert al binnen drie maanden na de 
ingreep tot bijna op het oude niveau, terwijl bij onbehandelde patiënten de kwaliteit van 
leven achteruit gaat. Een totaal-exenteratie lijkt dus een gerechtvaardigde ingreep. 
In hoofdstuk 10 is onderzoek verricht naar de invloed van leeftijd en het uitvoeren van 
een totaal-exenteratie voor het lokaal voortgeschreden of recidief rectumcarcinoom. Het 
is algemeen bekend dat ouderen vaak een hogere mortaliteit en morbiditeit ervaren bij 
operaties. De oncologische uitkomsten kunnen echter gelijkwaardig zijn. In dit hoofdstuk 
zien we dat binnen 30 dagen na de operatie de perioperatieve mortaliteit bij ouderen 
(≥ 70 jaar) significant hoger is. Maar na 30 dagen verdwijnt dit verschil. De algehele 
overleving is niet significant verschillend. Als patiënten vooraf goed geselecteerd worden 
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in een multidisciplinair overleg, moet leeftijd niet de weerhoudende factor zijn voor een 
totaal-exenteratie.
In hoofdstuk 11 vergelijken we de uitkomsten van het aanleggen van een colon-conduit 
en een ileum-conduit als urinedeviatie na een totaal-exenteratie. Beide procedures zijn 
geassocieerd met complicaties maar er zijn ook conduit-specifieke complicaties gerelateerd 
aan een conduit. In het geval van een ileum-conduit is er een kans op naadlekkage omdat 
er een extra ileo-ileale anastomose wordt gecreëerd, in ons cohort was dit 4%. Dit risico 
wordt vermeden bij het aanleggen van een colon-conduit. Daarnaast zagen wij een hoger 
percentage van postoperatieve ileus na het aanleggen van een ileum-conduit. De overige 
postoperatieve uitkomsten lieten geen significante verschillen zien. Het colon-conduit lijkt 






1. lisT of PubliCaTions
This thesis
The influence of hospital volume on long-term oncological outcome after 
rectal cancer surgery.
Jonker FHW, hagemans Jaw, Burger JWA, Verhoef C, Borstlap WAA, Tanis PJ; Dutch 
Snapshot Research Group.
Int J Colorectal Dis. 2017 Dec;32(12):1741-1747. doi: 10.1007/s00384-017-2889-2. Epub 
2017 Sep 7.
PMID: 28884251
hospital volume and outcome in rectal cancer patients; results of a 
population-based study in the netherlands.
hagemans Jaw, Alberda WJ, Verstegen M, de Wilt JHW, Verhoef C, Elferink MA, Burger 
JWA.
Eur J Surg Oncol. 2019 Apr;45(4):613-619. doi: 10.1016/j.ejso.2018.12.018. Epub 2018 
Dec 26.
PMID: 30600101
The impact of hospital volume on perioperative outcomes of rectal cancer.
Jonker FHW, hagemans Jaw, Verhoef C, Burger JWA.
Eur J Surg Oncol. 2017 Oct;43(10):1894-1900. doi: 10.1016/j.ejso.2017.07.009. Epub 
2017 Jul 29.
PMID: 28822603
Treatment of inguinal lymph node Metastases in Patients with Rectal 
adenocarcinoma.
hagemans Jaw, Rothbarth J, van Bogerijen GHW, van Meerten E, Nuyttens JJME, Verhoef 
C, Burger JWA.




feasibility of a subcutaneous gluteal turnover flap without donor site scar 
for perineal closure after abdominoperineal resection for rectal cancer.
Blok RD, hagemans Jaw, Burger JWA, Rothbarth J, van der Bilt JDW, Lapid O, Hompes 
R, Tanis PJ.
Tech Coloproctol. 2019 Aug;23(8):751-759. doi: 10.1007/s10151-019-02055-1. Epub 
2019 Aug 20.
PMID: 31432332 
a systematic Review and Meta-analysis on omentoplasty for the 
Management of abdominoperineal defects in Patients Treated for Cancer.
Blok RD*, hagemans Jaw*, Klaver CEL, Hellinga J, van Etten B, Burger JWA, Verhoef C, 
Hompes R, Bemelman WA, Tanis PJ.
Ann Surg. 2020 Apr;271(4):654-662. doi: 10.1097/SLA.0000000000003266.
PMID: 30921047
locally recurrent rectal cancer; long-term outcome of curative surgical and 
non-surgical treatment of 447 consecutive patients in a tertiary referral 
centre.
hagemans Jaw, van Rees JM, Alberda WJ, Rothbarth J, Nuyttens JJME, van Meerten E, 
Verhoef C, Burger JWA.
Eur J Surg Oncol. 2020 Mar;46(3):448-454. doi: 10.1016/j.ejso.2019.10.037. Epub 2019 
Nov 3.
PMID: 31761506 
Pelvic exenteration for invasive rectal cancer of the anterior compartment
hagemans Jaw, van Rees JM, Rothbarth J, Verhoef C, Burger JWA.
Wiley and Sons
Submitted
Total pelvic exenteration for locally advanced and locally recurrent rectal 
cancer in the elderly. 
hagemans Jaw, Rothbarth J, Kirkels WJ, Boormans JL, van Meerten E, Nuyttens JJME, 
Madsen EVE, Verhoef C, Burger JWA. Eur J Surg Oncol. 2018 Oct;44(10):1548-1554. doi: 




outcomes of urinary diversion after surgery for locally advanced or locally 
recurrent rectal cancer with complete cystectomy; ileal and colon conduit.
hagemans Jaw*, Voogt ELK*, Rothbarth J, Nieuwenhuijzen GAP, Kirkels WJ, Boormans 
JL, Koldewijn EL, Richardson R, Verhoef C, Rutten HJT, Burger JWA.
Eur J Surg Oncol. 2020 Feb 20. pii: S0748-7983(20)30123-2. doi: 10.1016/j.
ejso.2020.02.021. [Epub ahead of print] 
PMID: 32122756
not in this thesis
salvage abdominoperineal Resection for squamous Cell anal Cancer: a 
30-year single-institution experience.
hagemans Jaw, Blinde SE, Nuyttens JJ, Morshuis WG, Mureau MAM, Rothbarth J, Ver-
hoef C, Burger JWA.
Ann Surg Oncol. 2018 Jul;25(7):1970-1979. doi: 10.1245/s10434-018-6483-9. Epub 2018 
Apr 24. PMID: 29691737
aso author Reflections: salvage surgery for anal Cancer.
hagemans Jaw. Ann Surg Oncol. 2018 Dec;25(Suppl 3):852-853. doi: 10.1245/s10434-
018-7025-1. Epub 2018 Nov 9. No abstract available. PMID: 30414037
acute malignant obstruction in patients with peritoneal carcinomatosis: 
The role of palliative surgery.
de Boer NL, hagemans Jaw, Schultze BTA, Brandt-Kerkhof ARM, Madsen EVE, Verhoef 
C, Burger JWA.
Eur J Surg Oncol. 2019 Mar;45(3):389-393. doi: 10.1016/j.ejso.2018.12.015. Epub 2018 
Dec 21. PMID: 30594405
Management strategies for patients with advanced rectal cancer and liver 
metastases using modified delphi methodology: results from the Pelvex 
Collaborative.
PelvEx Collaborative.
Colorectal Dis. 2020 Feb 11. doi: 10.1111/codi.15007. [Epub ahead of print]
PMID: 32043753
246
Changing outcomes following pelvic exenteration for locally advanced 
and recurrent rectal cancer.
PelvEx Collaborative.
BJS Open. 2019 Mar 6;3(4):516-520. doi: 10.1002/bjs5.50153. eCollection 2019 Aug.
PMID: 31388644
Palliative pelvic exenteration: a systematic review of patient-centered 
outcomes.
PelvEx Collaborative. 
Eur J Surg Oncol. 2019 Oct;45(10):1787-1795. doi: 10.1016/j.ejso.2019.06.011. Epub 
2019 Jun 14. Review. 
PMID: 31255441
Pelvic exenteration for advanced nonrectal Pelvic Malignancy
Pelvex Collaborative
Ann Surg. 2019 Nov;270(5):899-905. doi: 10.1097/SLA.0000000000003533. 
PMID: 31634184
simultaneous pelvic exenteration and liver resection for primary rectal 
cancer with synchronous liver metastases: results from the Pelvex 
Collaborative
PelvEx Collaborative 













Amsterdam University Medical Center, Amsterdam
w.a.bemelman@amc.uva.nl






Amsterdam University Medical Center, Amsterdam
r.d.blok@amc.uva.nl
G.h.w. van bogerijen
Department of Radiation Oncology












Department of Surgical Oncology








Netherlands Comprehensive Cancer Organization (IKNL), Utrecht
m.elferink@iknl.nl
b. van etten
Department of Surgical Oncology
University Medical Center Groningen, Groningen
b.van.etten@umcg.nl 
J. hellinga
Department of Plastic Surgery


























Department of Plastic and Reconstructive Surgery
Amsterdam University Medical Center, Amsterdam
o.lapid@amc.uva.nl
e.v.e. Madsen
Department of Surgical Oncology
Erasmus MC Cancer Institute, Rotterdam
e.madsen@erasmusmc.nl
e. van Meerten
Department of Medical Oncology
Erasmus MC Cancer Institute, Rotterdam
e.vanmeerten@erasmusmc.nl
J.J.M.e. nuyttens
Department of Radiation Oncology
Erasmus MC Cancer Institute, Rotterdam
j.nuyttens@erasmusmc.nl
J.M. van Rees
Department of Surgical Oncology
Erasmus MC Cancer Institute, Rotterdam
j.vanrees@erasmusmc.nl
J. Rothbarth
Department of Surgical Oncology









Amsterdam University Medical Center, Amsterdam
p.j.tanis@amc.uva.nl
C. verhoef
Department of Surgical Oncology


















name Phd student: Jan Hagemans, MD
erasmus MC department: Surgery, Division 
of Surgical Oncology
Research school: Erasmus MC, MolMed
Phd period: March 2017 – March 2019
Promotor: prof. dr. C. Verhoef
Copromotor: dr. J.W.A. Burger
Phd Training Year ECTS
Research courses
- OpenClinica training
- Basic Introduction Course on SPSS
- Microsoft Excel 2010 Basic
- Research Integrity
- Biostatistical Methods I: Basic Principles Part A (NIHES)
- Microsoft Excel 2010 Advanced
















- Advanced Life Support Course
- Advanced Trauma Life Support








- annual Meeting dutch Colorectal Cancer Group (dCCG) 
REACT-Trial: Adjuvant chemotherapy for prevention of recurrence in 
patients with detectable ctDNA after surgery for stage II-III rectal cancer
- european society of Coloproctology (esCP), berlin, Germany
Total pelvic exenteration for primary locally advanced and locally 
recurrent rectal cancer
- society of surgical oncology (sso), Chicago, united states of 
america
Salvage abdominoperineal resection for squamous cell anal cancer: A 
30-year single institution experience
- european society of surgical oncology (esso), budapest, hungaria
- Treatment of inguinal lymph node metastases in patients with rectal 
adenocarcinoma
- Total pelvic exenteration for locally advanced and locally recurrent 
rectal cancer in the elderly
- Salvage abdominoperineal resection for squamous cell anal cancer: 










- Annual Science Day Surgery Erasmus MC 2017
- NVVH Chirurgendagen 2017
- Liver Metastasis Research Network 2017
- 18e Wondcongres 2017
- Annual Science Day Surgery Erasmus MC 2018
- NVVH Chirurgendagen 2018, NVVH
- 19e Wondcongres 2018
- Annual Science Day Surgery Erasmus MC 2019




















Teaching activities Year Workload 
(ECTS)
supervising practicals and excursions
- Basic Life Support examiner medical students 2018
- Basic Life Support examiner medical students 2017
supervising bachelor / Master students
- B.T.A. Schultze 
- B. Galjart















Promoveren gaat niet vanzelf en al helemaal niet alleen. Dit proefschrift is tot stand geko-
men door veel hulp, goede begeleiding en oneindige steun van anderen gedurende het 
gehele traject. De laatste loodjes wegen het zwaarst. Zonder de toewijding en energie 
van vele personen hadden deze nog zwaarder gewogen. Ik ben velen dankbaar voor het 
uiteindelijke resultaat. 
Geachte promotor, beste professor Verhoef, beste Kees, dit is denk ik de eerste keer dat ik u 
met professor aanspreek zonder dat ik iets van u wil hebben maar u juist iets van mij krijgt, 
mijn langverwachte proefschrift. Als coassistent heb ik al even aan de fantastische sfeer in 
‘’de Daniel’’ mogen proeven. Wat ben ik blij dat jij mij nog terug wilde zien als ANIOS en 
arts-onderzoeker. Het zegt wat over jouw vermogen om te motiveren, als je ook mensen 
voor wie wetenschappelijk onderzoek altijd een ver-van-mijn-bed-show is geweest een 
proefschrift kan laten schrijven. Jouw enthousiasme, goede humeur, humor en talent voor 
tafelvoetbal hebben mijn periode als onderzoeker er een om niet te vergeten gemaakt. Ik 
ken geen professor die 21 etages met de trap omhoogkomt om zijn onderzoekers een hart 
onder de riem te steken met kilo’s snoep. Zelfs tijdens de langdurige afrondende fase van 
mijn onderzoek had je geduld en rust om mij toch over de eindstreep te trekken. Heel veel 
dank voor de fantastische tijd en begeleiding! 
Geachte copromotor, beste dr. Burger, beste Pim, ik ben er trots op dat ik met jou in een 
relatief korte tijd veel werk heb kunnen verzetten, en voor het laatste gedeelte moet ik 
je nog bedanken voor je geduld. Het eerste A4-tje vol ideeën werden er steeds meer en 
altijd met boordevol energie. Op de gang van de Daniel was je altijd bereid tot overleg 
naast het standaard koffietje op vrijdagochtend met de radio op de achtergrond. Zelfs 
na de verhuizing, voor ons naar het centrum en voor jou naar je begeerde voetbalstad 
Eindhoven, bleven de lijntjes kort. Ook als het even tegenzat, had jij wel een idee om het 
tij te keren. Ik heb enorme waardering voor de tijd en energie die je in het proefschrift hebt 
gestoken, waarvoor heel veel dank!
Geachte leden van de promotiecommissie, ik wil u allemaal hartelijk danken voor uw tijd 
en aandacht voor het beoordelen van dit proefschrift. Daarnaast kijk ik uit naar het wis-
selen van gedachten over de inhoud van dit proefschrift.
Dr. van Meerten, dr. Nuyttens, dr. Boormans, beste Esther, Jan en Joost, zonder jullie nut-
tige commentaar en hier en daar een kritische noot zijn veel stukken uit dit proefschrift 
scherper op papier gezet. De multidisciplinaire aanpak en het overleg hebben mij op vele 
vlakken vooruitgeholpen.
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Paranimfen, beste Frans en Maarten. Wat vind ik het mooi dat jullie naast mij staan om 
mede mijn proefschrift verdedigen. Frans, jij kent mij langer dan ikzelf. Dus de droom om 
te promoveren ken jij ook langer dan ik. Dit kwam natuurlijk altijd ter sprake bij onze we-
kelijkse belletjes met de stimulerende vragen als: ga je ooit nog wel promoveren? Als je er 
niet om vraagt krijg je geen antwoord, heb ik van jou geleerd. Dus het continue vragen om 
mijn proefschrift heeft wellicht tot dit eindresultaat geleid. Maarten, ik heb je leren kennen 
als die gast uit Groningen, maar in de G-flat is onze vriendschap geboren. Zonder enige 
controle van welke begeleider dan ook, hebben wij daar een héél klein begin gemaakt aan 
onze proefschriften. We hebben tijdens onze periode als onderzoeker veel ups en downs 
meegemaakt en vonden onszelf soms zielige hardwerkende onderzoekers, vooral als de 
koffiebonen weer vervangen moesten worden. Eigenlijk hadden we de tijd van ons leven, 
denk ik nu. Bedankt voor alle mooie herinneringen en dat er nog veel mogen komen. 
Beste chirurgen van de Daniel, dr. Rothbarth, dr. Grünhagen, dr. Koppert, dr. Madsen, dr. 
van Ginhoven, beste Joost, Dirk, Linetta, Eva en Tessa. Mijn leven in de kliniek begon onder 
jullie vleugels en begeleiding. Om daarna door te stromen in het chirurgisch onderzoek 
was voor mij de perfecte opbouw. Door jullie begeleiding en voorbeeld in de kliniek kon 
ik weer met vertrouwen als ANIOS aan de slag. De gezellige overdrachten en lunches in 
restaurant Daniel zijn herinneringen om niet te vergeten.
Frederik, een goed begin is het halve werk. Zonder jou geen begin. Onwijs veel dank voor 
de kickstart die jij mij hebt gegeven onder jouw vleugels en daarnaast de introductie tot 
het congresleven in Berlijn!
Wijnand, in vele opzichten ben ik jou achternagegaan. We delen de kennis over een onwijs 
ingewikkelde database, hebben af en toe onze onderzoekteugels laten vieren, en hebben 
wat stukken achtergelaten voor onze opvolger. Je hebt mij in het zadel geholpen. Dank 
voor je hulp en motiverende teksten, quote: ‘’onderzoek is toch het mooiste wat er is’’!
Secretariaat ‘’de Daniel’’ bedankt voor alle hulp. In het bijzonder Sandra bedankt. Als wij 
weer even met onze handen in het haar zaten, wist jij altijd een oplossing voor alles. Hoe jij 
alles weet te managen, is bijzonder! Daarnaast was het onwijs gezellig om even ons hart te 
luchten, maar ook over koetjes en kalfjes te praten, als het onderzoek weer even tegenzat. 
Robin, eerlijk gezegd nooit gedacht dat we na ruim anderhalf jaar ploeteren toch een mooi 
review eruit zouden persen en uiteraard ook de BIOPEX. 
Eva, wat hebben we lief en leed gedeeld over jouw eerste en mijn laatste stuk, blij dat het 




Daniel-vriendjes, aan het mooie Lago di Daniel en op onze bekende gang op A1 hebben 
we een unieke leuke en hechte onderzoeksgroep gehad. Vrijdagochtend aan de pecan-
nootbroodjes en vrijdagmiddag op het dak. Hoe hebben we het ooit allemaal afgekregen. 
De mannenkamer, de vrouwenkamer, het grachtenpand, de tafelvoetbaltafel, de ping-
pongtafel en natuurlijk de Na-21-flat, iedere kamer heeft te veel herinneringen om op te 
noemen. Bedankt allemaal voor de mooie tijd. 
Diederik, Huppy, zonder jou geen proefschrift of in ieder geval een zonder figuren en tabel-
len. Jouw snelle oplossingen met computers hebben mij dagen aan overtikken bespaard. 
Als coin-investors hebben we het helaas niet gered, maar als onderzoekers gaat het ons 
vooralsnog aardig af! Bedankt voor alle hulp.
Pien, waar ik je heb leren kennen in de grotten van Maastricht is onze vriendschap pas echt 
tot leven gekomen tijdens het onderzoek. De Mathletes als een betweterig studiegroepje 
en uiteindelijk het Diamond Duo. We hebben zoveel ideeën dat er zelfs een bucketlist voor 
gemaakt moest worden. Concert at Sea is er al vanaf (helaas). De discipline en snelheid 
waarmee jij je proefschrift hebt afgerond heeft mij ook dat extra zetje in de rug gegeven 
en door jou kan ik tijdens mijn verdediging Engelse woorden moeiteloos uitspreken. Wat 
hebben we gelachen en wat gaan we nog lachen, bedankt! 
Flex 21-OGC, wat was het wennen na de samensmelting tussen Noord en Zuid, de verwoe-
de proeven om het bezit van de kamertjes en immuniteit. Expeditie Robinson was er niets 
bij. Het ultieme hoogtepunt na de samensmelting was natuurlijk de trip naar Boedapest en 
bar ‘’Click’’ waar de bar altijd rijkelijk bezet was. Maar de ontelbare lunches in de pantry 
als hoogtepunt van de dag waren een genot en een garantie voor gezelligheid.
Wondcongresvrienden, het Wondcongres heeft altijd een belangrijke rol gespeeld tijdens 
mijn onderzoek. Een week voorafgaand aan de vergadering kon ik iedere dag al een half 
uur besteden aan het eventuele menu voor die avond. De gezelligheid stond altijd voorop 
met als hoogtepunt het Lustrum in Het Nieuwe Luxor Theater. Wound Wound Wound…..!
Chirurgen, assistenten en Forgerons van het Ikazia. Hier is het eigenlijk allemaal begonnen, 
in het kleine hokje van de SEH is mijn interesse voor de chirurgie meer en meer gegroeid. 
De tijd als Forgerons was fantastisch en nadat ik zelf was geopereerd in het Ikazia wist 
ik het zeker, ik wilde graag terugkeren naar het oude nest. Ik ben dan ook zeer gelukkig 
dat ik in deze mooie groep chirurgen en assistenten mijn opleiding kan vervolgen. Dr. den 
Hoed, dr. Vles, beste Ted en Wouter dank voor alle hulp en adviezen door de jaren heen!
Ketsheuvel, wat begonnen is als een GVB-cursus waar ik nooit aan deelgenomen heb, 
is uitgegroeid tot een gezellige club in Rotterdam. Eindeloze borrels en lunches bij WP 
en talloze LAN-avonden, die altijd garant staan voor onwijze gezelligheid. Uiteindelijk 
uitgegroeid tot ons eigen Team West waarmee we ook op sportief vlak elkaar tot het 
uiterste drijven. Louis en Hylke in het bijzonder, we hebben, denk ik, de meeste uren bij WP 
en online gezamenlijk doorgebracht en daar over uiterst belangrijke levensvragen en op 
medisch gebied enorm met elkaar kunnen relativeren. Dat we nog vele jaren door mogen 
gaan.
Matteo, Mick en Romke, de schaarse vrijdagavonden eens in de paar maanden voelen 
altijd alsof het een wekelijks samenzijn is. Een onwijs gelukkig toeval dat in Berlijn heeft 
plaatsgevonden is uitgegroeid tot een bijzonder waardevolle vriendschap tussen drie Bos-
schenaren en een eigenwijze Hagenees. Ik kijk uit naar de volgende vrijdag.
Tom, Geus, anderhalf jaar lang heb jij de Binnenweg en Breitnerstraat een stuk gezelliger 
gemaakt. Je hebt veel ups en downs van het promotietraject meegekregen, en daarnaast 
heb je het roer een paar keer om zien gaan, maar ik kan je nu vertellen: het roer is om. 
Hockeymaatjes, hockey was altijd een rode draad en enorm genieten zowel bij Victoria 
als Rotterdam. Met name de TD’s en iedere rit met Autootje Uno was onvergetelijk. De 
donderdagavonddinertjes met jullie, Linho, Kaas, Geus en Jaac waren een genot om te 
mee te maken. 
JC Mañana, volgens mij heeft iedereen, behoudens Romke, nooit precies begrepen wat ik 
nou heb uitgevoerd. Een proefschrift over zonnebrand was wellicht een stuk interessanter 
geweest. Echter alle Saturdays, spelletjesavonden en vakanties gaven mij genoeg afleiding 
om de week iedere keer met een halve batterij te beginnen. 
Eetclub, wat begonnen is als een avondje lasagne van Gis en knapperige asperges van 
Carl en Bert, is uitgegroeid tot een heerlijke avond waar jullie al mijn sappige ziekenhuis-
verhalen aanhoren. Maar ook het eindeloze geklaag over onderzoek en de uitleg dat ik 
geen coassistent meer ben. Het ventileren op avonden als deze maken mijn leven een stuk 
aangenamer. Dat er nog maar vele eetclubavonden en vakanties mogen volgen. 
Lieve Carlijn en Frans, ik ben gelukkig dat ik jullie als leuke zus en broer mag hebben. Met 
jullie om mij heen is het leven altijd een feest. Wat bijzonder dat we allemaal arts zijn ge-
worden, wellicht omdat de broertjes allebei hun oudere zus hebben gevolgd. Hoewel we 
allemaal arts zijn, kennen wij geen borrels en etentjes waar het altijd over het ziekenhuis 




maar geven ook ruimte om lekker te ventileren over het leven. Ik kijk weer enorm uit 
naar onze eerstvolgende gezamenlijke vakantie, want voor mijn gevoel gaan we dan weer 
vijftien tot twintig jaar terug in de tijd toen we met ons drieën op de achterbank zaten met 
alle gevolgen van dien.
Lieve mama en papa, eindelijk is het zover. Zonder jullie steun was dit boekje er niet 
geweest. Jullie zijn altijd trouwe supporters, was het niet met applaus langs het veld dan 
was het wel met Bossche bollen aan de keukentafel. Ik word er onwijs gelukkig van als we 
‘even’ kunnen bellen en dan weer helemaal up to date zijn over van alles en nog wat. Het 
is altijd een verademing om op de Willem van Oranjelaan te komen. De gezelligheid en 
gastvrijheid in combinatie met de beste chef-kok koester ik enorm. Ik hoop dat er nog vele 
mooie herinneringen zullen volgen. Bedankt voor alle steun alle jaren.
Lieve Chenette, jij kent mij eigenlijk al net zo lang of eigenlijk langer dan de weg naar dit 
proefschrift. De jaren voorafgaand waren vooral lang leve de lol samen. Daarna zijn we 
‘’iets’’ serieuzer geworden en ben ik onwijs trots op je hoe hard je werkt, en toch altijd 
voor mij klaar staat. De laatste periode werd het gezeur over het proefschrift je wellicht 
eventjes te veel en ben je een jaartje naar Zwitserland verhuisd. Het was een jaar waarin 
we allesbehalve stil hebben gezeten, ontelbare tripjes voor dag en dauw hebben gemaakt 
die ons nog dichter bij elkaar hebben gebracht. Maar wat ben ik blij dat je weer bent 
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